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Abstract 
The mechanisms by which mesenchymal cells can repair the infarcted 
myocardium are still unclear and are made more challenging by the fact that 
hMSCs engraft in the myocardium for only a short amount of time. This thesis first 
examined the ability of commercial bone marrow (BM) MSCs expanded in low 
serum (<5% FBS medium), umbilical cord (UC) MSCs and individual donor BM-
MSCs to perform biologically relevant functions. The characterization studies 
showed that the differently-sourced hMSCs successfully underwent tri-lineage 
differentiation and displayed similar expression levels of positive MSC markers. 
Additionally to this, there was a tendency for cells at increased in vitro age to 
display reduced expression of CD105. 
 
Biologic priming of cells using sJag1 typically enhanced MSC attachment to 
fibronectin, although to varying degrees in the different MSC types. In addition, 
vascular support assays revealed that MSCs displayed pericyte-like behaviour 
lining the outside of the vessels and bridging in between endothelial cells during 
network formation. 
 
Assessment of how bioprocess parameters affect vascular tubule formation 
revealed that economic benefits can be derived by using lower volumes of 
alternative matrix substrates. In addition, automated counting tools achieved an 
unbiased measurement compared to manual counting processes. Finally, from a 
perspective of the vascular endothelial cells used in the assays, it was possible to 
extend their use an additional 50%, from passage 10 to passage 15 before losing 
functional capacity. 
 
With further work, these assays could be optimized for high-throughput screening 
and be used in industry as surrogate tests for quality control (QC) hence enabling 
the advancement of well-characterized cell therapy products. 
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Impact statement  
Currently, there are no potency assays in the clinical setting that give a reliable 
measurement of MSC mode of action other than simple surface marker 
expression, which does not predict function. This thesis aimed to take a 
methodological approach to measure key functions of hMSCs and endothelial 
tubule formation and to study the interactions between key bioprocess 
parameters affecting assay costs, robustness and reproducibility. Furthermore, 
from an engineering perspective, it was vital to control and mimic variables found 
in the in vivo environment such as oxygen tension and biological substrates to 
make measurements closer to the values obtained when injecting the cells in 
physiological areas. Additionally, another focus of this project was to biologically 
prime the MSCs to enhance their predicted mode of action and therefore to 
enhance the ease with which it can be measured.  
 
Not much work has been done on potency assays in cell therapy. Therefore, the 
results from this study will also fill a void in the literature and can form the basis of 
future assay development work in both industry and academia. The comparative 
studies between differently-sourced MSCs and the data obtained from priming the 
mesenchymal cells with biological ligands will be useful to companies looking to 
develop products catering to research and industrial application. The results from 
this project will also validate or reject both the proposed mechanisms of action of 
MSCs and the differences between differently-sourced MSCs by revealing key 
critical quality attributes of mesenchymal cells. 
 
Heart transplantation is scarce due to the high costs associated with it, the lack of 
donors and the need for patient-donor matched organ. For this reason, gaining an 
understanding of the MOA of MSCs will also accelerate their application in the 
treatment of ischemic injury and enable their use as a viable alternative to heart 
transplantation.  
5 
 
Acknowledgments  
First, praises and thanks to Allah S.W.T for giving me the strength to persevere 
and have a positive attitude during the most difficult times of my PhD. I would like 
to express my gratitude to my supervisor Professor Ivan Wall for allowing me to 
take on this exciting project in an area that I enjoy, for his guidance and for the 
valuable feedback on my thesis writing. I would like to extend my gratitude to 
Professor Mike Hoare for his support, valuable feedback and for always keeping 
me on track, all of which have also contributed to improving the quality of my 
writing. Also, Professor Nicolas Szita for his insight and advice in personal and 
professional matters, Professor Gary Lye, and Kim Morgan for believing in me 
and being supportive of my science communication adventures.  
 
My sincerest thanks go to my colleagues within the Advanced Centre for 
Biochemical Engineering to name a few: Nehal, Elisabetta, Tania, Luba, Mike, 
Hadiza, Shaleem, Dave, Damiano, Carlotta, Gregorio, Chika and Daniel for your 
friendship and for always having words of encouragement when things were not 
always working, as it happens in science! Special thanks to Giulia Detela, Billy, 
Ya, Reema, and Zhuming for always being happy to help, for the laughs and for 
making the lab a positive space to work in. Also, many thanks to the Engineering 
and Physical Sciences Research Council (EPSRC) for funding this doctorate. A 
special thank you to Asma, for being my Ride or Die throughout this PhD. 
Working days (and nights) in the lab would not have been as much fun without 
our chats, tea breaks and every memorable experience we have shared together. 
 
Finally, special recognition goes out to my siblings Sabrina, Mohamed, and 
Sheima for their love and encouragement. In particular, Sheima for believing in 
me, listening to all of my dilemmas and giving me tough love when needed. To 
my family and friends especially Safa and Hafsa for constantly motivating me and 
having no doubts in my abilities to succeed. To my parents Dr Said Abukar Abati 
and Khadija Omar Mohamed for being my inspirations and for teaching me the 
importance of hard work and perseverance and to my aunty Fatma and uncle 
Amir for their selfless love and constant support during the past fifteen years. No 
words can describe how lucky I feel to have you in my life.  
6 
 
Table of contents 
Abstract ............................................................................................................... 3 
Impact statement ................................................................................................ 4 
Acknowledgments .............................................................................................. 5 
List of figures .................................................................................................... 12 
List of tables ..................................................................................................... 21 
List of abbreviations ........................................................................................ 22 
Chapter 1: Literature review ............................................................................ 26 
1.1: Overview of the vascular system .............................................................. 26 
1.1.1: The process of vessel formation ........................................................ 27 
1.1.2: Regulation of angiogenesis by hypoxia .............................................. 28 
1.2: Dual pumping function of the heart ........................................................... 29 
1.2.1: Cell types found in the heart .............................................................. 29 
1.3: Myocardial infarction and remodelling process ......................................... 30 
1.3.1: Therapeutic treatments for MI ............................................................ 31 
1.4: What is regenerative medicine? ............................................................... 32 
1.4.1: Potency assays for assessing biological function of cell-products ..... 33 
1.4.1.1: Culture medium considerations ................................................... 34 
1.5: Cell types used for myocardial tissue regeneration .................................. 35 
1.5.1: Embryonic stem cells (ESCs) ............................................................. 35 
1.5.2: Adult stem cells for cardiac therapy ................................................... 36 
1.5.2.1: Skeletal myoblasts ....................................................................... 36 
1.5.2.2: Haematopoietic stem cells (HSCs) .............................................. 36 
1.5.2.3: Endothelial progenitor cells (EPCs) ............................................. 38 
1.5.2.4: Cardiac stem cells (CSCs) ........................................................... 38 
1.6: Overview of MSCs ................................................................................... 39 
1.6.1: Biological differences between BM-MSCs and umbilical cord MSCs 
(UC-MSCs) .................................................................................................. 41 
1.6.2: Characterization of MSCs ................................................................ 45 
1.6.3: Effect of cell age on the potency of MSCs ......................................... 45 
1.7: Potential of MSCs for MI in clinical trials................................................... 46 
1.7.1: Clinical outcomes of stem cells looking at LVEF ............................ 47 
7 
 
1.8: Clinical and pre-clinical outcomes of therapeutic angiogenesis and 
engraftment ..................................................................................................... 51 
1.9: Mode of action of MSCs for cardiac repair ............................................... 54 
1.10: Preconditioning MSCs for clinical efficacy .............................................. 56 
1.10.1: Hypoxia pre-conditioning of MSCs in vitro ....................................... 56 
1.10.2: Engraftment strategies to increase angiogenesis, adhesion and 
migration ..................................................................................................... 58 
1.10.2.1: Engraftment of MSCs and Notch pathway ................................. 59 
1.11: In vitro angiogenesis assay methods ..................................................... 61 
1.11.1: ECs for in vitro studies ..................................................................... 61 
1.11.1.1: HUVECs ................................................................................... 62 
1.11.1.2: Heterogeneity of ECs ................................................................ 63 
1.11.2: Endothelial cell tubule formation assays .......................................... 63 
1.11.2.1: Co-culture functional assays ...................................................... 64 
1.12: In vivo angiogenesis assays ................................................................... 65 
1.13: In vitro versus in vivo angiogenesis assays ............................................ 66 
1.14: Quantification of release assays ............................................................. 66 
1.14.1: ELISA for growth factor release ....................................................... 67 
1.14.2: Gene expression microarrays and qPCR ......................................... 68 
1.14.3: Metabolomics screening .................................................................. 69 
1.15: QbD for process standardization ............................................................ 69 
1.15.1: Development of cell-based potency assays ..................................... 71 
1.16: Research aims ....................................................................................... 73 
Chapter 2: Materials and methods .................................................................. 74 
2.1: Culture of human mesenchymal stromal cells (hMSCs) ........................... 74 
2.1.1: Culture and expansion of human bone marrow MSCs (hBM-MSCs) 
and human umbilical cord MSCs (hUC-MSCs) ............................................ 74 
2.1.2: Culture and expansion of low serum commercial hBM-MSCs ............ 75 
2.1.3: Cell counting ...................................................................................... 76 
2.1.4: Cell banking ....................................................................................... 76 
2.1.5: Cell thawing ....................................................................................... 77 
2.2: Characterizing the growth kinetics of hMSCs ........................................... 77 
8 
 
2.2.1: Fold increase ..................................................................................... 77 
2.2.2: Population doubling level (PDL) ......................................................... 78 
2.3: Characterization of human MSCs (hMSCs) .............................................. 78 
2.3.1: Tri-lineage differentiation of hMSCs ................................................... 78 
2.3.1.1: Adipogenic differentiation ............................................................ 78 
2.3.1.2: Osteogenic differentiation ............................................................ 79 
2.3.1.3: Chondrogenic differentiation ........................................................ 79 
2.4: Immunophenotype profile of hMSCs ........................................................ 79 
2.5: Priming of hMSCs by soluble Notch ligands ............................................. 81 
2.6: RNA extraction and quantitative polymerase chain reaction (qPCR) for 
gene expression analysis ................................................................................ 81 
2.6.1: RNA extraction ................................................................................... 81 
2.6.2: gDNA elimination ............................................................................... 81 
2.6.3: cDNA synthesis ................................................................................. 82 
2.6.4: Two-step qPCR ................................................................................. 82 
2.6.4.1: Calculation of expression fold change ......................................... 83 
2.7: Macro design to quantify staining ............................................................. 84 
2.8: Hypoxic chamber oxygen measurements ................................................. 84 
2.9: Cell culture techniques of primary human umbilical vein endothelial cells 
(HUVECs) ....................................................................................................... 85 
2.9.1: Thawing, culture and expansion of HUVECs ..................................... 85 
2.9.2: Characterization of HUVECs .............................................................. 86 
2.9.3: Cell banking of HUVECs .................................................................... 86 
2.10: In vitro vascular assays .......................................................................... 87 
2.10.1: Gel coating ....................................................................................... 87 
2.10.2: Tubule assay formation on Matrigel and Geltrex .............................. 87 
2.10.3: In vitro vascular assay quantification ................................................ 89 
2.11: Statistical analysis .................................................................................. 89 
Chapter 3: A comparative analysis of cell retention responses of 
differently-sourced hMSCs .............................................................................. 90 
3.1: Introduction .............................................................................................. 90 
3.2: Aim and hypotheses ................................................................................. 92 
9 
 
3.2.1: Aim .................................................................................................... 92 
3.2.2: Hypotheses ........................................................................................ 92 
3.3: Materials and methods ............................................................................. 93 
3.3.1: Adhesion assay ................................................................................. 93 
3.3.1.1: Adhesion ligand expression analysis ........................................... 94 
3.3.2: Hypoxia .............................................................................................. 94 
3.3.3: Transwell migration assay ................................................................. 96 
3.4: Results ..................................................................................................... 97 
3.4.1: Characterization of hMSCs ................................................................ 97 
3.4.1.1: Cell morphology........................................................................... 97 
3.4.1.2: Tri-lineage differentiation ............................................................. 98 
3.4.1.3: Immunophenotype ....................................................................... 98 
3.4.2: Attachment Assays .......................................................................... 105 
3.4.2.1: Cell attachment quantification .................................................... 105 
3.4.2.2: Attachment of differently-sourced hMSCs ................................. 106 
3.4.2.3: Comparing the effect of different sJag1 and sDll4 concentrations 
on the adhesion of commercial hBM-MSCs ............................................ 109 
3.4.2.4: Beta integrin staining for commercial hBM-MSCs ...................... 111 
3.4.3: Effect of low oxygen on the migration abilities of commercial low-serum 
hBM-MSCs ................................................................................................ 113 
3.5: Discussion .............................................................................................. 116 
Chapter 4: Optimization of endothelial cell in vitro vascular assays as 
platforms to examine the supportive role of hMSCs in ischemic injury .... 123 
4.1: Introduction ............................................................................................ 123 
4.2: Aims and hypotheses ............................................................................. 126 
4.2.1: Aims ................................................................................................. 126 
4.2.2: Hypotheses ...................................................................................... 126 
4.3: Materials and methods ........................................................................... 127 
4.4: Results ................................................................................................... 127 
4.4.1: Cell morphology and immunostaining .............................................. 127 
4.4.2: Hypoxic chamber oxygen measurements ........................................ 130 
4.4.3: Branch network formation on gel coated wells ................................. 131 
10 
 
4.4.4: Time lapse experiment for vascular tubule formation ....................... 131 
4.4.5: Effect of cell seeding density, passage number and oxygen tension on 
vascular efficiency ..................................................................................... 133 
4.4.6: Cost comparison of Matrigel and Geltrex at 55 µl and 35 µl ............. 135 
4.4.7: Cell morphology and vascular network formation in younger and older 
HUVECs .................................................................................................... 138 
4.4.8: Manual versus automated counting techniques ............................... 139 
4.4.9: Multivariate analysis of the effect of passage number, type of matrix 
and matrix volume in tubule angiogenesis assays ..................................... 141 
4.5: Discussion .............................................................................................. 143 
Chapter 5: Effect of vasculogenic enhancement potential of hMSCs from 
different sources ............................................................................................ 147 
5.1: Introduction ............................................................................................ 147 
5.2: Aim and hypotheses ............................................................................... 149 
5.2.1: Aim .................................................................................................. 149 
5.2.2: Hypotheses ...................................................................................... 149 
5.1 Materials and methods ............................................................................ 150 
5.2.3: Cell staining to distinguish hMSCs from HUVECs ............................ 150 
5.2.4: Co-culture vascular assay ................................................................ 150 
5.2.5: Vascular support assay .................................................................... 152 
5.3: Results ................................................................................................... 153 
5.3.1: Cell morphology ............................................................................... 153 
5.3.2: qPCR ............................................................................................... 154 
5.3.3: Co-culture assays ............................................................................ 160 
5.3.3.1: Staining of cell monolayer with viable cell fluorescent dyes ....... 160 
5.3.3.2: Interaction of hMSCs with HUVECs in co-culture assays .......... 161 
5.3.3.3: Branch point quantification of co-culture assays using P10 
HUVECs and individual donor P5 (PDL 7) hBM-MSCs .......................... 167 
5.3.3.4: Average tubule length quantification of co-culture assays using 
P10 HUVECs and individual donor P5 (PDL 7) hBM-MSCs ................... 169 
5.3.3.5: Cumulative tubule length quantification of co-culture assays using 
P10 HUVECs and individual donor P5 (PDL 7) hBM-MSCs ................... 170 
5.3.3.6: Quantification of vessel-like networks in the presence of 
commercial hBM-MSC/HUVEC co-cultures ............................................ 172 
11 
 
5.3.3.7: Average tubule length quantification of co-culture assays using 
P10 HUVECs and commercial low serum hBM-MSCs ........................... 175 
5.3.3.8: Cumulative tubule length quantification of co-culture assays using 
P10 HUVECs and commercial low serum hBM-MSCs ........................... 175 
5.3.3.9: Quantification of P11 hUC-MSCs/HUVECs vascular structures 176 
5.3.4: Testing the functionality of commercial hBM-MSCs in support assays
 .................................................................................................................. 178 
5.4: Discussion .............................................................................................. 181 
Chapter 6: Discussion and future work ........................................................ 187 
6.1: Key findings, process development and limitations ................................ 187 
6.2: Future work ............................................................................................ 191 
Chapter 7: References.................................................................................... 194 
Chapter 8: Appendices................................................................................... 227 
8.1: Appendix A Analysis of the effect of passage number, type of matrix and 
matrix volume on number of branch points ................................................... 227 
8.2: Appendix B Effect of matrix volume and type of matrix on vascular network 
formation in co-cultures ................................................................................. 229 
8.3: Appendix C Co-culture optimization study .............................................. 231 
8.3.1: Effect of commercial low-serum hMSCs:HUVECs ratio and type of 
matrix on vascular efficiency ...................................................................... 232 
8.3.2: Effect of low oxygen and type of matrix on vascular efficiency ......... 235 
12 
 
List of figures 
Figure 1-1: Different cell types in the heart (Xin et al., 2013). ............................. 30 
Figure 1-2: Notch signalling pathway- Notch receptors can be found on the cell 
surface. When Notch ligands bind to the Notch receptors (Notch1, Notch2, 
Notch3, and Notch4), two proteolytic cleavages take place leading to the release 
of the active form of Notch (NIC). NIC then migrates to the nucleus and binds to 
the transcription factor RBP-jk (recombination signal binding protein for the 
immunoglobulin kappa j region) and controls the transcription of specific genes 
(Rizzo et al., 2014). ............................................................................................ 60 
Figure 1-3: Quality by design (QbD) concept as presented by the FDA ............. 70 
Figure 2-1:A) Set up for oxygen chamber measurement B) oxygen sensors were 
attached to the chambers C) the partial pressure of oxygen (PO2) in the chambers 
was measured in a 5%CO2/20% O2 incubator to ensure optimum growth 
environment for the cells..................................................................................... 85 
Figure 2-2: Diagram summarizing experimental setup for vascular tubule assays.
 ........................................................................................................................... 88 
Figure 3-1: Cell morphology characterization of hMSCs after 5 days in culture. (A) 
Individual donor gx11 P4 (PDL 5) hBM-MSCs and (B) Individual donor P6 (PDL 8) 
gx11 hBM-MSCs were expanded in complete medium (C) PDL 14 commercial 
hBM-MSCs (D) and PDL 17 hBM-MSCs were expanded in their low-serum 
medium (E) P11 hUC-MSCs and (F) P13 hUC-MSCs were expanded in complete 
medium. Scale bars = 400 µm. ........................................................................... 97 
Figure 3-2: All different source hMSCs successfully underwent osteogenic, 
adipogenic and chondrogenic differentiation. hMSCs were stained with Alizarin 
Red for osteogenesis after 30 days in culture (4, 5 and 6), Oil-Red-O for 
adipogenesis after 14 days in culture (7, 8 and 9) and Alcian Blue for 
chondrogenesis after 23 days in culture (10, 11 and 12) respectively. Scale bars = 
200 μm (1, 2, 3 and 4, 5 and 6), 50 µm (7, 8 and 9) and 100 µm (10, 11 and 12).
 ........................................................................................................................... 98 
Figure 3-3: Immunophenotype by flow cytometry analysis of individual donor P6 
(PDL 8) hBM-MSCs expanded in complete medium. (A) isotype controls were run 
in parallel to the experimental samples. (B, 1) results reported positive expression 
of hMSC markers (CD90, CD73, and CD105); (B, 2) less than 1% of hMSCs 
expressed negative markers (CD45, CD34, and CD11b). The red horizontal line 
on each histogram represents the percentage of positive cells for each surface 
protein. ............................................................................................................. 100 
Figure 3-4: Immunophenotype by flow cytometry analysis of low-serum PDL 14 
hBM-MSCs. (C) isotype controls were run in parallel to the experimental samples. 
(D, 1) results reported positive expression of hMSC markers (CD90, CD73, and 
CD105); (D, 2) less than 1% of hMSCs expressed negative markers (CD45, 
13 
 
CD34, and CD11b). The red horizontal line on each histogram represents the 
percentage of positive cells for each surface protein. ....................................... 101 
Figure 3-5: Immunophenotype by flow cytometry analysis of low-serum PDL 17 
hBM-MSCs. (E) isotype controls were run in parallel to the experimental samples. 
(F, 1) results reported positive expression of hMSC markers (CD90, CD73, and 
CD105); (F, 2) less than 1% of hMSCs expressed negative markers (CD45, 
CD34, and CD11b). The red horizontal line on each histogram represents the 
percentage of positive cells for each surface protein. ....................................... 102 
Figure 3-6: Immunophenotype by flow cytometry analysis of low-serum P11 hUC-
MSCs. (G) isotype controls were run in parallel to the experimental samples. (H, 
1) results reported positive expression of hMSC surface markers (CD90, CD73, 
and CD105); (H, 2) less than 1% of hMSCs expressed negative markers (CD45, 
CD34, and CD11b). The red horizontal line on each histogram represents the 
percentage of positive cells for each surface protein. ....................................... 103 
Figure 3-7: Immunophenotype by flow cytometry analysis of low-serum P13 hUC-
MSCs. (I) isotype controls were run in parallel to the experimental samples. (J, 1) 
results reported positive expression of hMSC surface markers (CD90, CD73, and 
CD105); (J, 2) less than 1% of hMSCs expressed negative markers (CD45, 
CD34, and CD11b). The red horizontal line on each histogram represents the 
percentage of positive cells for each surface protein. ....................................... 104 
Figure 3-8: Sample phase contrast images of P11 hUC-MSCs after 20 min of 
adhesion on FN coated wells. Cells were quantified using the ImageJ cell plugin 
software. Scale bars = 1000 µm. ...................................................................... 105 
Figure 3-9: (A) Quantification of cell count adhesion of P4 (PDL 5) gx11 hBM-
MSCs and P6 (PDL 8) gx11 hBM-MSCs on FN coated surfaces at 20 min and 45 
min. The data indicated the mean ± SEM of triplicate samples from 3 independent 
experiments. (B) Raw data from (A) of the three independently repeated 
experiments. ..................................................................................................... 106 
Figure 3-10: (A) Quantification of cell count adhesion of PDL 15 commercial hBM-
MSCs on FN coated surfaces at 20 min and 45 min. The data indicated the mean 
± SEM of triplicate samples from 5 independent experiments. (B) Raw data from 
(A) of the four independently repeated experiments. ........................................ 107 
Figure 3-11: Comparison of cell adhesion using P11 (A) and P13 (B) hUC-MSCs 
at 20% and 2% oxygen tensions for 20 min and 45 min time points. (C) 
Comparison of P11 and P13 hUC-MSCs at different conditions. The results in (A), 
(B) and (C) indicated the mean ± SEM of triplicate samples from n = 4 
independent experiments. ................................................................................ 108 
Figure 3-12: Effect of different sJag1 and sDll4 concentrations on the adhesion of 
PDL 15 commercial hBM-MSCs. Cells were seeded on FN coated plates at 5 
µg/ml and 20 µg/ml respectively. The data in (A) indicates the mean ± SEM of 
triplicate samples from 3 independent experiments. The data in (B) indicates the 
mean ± SD of triplicate samples from 2 independent experiments. .................. 110 
14 
 
Figure 3-13: (A) Positive staining for total (stained red) and active integrin β-1 
(stained green) using commercial low-serum PDL15 hBM-MSCs primed with 
different concentrations of sJag1 after 45 min adhesion at 20% O2. DAPI stain (in 
blue) was performed to visualize the nuclei of the cells. Scale bars = 200 µm. (B) 
Quantification of cell fluorescence using ImageJ, where mean intensity 
represented integrated density/area occupied by integrin β-1. The data indicated 
the mean ±SD of five pictures of a well for sJag1 at 300 ng/ml, 500 ng/ml and 800 
ng/ml respectively, and triplicate values for UT with each value representing five 
pictures per well. ............................................................................................... 112 
Figure 3-14: (A) Representative transwell migration phase contrast images of 
normoxic PDL 15 commercial hBM-MSCs. Assays were performed in ambient 
oxygen conditions. Scale bars = 200 μm. (B) Quantification of the number of 
migrated cells across fibronectin. The data in indicated the mean ± SEM of 
triplicate samples from 3 independent experiments. ......................................... 113 
Figure 3-15: (A) Representative transwell migration phase contrast images of 
hypoxic PDL 15 commercial hBM-MSCs for each independently Assays were 
carried out in ambient oxygen conditions. Scale bars = 200 μm. (B) Quantification 
of the number of migrated cells across fibronectin. The data in indicated the mean 
± SEM of triplicate samples from 3 independent experiments. (C) Raw data from 
(B) of the three independently repeated experiments. ...................................... 114 
Figure 3-16: Quantification of number of migrated cells using either normoxic 
hMSCs or hypoxic hMSCs. Experiments were carried out at ambient oxygen 
conditions. The data indicated the mean ± SEM of triplicate samples from 3 
independent experiments. ................................................................................ 115 
Figure 4-1: Morphology of P9 HUVECs. Representative phase-contrast images of 
P9 HUVECs displaying a cobblestone morphology. Scale bars = 1000 µm. ..... 127 
Figure 4-2: Immunostaining. Characterization of P7 HUVECs. Cells were stained 
for the expression of the endothelial markers: vWF and CD31. After three days in 
culture, HUVECs showed the expression of vWF and CD31 respectively (A and 
C). Controls for both markers were negative for the expression of vWF and CD31 
(B and D). Nuclei were stained with 4’, 6-Diamidino-2-phenylindole (DAPI). Scale 
bars = 200 µm. ................................................................................................. 128 
Figure 4-3: Immunostaining. Characterization of green fluorescent protein (GFP) 
stained P13 HUVECs. Cells were stained for the expression of the endothelial 
markers: vWF and CD31. After one day in culture, HUVECs showed the 
expression of vWF and CD31 respectively (A and C). Controls for both markers 
were negative for the expression of vWF and CD31 (B and D). Nuclei were 
stained with DAPI. Scale bars = 200 µm. ......................................................... 129 
Figure 4-4: Hypoxic chamber oxygen measurements. Oxygen tension was 
measured every minute by Oxy-4 using fibre optic transmission. The oxygen 
measurement was done over 24 hours. ............................................................ 131 
15 
 
Figure 4-5: Branch network formation on gel coated wells. (A) Representative 
image showing network formation after 18 hours under an inverted light 
microscope. Scale bars = 1000 µm. ................................................................. 131 
Figure 4-6: Time course dynamics of P9 HUVECs after plating on Matrigel at 35 
µl (A) and 55 µl (B) and Geltrex at 35 µl (C) and 55 µl (D). Images were taken 
every 3 hours. Scale bars = 1000 µm. .............................................................. 133 
Figure 4-7: (A-C) Phase contrast representative images showing tubule network 
formation of P9 HUVECs on (A) Cell Start, (B) GFR Matrigel, and (C) GFR 
Geltrex. Tubule network formation was not observed on Cell Start (A). Pictures 
were taken at 10X (A) and 4X (B and C). Scale bars = 400 μm (A), 1000 μm (A 
and B). .............................................................................................................. 134 
Figure 4-8: Phase contrast representative images of tubule networks formed 
using P10 HUVECs in GFR Matrigel (A) and GFR Geltrex (B). Three different 
seeding densities were used: 0.67 x 105 cells/ml, 1 x 105 cells/ml and 1.3 x 105 
cells/ml Tubules were imaged after 18 hours (ambient oxygen 20%). Scale bars = 
1000 µm. .......................................................................................................... 134 
Figure 4-9: Phase contrast representative images of tubule networks formed 
using P10 HUVECs in GFR  Matrigel (A) and GFR Geltrex (B). Three different 
seeding densities were used: 0.67 x 105 cells/ml, 1 x 105 cells/ml and 1.3 x 105 
cells/ml. Tubules were imaged after 18 hours (ambient oxygen 2%). Scale bars = 
1000 µm. .......................................................................................................... 135 
Figure 4-10: Branch point quantification for different seeding densities. Effect of 
cell seeding density and oxygen tension on vascular network efficiency using 
HUVECs at P7 and P10 at low oxygen (2% O2) and ambient oxygen (20% O2). 
The error bars indicate the mean ± SEM of n = 3 experiments for each condition 
performed on different HUVEC donors with triplicate wells for each experiment. 
There were no statistically significant differences between seeding densities, 20% 
O2 versus 2% O2, Matrigel versus Geltrex groups, and 55 µl versus 35 µl group 
means as determined by two-way ANOVA (p > 0.05). ...................................... 137 
Figure 4-11: A) Phase contrast representative images of P7, P10, P13 and P15 
HUVECs after four days of culture. Scale bars = 400 µm. (B) Effect of passage 
number on vascular efficiency for GFR Matrigel and GFR Geltrex respectively at 
low (2%) oxygen. Scale bars = 1000 µm. The data shows that the endothelial 
cells are able to still proliferate in culture and form robust branches at the higher 
passage numbers (> P10). ............................................................................... 138 
Figure 4-12: Image before (A) and after (B) being processed using the 
angiogenesis imageJ analyser. Branches are shown in yellow. Branch points are 
shown in pink. Meshes represent the enclosed areas between the branches. 
Images were taken at x4 magnification. Scale bar = 1000 μm. ......................... 139 
Figure 4-13: Data comparison between manual and automated counting 
techniques for A) P10 HUVECs B) P13 HUVECs C) P7 HUVECs and D) P15 
HUVECs . All conditions were carried out using a seeding density 1 x 105 cells/ml. 
The error bars indicate the mean ± SEM of n = 3 experiments for each condition 
16 
 
performed on different HUVEC donors with triplicate wells for each experiment. 
One Way ANOVA for each group- Bonferroni post-hoc analysis revealed p > 0.05.
 ......................................................................................................................... 140 
Figure 4-14: Branch point quantification for P7, P10, P13 and P15 HUVECs at 
high (55 µl) and low (35 µl) matrix volumes. The error bars indicate the mean ± 
SEM of n = 3 experiments for each condition performed on different HUVEC 
donors with triplicate wells for each experiment. There were statistically significant 
differences between group means for passage number as determined by two-way 
ANOVA, Bonferroni post-hoc analysis. One-way ANOVA, Bonferroni post-hoc 
analysis revealed significant differences between Matrigel 55 µl and Geltrex 35 µl 
for the P13 HUVECs (p ≤ 0.05). Matrigel 55 µl was used as a control group for 
comparison. Refer to text for a detailed description of the results. .................... 141 
Figure 4-15: Number of meshes quantification for P7, P10, P13 and P15 HUVECs 
at high (55 µl) and low (35 µl) matrix volumes. There were no statistically 
significant differences between group means for passage number as determined 
by two-way ANOVA, post-hoc analysis (p = 0.9647). Values are mean ± SEM of n 
= 4 (P7 HUVECs) and n = 3 (P10 to P15 HUVECs) experiments performed on 
different HUVEC donors with triplicate wells for each experiment. ................... 142 
Figure 5-1: Diagram summarizing experimental setup for co-culture assay. ..... 151 
Figure 5-2: Diagram summarizing experimental setup for support assay. ........ 152 
Figure 5-3: Cell morphology of hMSCs after 5 days in culture. Individual donor 
gx11 P5 (PDL 7) hBM-MSCs at 20% O2 (A) and 2% O2 (B) were expanded in 
complete medium; PDL 14 commercial hBM-MSCs at 20% O2 (C) and 2% O2 (D) 
were expanded in their own High Performance Medium; P11 hUC-MSCs at 20% 
O2 (E) and 2% O2 (F) were expanded in complete medium. Scale bars = 400 µm.
 ......................................................................................................................... 153 
Figure 5-4: The normalised relative expression of HIF1, JAG1, HES1 and HEY1, 
was analysed for normoxic or hypoxic individual donor P5 (PDL 7) hBM-MSCs 
after they were preconditioned with either sJag1 or sDll4 or left untreated and 
seeded on FN-coated wells for 45 min. Data for A, B, C and D are shown as one 
independent experiment with duplicate observations for each sample (UT, sJag1, 
and sDll4) as mean ± SD. ................................................................................. 155 
Figure 5-5: The normalised relative expression of (A) HIF1 (B) HIF3, (C) JAG1, 
(D) HES1 and (E) HEY1 was analysed for normoxic or hypoxic commercial PDL 
14 hBM-MSCs after they were preconditioned with either sJag1 or sDll4 or left 
untreated and seeded on FN-coated wells for 45 min. Gene expression was 
normalised to 18S and control group. Data are shown for single representative 
experiments carried out with separately prepared cell suspensions on 2 different 
days with duplicate observations for each bar as mean ± SD. .......................... 157 
Figure 5-6: The normalised relative expression of (A) HIF1 (B) JAG1, (C) DLL4, 
(D) HES1 and (D) HEY1 was analysed for normoxic or hypoxic P11 hUC-MSCs 
after they were preconditioned with either sJag1 or sDll4 or left untreated and 
seeded on FN-coated wells for 45 min. Data are shown for single representative 
17 
 
experiments carried out with separately prepared cell suspensions on 2 different 
days with duplicate observations for each bar as mean ± SD. .......................... 159 
Figure 5-7: Representative phase contrast and staining images of P5 (PDL 7) 
gx11 hBM-MSCs and P10 HUVECs with viable fluorescent cell dyes for in vitro 
vascular assays. Successful staining was confirmed by observing the uptake of 
the dye using a fluorescence microscope where hMSCs were stained in red and 
HUVECs were stained in green. Scale bars = 400 µm. .................................... 160 
Figure 5-8: Representative staining images of P10 HUVECs (control groups) in 
(A) phase contrast and (B) stained with CellTracker Green CMFDA using Matrigel 
and Geltrex. Experiments were carried out at 20% O2 and 2% O2. Scale bars = 
400 µm. ............................................................................................................ 161 
Figure 5-9: Co-culture vessel formation after 18 hours of P5 (PDL 7) gx11 hBM-
MSCs (in red) and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments 
were carried out on GFR Matrigel. Images were visualised using a fluorescence 
microscope. Yellow arrows represent the hBM-MSCs bridging between HUVECs. 
White arrows represent the hBM-MSCs surrounding the network structures. Scale 
bars = 400 µm. ................................................................................................. 162 
Figure 5-10: Co-culture vessel formation after 18 hours of P5 (PDL 7) gx11 hBM-
MSCs (in red) and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments 
were carried out on GFR Geltrex. Images were visualised using a fluorescence 
microscope. Yellow arrows represent the hBM-MSCs bridging between HUVECs. 
White arrows represent the hBM-MSCs surrounding the network structures. Scale 
bars = 400 µm. ................................................................................................. 163 
Figure 5-11: Co-culture vessel formation after 18 hours of commercial PDL14 
hBM-MSCs (in red) and P10 HUVECs (in green) seeded at a 1:1 ratio. 
Experiments were carried out on GFR Matrigel. Images were visualised using a 
fluorescence microscope. Yellow arrows represent the hBM-MSCs bridging 
between HUVECs. White arrows represent the hBM-MSCs surrounding the 
network structures. Scale bars = 400 µm. ........................................................ 164 
Figure 5-12: Co-culture vessel formation after 18 hours of commercial PDL14 
hBM-MSCs (in red) and P10 HUVECs (in green) seeded at a 1:1 ratio. 
Experiments were carried out on GFR Geltrex. Images were visualised using a 
fluorescence microscope. Yellow arrows represent the hBM-MSCs bridging 
between HUVECs. White arrows represent the hBM-MSCs surrounding the 
network structures. Scale bars = 400 µm. ........................................................ 165 
 Figure 5-13: Co-culture vessel formation after 18 hours of P11 hUC-MSCs (in 
red; hUC-MSCs were previously cultured in either 20% O2 or 2% O2) and P10 
HUVECs (in green; previously cultured in ambient oxygen conditions). 
Experiments were carried out using either GFR Matrigel or GFR Geltrex. Images 
were visualised using a fluorescence microscope. White arrows represent the 
hUC-MSCs surrounding the HUVEC structures. Scale bars = 400 µm. ............ 166 
Figure 5-14: (A) Positive controls were run for the co-culture assays by seeding 
P10 HUVECs on either GFR Matrigel or GFR Geltrex. Co-cultures were carried 
18 
 
by seeding P10 HUVECs with either (B) normoxic P5 (PDL 7) gx11 hBM-MSCs or 
(C) hypoxic P5 (PDL 7) gx11 hBM-MSCs mixed at a ratio of 1:1 and seeded on 
either 35 µl of GFR Matrigel or 35 µl of GFR Geltrex. Experiments were carried 
out at 2% O2. Scale bars = 1000 µm. ............................................................... 167 
Figure 5-15: Branch point quantification of P10 HUVECs seeded with either (A) 
gx11 P5 (PDL 7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs previously 
cultured under normoxic (20% O2) and hypoxic (2% O2) conditions respectively 
for 5 days. Error bars represent observations of three technical replicates for each 
biological repeat as mean ± SD. Experiments were carried out twice using hMSC 
batches isolated and expanded from two different donors; A (gx11) and B (gx10).
 ......................................................................................................................... 169 
Figure 5-16: Average tubule length quantification of P10 HUVECs seeded with 
either (A) gx11 P5 (PDL 7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs 
previously expanded in normoxic (20% O2) or hypoxic (2% O2) conditions. Error 
bars represent observations of three technical replicates for each biological 
repeat as mean ± SD. Experiments were carried out twice using hBM-MSC 
batches isolated and expanded from two individual donors; A (gx11) and B 
(gx10). .............................................................................................................. 170 
Figure 5-17: Cumulative tubule length quantification of P10 HUVECs seeded with 
either (A) gx11 P5 (PDL 7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs 
previously cultured under normoxic (20% O2) or hypoxic (2% O2) conditions. Error 
bars represent observations of three technical replicates for each biological 
repeat as mean ± SD. Experiments were carried out twice using hBM-MSC 
batches isolated and expanded from two individual donors; A (gx11) and B 
(gx10). .............................................................................................................. 171 
Figure 5-18: (A) Positive controls were run for the co-culture assays by seeding 
P10 HUVECs on either GFR Matrigel or GFR Geltrex. Co-culture assays were 
carried out by seeding P10 HUVECs with either (B) normoxic commercial PDL14 
hBM-MSCs or (C) hypoxic commercial PDL14 hBM-MSCs mixed at a ratio of 1:1 
and seeded on either 35 µl of GFR Matrigel or 35 µl of GFR Geltrex. Experiments 
were carried out at 2% O2. Scale bars = 1000 µm. ........................................... 172 
Figure 5-19: Branch point quantification for P10 HUVECs seeded at a 1:1 ratio 
with commercial PDL14 hBM-MSCs expanded in normoxic (20% O2) and hypoxic 
(2% O2) conditions. The results in (A), (B) and (C) are shown as three 
independent experimental repeats using different hMSC batches derived from the 
same donor. Error bars represent observations of three technical replicates for 
each experimental repeat as mean ± SD. Cumulative data is shown in (D) and 
error bars represent the mean ± SEM of the three independent experimental 
repeats. Raw data of the three repeated experiments are shown in (E). .......... 174 
Figure 5-20: Average tubule length quantification for P10 HUVECs seeded with 
commercial PDL 14 hBM-MSCs which were previously cultured under normoxic 
(20% O2) and hypoxic (2% O2) conditions respectively. Error bars represent the 
mean ± SEM of three independent experimental repeats carried out using 
different hMSC batches derived from the same donor. Refer to text for a detailed 
description of results. ........................................................................................ 175 
19 
 
Figure 5-21: Cumulative tubule length quantification for P10 HUVECs seeded with 
commercial PDL 14 hBM-MSCs which were previously cultured under normoxic 
(20% O2) and hypoxic (2% O2) conditions respectively. Error bars represent the 
mean ± SEM of three independent experimental repeats carried out using 
different hMSC batches derived from the same donor. Refer to text for a detailed 
description of results. ........................................................................................ 176 
Figure 5-22: (A) Positive controls were run for the co-culture assays by seeding 
P10 HUVECs on either GFR Matrigel or GFR Geltrex. Co-cultures were carried 
out with either (B) normoxic P11 hUC-MSCs or (C) hypoxic P11 hUC-MSCs 
mixed at a ratio of 1:1 with P10 HUVECs using either 35 µl of GFR Matrigel or 35 
µl of GFR Geltrex. Experiments were carried out at 2% O2. No tubule formation 
was observed after 18 hours incubation. n = 8 independent experimental repeats 
were carried out using different hMSC batches derived from the same donor. 
Scale bars = 1000 µm. ..................................................................................... 177 
Figure 5-23: Vessel formation in support assays after 18 hours of seeding P10 
HUVECs (green cells) on top of the commercial PDL14 hBM-MSCs (red cells) 
stacked with either Matrigel or Geltrex and previously left untreated or primed with 
either sJag1 or sDll4. HUVECs-only positive controls were run in parallel. Scale 
bars = 400 µm. ................................................................................................. 178 
Figure 5-24: Phase contrast representative images of (A) HUVECs-only control 
groups (B) support assays using normoxic hBM-MSCs and (C) support assays 
using hypoxic hBM-MSCs. Scale bars = 1000 µm. ........................................... 179 
Figure 5-25: Branch point quantification of vascular support by commercial PDL14 
hBM-MSCs previously cultured under hypoxic (2% O2) or normoxic (20% O2) 
conditions followed by priming with either sJag1, sDll4 or left untreated (UT). Error 
bars represent the mean ± SEM of n = 3 independent experimental repeats 
carried out using different hBM-MSC batches derived from the same donor. ... 180 
Figure 8-1: Interaction plot comparing the effect of passage number for GFR 
Matrigel and GFR Geltrex at higher (55 µl) and lower (35 µl) volumes. ............ 227 
Figure 8-2: Interaction plot comparing the effect of passage number for (A) GFR 
Matrigel and (B) GFR Geltrex at higher (55 µl) and lower (35 µl) volumes. ...... 228 
Figure 8-3: Co-culture vessel formation after 18 hours of individual donor gx11 P5 
(PDL 7) hBM-MSCs (in red) and P10 HUVECs (in green; previously cultured in 
ambient oxygen conditions) seeded at a 1:1 ratio. Experiments were carried out 
on GFR Matrigel (M) and GFR Geltrex (G) at 35 µl and 55 µl respectively. Images 
were visualised using a fluorescence microscope. Yellow arrows represent the 
hBM-MSCs bridging between HUVECs. White arrows represent the hBM-MSCs 
co-localizing with the HUVECs. Scale bars = 1000 µm. .................................... 229 
Figure 8-4: Representative phase contrast images of gx11 P5 (PDL 7) hBM-
MSCs: P10 HUVECs co-cultures seeded at a 1:1 ratio for a total cell 
concentration of either 0.3 x 105 cell/ml, 0.5 x 105 cell/ml or 0.67 x 105 cell/ml 
respectively using either 35 µl or 55 µl of GFR Matrigel and GFR Geltrex 
respectively. Scale bars = 2000 µm. ................................................................. 230 
20 
 
Figure 8-5: Branch point quantification of gx11 P5 (PDL 7) hBM-MSCs: P10 
HUVECs co-cultures seeded at a 1:1 ratio for a total cell concentration of either 
0.3 x 105 cell/ml, 0.5 x 105 cell/ml or 0.67 x 105 cell/ml respectively. Experiments 
were carried out at 2% O2. The data indicated the mean ± SEM of triplicate 
samples from 3 independent experiments using different hBM-MSC batches 
derived from the same donor (gx11 donor). ...................................................... 231 
Figure 8-6: Sample phase contrast representative images of tubule networks 
formed in commercial PDL 14 hBM-MSCs:P10 HUVECs co-cultures seeded at 
1:1, 1:4 and 4:1 ratios on 35 µl Gelltrex. Experiments were carried out at 2% O2. 
Scale bars = 1000 µm ...................................................................................... 232 
Figure 8-7: Branch point quantification of normoxic commercial PDL 14 hBM-
MSCs:P10 HUVECs co-cultures seeded at 1:1, 1:4 and 4:1 ratios. Experiments 
were carried out at 2% O2. The data indicated the mean ± SEM of triplicate 
samples from 3 independent experiments using different hBM-MSC batches 
derived from the same donor. Refer to text for a detailed description of the results.
 ......................................................................................................................... 233 
Figure 8-8: Branch point quantification for hypoxic commercial PDL 14 hBM-
MSCs:P10 HUVECs co-cultures seeded at 1:1, 1:4 and 4:1 ratios. Experiments 
were carried out at 2% O2. The data indicated the mean ± SEM of triplicate 
samples from 3 independent experiments using different hBM-MSC batches 
derived from the same donor. Refer to text for a detailed description of the results.
 ......................................................................................................................... 234 
Figure 8-9: Comparative study between co-cultures carried out using normoxic 
(20% O2) and hypoxic (2% O2) commercial PDL 14 hBM-MSCs at 1:1 and 4:1 
MSC:HUVEC ratios using either GFR Matrigel (M) or Geltrex (G). Experiments 
were performed under 2% O2. The data indicated the mean ± SEM of triplicate 
samples from 3 independent experiments using different hBM-MSC batches 
derived from the same donor. Refer to text for a detailed description of the results.
 ......................................................................................................................... 235 
 
21 
 
 
List of tables  
Table 1-1: Summary of the drawbacks of using serum in cell culture systems. .. 34 
Table 1-2: Mode of action of MSCs. ................................................................... 54 
Table 1-3: Summary table of in vivo angiogenesis assays. ................................ 65 
Table 1-4: Summary of advantages and disadvantages of in vitro and in vivo 
angiogenesis assays. ......................................................................................... 66 
Table 2-1: list of isotype controls used for the staining of hMSCs. ...................... 80 
Table 2-2: List of negative and positive antibodies used for the staining of hMSCs.
 ........................................................................................................................... 80 
Table 2-3: Summary of cycling conditions for qPCR. .......................................... 83 
Table 2-4: List of qPCR primers used. ................................................................ 83 
Table 3-1: List of antibodies used to assess the adhesion of MSCs on FN 
surfaces. ............................................................................................................. 94 
Table 3-2: Summary of attachment assays......................................................... 95 
Table 3-3: Summary of transwell migration assays. ........................................... 96 
Table 3-4: Immunophenotypic data for differently-sourced hMSCs. ................... 99 
Table 4.1: Cost comparison for GFR Matrigel and GFR Geltrex using 55 µl and 35 
µl matrix volumes. The CoG analysis indicated a 25% reduction in costs when 
using the lower matrix volumes (35 µl). ............................................................ 136 
22 
 
List of abbreviations 
AM - Acute myocardial infarction 
AMI - Acute myocardial infacrtion  
AM-MSC - Amniotic membrane mesenchymal stromal cell 
ANOVA - Analysis of variance  
AT - Adipose tissue 
bFGF - Basic fibroblast growth factor 
BM - Bone marrow 
BM-MNC - Bone marrow mononuclear cell 
BM-MSC - Bone marrow mesenchymal stromal cell 
BSA - Bovine serum albumin 
CAM - Chick chorioallantoic membrane 
cDNA - Complementary DNA 
CHD - Coronary heart disease 
CM - Cardiomyocyte 
CO2 - Carbon dioxide  
CPP - Critical process parameter 
CQA - Critical quality attribute 
CSC - Canadian Cardiovascular Society 
CSC - Cardiac stem cell 
CXCR4 - C-X-C chemokine receptor type 4 
DAPI - 4, 6-diamidino-2-phenylindole 
dH2O - Distilled water 
Dll - Delta-like ligand  
DMEM - Dulbecco's Modified Eagle's Medium 
DMSO - Dimethyl sulfoxide 
DNA - Deoxyribonucleic acid 
DOE - Design of experiments 
EBM-2 - Endothelial Growth Basal Medium-2 
EC - Endothelial cell 
23 
 
ECM - Extracellular matrix 
EDTA - Ethylenediaminetetraacetic acid 
EDV - End-diastolic volume  
EF - Ejection fraction  
EGFP - Enhanced green fluorescent protein 
EGM-2 - Endothelial Growth Medium-2 
ELISA - Enzyme-linked immunosorbent assay 
EMA - European Medicines Agency 
EPC - Endothelial progenitor cell 
ESC - Embryonic stem cell 
ESV - End-systolic volume  
FBS - Foetal bovine serum 
FDA - Food and Drug Administration 
FGF - Fibroblast growth factor  
FN - Fibronectin 
G-CSF - Granulocyte – colony stimulating factor 
gDNA - Genomic DNA 
GFR - Growth factor reduced  
GvHD - Graft versus host disease 
HCL - Hydrochloric acid 
hEGF - Human epidermal growth factor  
hESC - Human embryonic stem cell 
HGF - hepatocyte growth factor  
HIF- Hypoxia-inducible factor  
HLA-ABC - Human leukocyte antigens-ABC  
HMEC - Human microvascular endothelial cell 
hMSC - human mesenchymal stromal cell 
HSC - Hematopoietic stem cell 
hUC-MSC - Human umbilical cord mesenchymal stromal cell  
HUVEC - Human umbilical vein endothelial cell 
ICH - International Conference on Harmonization 
24 
 
IL-1ra - Interleukin-1 receptor antagonist 
iPSC - Induced pluripotent stem cell 
ISCT - International Society for Cellular Therapy 
Jagged - Jag 
KIPV - Key process input variable 
KPOV - Key process output variable 
l - Litre 
LVEF - Left ventricular ejection  
LVGFP - Lentiviral green fluorescent protein  
M- CSF - Macrophage colony-stimulating factor 
MCP-1 - Monocyte chemoattractant protein 1 
mg - Milligram 
MI - Myocardial infarction  
ml - Millilitre 
mm - Millimetre 
MOA - Mechanism of action 
MSC - Mesenchymal stromal cell  
N2 - Nitrogen  
NC - Negative control  
ng - Nanogram 
NRT - No reverse transcriptase control 
NTC - No template control 
O2 - Oxygen 
P - Passage  
PAT - Process analytical technology 
PBS - Phosphate buffered saline 
PDGF - Platelet-derived growth factor 
PDL - Population doubling level 
PFA - Paraformaldehyde 
pO2 - Partial pressure of oxygen  
QbD - Quality by design  
25 
 
QC - Quality control  
qPCR - Quantified polymerase chain reaction 
QTPP - quality target product profile 
R3-IGF-1 - Recombinant 3-insulin-like growth factor-1 
RNA - Ribonucleic acid  
SV - Stroke volume  
T/E - Trypsin/EDTA 
TNF - Tumour necrosis factor  
UC - Umbilical cord  
UCB - Umbilical cord blood 
UT - Untreated  
VEGF - Vascular endothelial growth factor 
VEGFR - Vascular endothelial growth factor receptor 
vWF - Von Willebrand factor 
μm - Micrometre 
 
 
 
26 
 
Chapter 1: Literature review  
1.1: Overview of the vascular system 
The vascular network is organized in a hierarchical fashion and it branches in a 
complex network of vessels which enables the circulation of nutrients as well 
as blood, immune cells and other molecules to the body tissues via diffusion 
and convection (Jain, 2003). The heart pumps oxygenated blood through the 
circulatory system via the arteries. The arteries successively branch into smaller 
branches until they divide into arterioles. These vessels supply blood to the cells 
of the body’s tissues and organs. The arterioles then divide into capillaries, 
which are the smallest blood vessels in the body, and they are the sites 
through which exchange of substances between blood and the cells of tissues 
and organs takes place. As blood flows through the capillaries, oxygen and 
nutrients move out into the cells and waste matter from the cells moves into the 
capillaries. These then merge to form venules and veins which transport the de-
oxygenated blood to the heart and the lungs (Jain, 2003).  
 
Blood cells are composed of two main cell types: endothelial cells 
(ECs) and perivascular cells- also known as pericytes, vascular smooth muscle 
cells or mural cells. ECs line the inner wall of vessels in contact with the 
blood, whilst perivascular cells form a thick wall around the endothelial layer 
(Wanjare et al., 2013). Pericytes are perivascular cells that wrap around the 
endothelial cells of capillaries (diameter <10 μm) and micro-vessels (10 μm - 
100 μm) throughout the body (Crisan et al., 2012). These are usually found at the 
junction points of small vessels and capillaries where they stretch themselves 
along the length of the vessels across several capillaries in the vasculature 
(Armulik et al., 2011). Differently from ECs, pericytes have a prominent round 
nucleus and protruding finger-like extensions that they use to attach to the wall of 
endothelial cells. In addition, they can be easily distinguished from other 
perivascular cells such as smooth muscle cells which can be found wrapping 
around larger blood vessels (Crisan et al., 2012). Previous work showed that 
the EC-pericyte ratio around blood vessels is tissue-specific and that it ranges 
from 1:1 in retina tissues to 10:1 in lungs (Herrmann et al., 2016).  
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Pericytes provide a fundamental structural support role for blood vessels. For 
example, one of their main functions is to prevent blood vessels from 
becoming haemorrhagic and hyperdilated, which can lead to serious 
conditions such as diabetic retinopathy. These particular groups are known 
as microvascular pericytes and they are usually found around the walls of 
capillaries. Here they communicate with endothelial cells via gap junctions 
which in turn control the proliferative abilities of endothelial cells (Berger et 
al., 2005). 
 
1.1.1: The process of vessel formation 
The key processes involved in vessel formation are vasculogenesis and 
angiogenesis. Vasculogenesis is the de novo synthesis of blood vessels from 
endothelial cell precursors (angioblasts) and stem cells, whereas angiogenesis 
is the formation of new blood vessels from existing blood vessels e.g. 
sprouting and branching (Jain, 2003). During embryonic development, one of 
the first organs that forms is the vasculature (Jain, 2003; Velazquez, 2009). 
Firstly, the angioblasts (i.e. endothelial cell precursors) differentiate into 
endothelial cells which ultimately assemble into the immature vascular 
network through vasculogenesis (Carmeliet and Jain, 2011). The vascular 
network then expands through sprouting of vessels via angiogenesis. The 
immature vascular network is stabilized through the recruitment of mural cells 
(vascular smooth muscle cells and pericytes), and the generation of the 
extracellular matrix (ECM). Branching, remodelling, and pruning of the vascular 
network is achieved using signalling pathways involved in branch formation as 
well as cues coming from various basement membranes and ECM components 
(Jain, 2003). 
 
Signalling molecules and mechanical factors triggered by cell-cell contact 
promote the migration of ECs. During angiogenesis, the breakdown of 
proteins of the basal lamina leads to a localized thinning of the basement 
membrane which reduces the stiffness of the ECM (Ingber, 2002). 
Subsequently, the cells adhering to the thinned local sections of the ECM 
experience increased tension on their adhesion receptors. The mechanical 
signals triggered by this change in stiffness are converted into 
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biochemical cues which trigger movement and result in the formation of 
branching patterns characteristic of growing vascular networks (Shin et al., 
2001). Both angiogenesis and vasculogenesis are also key processes during 
wound healing, which consists of the activation and migration of pre-existing 
mature endothelial cells, degradation of the ECM and remodelling of the 
vasculature (Jain, 2003, Velazquez, 2009). 
 
1.1.2: Regulation of angiogenesis by hypoxia 
One of the key variables that decide on the extent of angiogenesis and vessel 
growth is the oxygen level in a given tissue. Moreover, it has been reported that 
a hypoxic environment up-regulates many angiogenic factors including vascular 
endothelial growth factor (VEGF), in both normal and pathological conditions 
(Semenza, 1999). Such growth factors induce endothelial cells to break out of 
their stable positions in the vessel and sprout, branch and pattern in a stable 
network until reaching quiescence (Fraisl et al., 2009; Stamati et al., 2014). The 
up-regulation of angiogenic factors is achieved through the hypoxia-inducible 
factor-1α (HIF-1α). HIFs are a group of transcription factors that are 
expressed by endothelial cells based on the amount of oxygen within the 
cellular environment, especially hypoxia (Krock et al., 2011). Most of the 
tissues in the body have a partial pressure of oxygen (pO2) of 1% to 7%; for 
example bone marrow stem cells can be found in oxygen environments of less 
than 1% whilst blood vessels have a pO2  of 5% to 7% (Krock et al., 2011; 
Kusuma et al., 2014). Several studies have demonstrated that hypoxia is a key 
component of some cellular niches (Kusuma et al., 2014). Furthermore, HIF-1 
promotes angiogenesis and vascular remodelling in wound healing, through the 
mobilization of angiogenic cells from distant sites (including bone marrow, 
pericytes and endothelial cells from other tissues; (Rezvani et al., 2011). Earlier 
studies demonstrated that when constant amounts of the active form of HIF-1α 
were expressed in a mouse skin, this was enough to mobilize circulating 
angiogenic cells and improve wound healing in diabetic mice (Liu et al., 
2008). Several research groups have also reported that subjecting stem cells 
to hypoxia improved their migration abilities in both in vitro and in vivo studies 
(De Becker and Riet, 2016). In support to these findings, It has also been 
shown that decrease in HIF-1α expression causes poor wound 
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vascularization and healing (Zhang et al., 2010). Furthermore, these studies 
suggest that the hypoxia/HIF signalling pathway has a key role in the 
formation of a “normal vasculature” and it could be a key therapeutic target for 
vascular diseases. In addition, since the majority of the tissues in the body have 
a pO2 of ~5% (Krock et al., 2011), it may be beneficial for in vitro experiments to 
be carried out in environments that closely mimic these conditions.  
 
1.2: Dual pumping function of the heart 
The heart is a highly vascularized muscular organ found between the 
sternum (breastbone) and the vertebrae (backbone). Its function is to pump 
blood through the blood vessels for oxygen and nutrient distribution to all cells 
in the body. The heart is divided into four chambers: left and right ventricles 
(lower chambers) and left and right atria (upper chambers). Both atria and 
ventricles act as functional syncytium respectively, meaning that they work 
electrically and mechanically as a single unit. During the cardiac cycle, 
deoxygenated blood coming from the systemic circulation enters the right side 
of the heart which pumps the blood through the pulmonary artery, into the 
pulmonary circulation (closed loop vessels carrying blood between the heart 
and the lungs). Then oxygenated blood coming from the pulmonary 
circulation is returned to the left side of the heart, which pumps the blood 
into the systemic circulation via the aorta (Katz, 2011).  
 
1.2.1: Cell types found in the heart  
The four chambers of the heart are made of different cell types which allow for its 
normal structural, biochemical, mechanical and electrical functioning (Xin et al., 
2013). The cardiac muscle is made of cardiomyocytes (CMs) whilst cardiac 
fibroblasts which make more than 50% of the cells in the heart can be found in 
the cardiac skeleton and within the myocardial interstitium (Xin et al., 2013; 
Furtado et al., 2016;). Fibroblasts are also highly connected to other cell types 
including ECs and cardiomyocytes (Katz et al., 2012; Furtado et al., 2016). The 
coronary arteries, which carry blood between the heart and the lungs, are made 
of smooth muscle cells that allow for the circulation of blood within the heart 
vessels.  
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The electric impulses coming from the sinoatrial node, which is made of a group 
of specialised cardiomyocytes (pacemaker cells) initiate heart contraction. This 
activates the atrioventricular node (found between the atria and the ventricles). 
The ventricles are then made of Purkinje fibres which is another group of 
specialised cardiomyocytes that receive the conductive signal from the 
atrioventricular node to stimulate ventricular contraction (Xin et al., 2013). 
 
  
Figure 1-1: Different cell types in the heart (Xin et al., 2013). 
 
 
1.3: Myocardial infarction and remodelling process  
Heart failure initiated by myocardial infarction (MI) accounts for 29% of deaths 
worldwide, and it is caused by the interruption of the blood supply to a part of the 
heart caused by a blocked coronary artery (Li et al., 2014; Richardson et al., 
2015). The inefficient supply of oxygen to the heart leads to a high loss of mature 
contracting cardiomyocytes in the infarcted zone which is then subject to a 
pathological remodelling process, consisting of an inflammatory response and 
the formation of a dense collagenous scar (Richardson et al., 2015). This scar 
tissue does not have the contractile, mechanical and electrical properties of 
the normal myocardium and it hinders the ability of the heart ventricles to pump 
blood efficiently (Jawad et al., 2007; Richardson et al., 2015). The process of 
wound healing is divided into three stages: inflammation/necrosis, 
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fibrosis/proliferation and long-term remodelling/maturation (Richardson et al., 
2015; Dobaczewski et al., 2010).  
 
During necrosis which lasts for the first week or more of infarct healing in large 
animals and humans, the dying CMs undergo a wound healing process involving 
the secretion of intracellular proteins into the circulation and they trigger an 
inflammatory response (Burchfield et al., 2013). Following this, several 
inflammatory cells such as neutrophils, macrophages, and lymphocytes infiltrate 
in the necrotic tissue within hours of injury and remove the dead myocytes 
(Richardson et al., 2015). Fibroblasts then proliferate to the zone of injury and 
differentiate into myofibroblasts to release extracellular matrix proteins such as 
collagen I and fibronectin (FN) to replace the infarcted tissue with a fibrotic scar, 
this proliferative phase can last from one to several weeks (Burchfield et al., 2013; 
Richardson et al., 2015). The proliferation and activation of the fibroblasts are 
triggered by several cell sources including adult epicardial cells undergoing 
endothelial to mesenchymal transition and collagen-secreting bone marrow-
derived cells (Haudek et al., 2006; Burchfield et al., 2013).  
 
The final phase which is also known as long-term remodelling/maturation lasts a 
couple of months in large animals and humans (Richardson et al., 2015). This 
stage involves the increase in collagen crosslinking as well as the expression of 
cross-linking enzymes and proteoglycans which bind to collagen to support scar 
maturation. The myocyte hypertrophy which involves the increase in size of the 
skeletal muscle and the tightly cross-linked collagen fibres reduces the contractile 
ability and cardiac output of the heart (Richardson et al., 2015). Since the heart 
has limited regenerative abilities after injury, there is a need to develop therapies 
that can target the scar tissue and promote heart regeneration (Bartunek et al., 
2013). 
 
1.3.1: Therapeutic treatments for MI  
Currently, there are no treatments that can reverse the loss of myocardial tissue 
and whilst treatments for heart failure are available, they do not lead to sufficient 
heart recovery (Bartunek et al., 2013). Examples of medical heart failure 
treatments include the use of angiotensin-converting enzyme inhibitors which 
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work by relaxing and opening the blood vessels to reduce the amount of force 
needed by the heart to pump blood (Donnelly and Manning, 2007). Other 
treatments involve the use of beta-adrenoceptor antagonists which reduce the 
myocardial oxygen requirement below the level that would cause angina 
(O’Rourke, 2007). This is a term used to describe the sensation of chest pain 
experienced by several patients and it is caused by the imbalance between 
oxygen supply and oxygen demand in the heart; antianginal therapies can also 
be taken together hence taking advantage of their different modes of action 
(O’Rourke, 2007).  
 
In the case of patients suffering from severe forms of heart failure, their only 
viable alternative is to undergo heart transplantation which is scarce because of 
the high costs associated with it, the lack of donors and the need for patient-
donor matched organs (Zammaretti and Jaconi, 2004; Menasché, 2008). 
Usually, patients are treated with a left ventricular assist device, a mechanical 
pump connected to the myocardium through surgery which enables the heart to 
pump blood (Kirklin et al., 2013; Wilson et al., 2009). The left ventricular assist 
device is sometimes given to patients on the waiting list however, this method 
can prolong the patient’s life for only several weeks or months (Kirklin et al., 
2013; Wilson et al., 2009). As a result, stem cell therapy is increasingly being 
considered as a potential means to trigger innate mechanisms of heart 
regeneration (Bartunek et al., 2013). 
 
1.4: What is regenerative medicine? 
Regenerative medicine is a multidisciplinary approach to heal, replace or 
regenerate organs damaged by age, disease, or trauma (Mao and Mooney, 
2015). The current methods for organ transplantation suffer from severe immune 
complications and lack of donor supply (Mao and Mooney, 2015). For this reason, 
during the past 20 years the cell therapy industry has focused on a combination of 
technologies including the use of soluble molecules such as growth factors, gene 
therapy, stem cell transplantation, tissue engineering and cell reprogramming for 
the treatment of several diseases including diabetes, cardiovascular conditions 
and cancer (Mason and Dunnill, 2008; Ratcliffe et al., 2011). However, the 
success of this industry depends on the manufacture of sufficient and consistent 
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cell numbers without significant batch variation (Ratcliffe et al., 2011). For this 
reason, it is fundamental for the critical quality attributes of identity, potency, 
purity, and safety of the cell-based products to be identified  (Carmen et al., 
2012).  
 
1.4.1: Potency assays for assessing biological function of cell-
products 
Critical characteristics to be specified as part of good manufacturing practices 
are Identity, potency, purity, and safety (Carmen et al., 2012). Potency 
characterization is one of the earliest studies to be carried and it can be defined 
as the measurement of biologic function based on the cell product attributes 
(Bravery et al., 2013). Potency assays generally focus on a key aspect of 
product function and they require short time scales. According to the European 
Medicines Agency, potency assays must be established by phase 3 
(European Medicines Agency, 2016). In the context of regenerative therapy for 
ischemic injuries, it makes sense to predict that functional requirements of the 
cell therapy product include the ability to support vasculature around the 
affected region. Therefore, there is a need to develop rapid and easy-to-use 
assays that can provide process conditions that closely reflect the physiologic 
environment. These assays would then become ideal precursors to second-
generation surrogate tests that make rapid measurements of protein, transcript 
or metabolite components. 
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1.4.1.1: Culture medium considerations  
The large-scale expansion of stem cell in vitro involves the use of various cell 
culture media. However, the majority media used are supplemented with serum to 
achieve effective cell proliferation (Tekkatte et al., 2011). FBS is the most 
commonly used serum source for cell expansion because it enhances cell 
proliferation capacity (Tekkatte et al., 2011). Due to its properties, most hMSC 
expansion systems make use of 5-15% FBS (Chen et al., 2013). In the past 
couple of years, the scientific community has been pressurized by regulatory 
agencies to reduce/eliminate the dependence or to find alternatives to serum 
medium, such as human blood-derived supplements and chemically defined 
serum-free medium (A. K.-L. Chen et al., 2013; Tekkatte et al., 2011). Table 1-1 
highlights some of the disadvantages of the use of serum in culture systems. 
 
Table 1-1: Summary of the drawbacks of using serum in cell culture systems. 
 
Disadvantages References 
High risk of contamination: virus, bacteria and 
mycoplasma. 
(Erickson et al., 
1991; Escobedo-
Lucea et al., 
2013) 
Undefined media: batch-to-batch variation even within 
the same type of serum, making standardization of cell-
based assays difficult.   
(A. K.-L. Chen et 
al., 2013) 
Enhanced attachment of non-MSCs to culture dishes by 
FBS, leading to heterogeneous population.  
(Knepper et al., 
1998; Chen et al., 
2013) 
FBS xenogeneic proteins internalized into stem cells with 
the risk of transmitting unknown infection agents after 
transplantation of cells into patients. 
(Mackensen et 
al., 2000; 
Escobedo-Lucea 
et al., 2013) 
Ethical issues: pain inflicted to foetal calves using 
inhumane methods to extract the blood and limited 
availability of serum. 
(A. K.-L. Chen et 
al., 2013; 
Jochems et al., 
2002) 
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1.5: Cell types used for myocardial tissue regeneration   
Current regenerative medicine approaches involve the transplantation of 
endogenous or exogenous stem cell populations to the ischemic injured heart 
where they have displayed the ability to differentiate into cardiomyocytes or ECs, 
inhibit cell death, promote neovascularization, and activate endogenous 
progenitors and in some cases to also positively modulate the ECM 
(Sanganalmath and Bolli, 2013). The following section will describe the best cell 
types that showed positive outcomes in vitro and in vivo for cardiac regeneration.   
 
1.5.1: Embryonic stem cells (ESCs) 
ESCs are sourced from the inner mass of blastocysts and their ability to give rise 
to several cell types makes them a potential therapy for the regeneration of 
organs such as the heart (Elnakish et al., 2012). For example, Wu and 
colleagues showed that when ESCs were cultured as single cells for 13 days, 
they differentiated into cardiomyocytes and smooth muscle cells (Wu et al., 2006). 
Moreover in vivo studies showed that when ESCs were transplanted into the 
ischemic injured myocardium in rats these were able to differentiate into 
myocardial cells with structural and functional properties similar to those of the 
endogenous myocardial cells, hence leading to improved cardiac function (Min et 
al., 2002; Menasché et al., 2014). Even though ESCs may be an optimal cell 
source for cardiac regeneration, there are still challenges that need to be 
overcome for their successful application in clinics; some of these are listed 
below: 
 
 Their infinite proliferation properties mean that cells can divide non-stop in 
vivo and lead to teratoma formation (Menasché et al., 2014). 
 Give rise to heterogeneous cell populations (Menasché et al., 2014; 
Osafune et al., 2008). 
 ESC therapy will be allogeneic hence requiring immunosuppression of the 
patients before transplantation - giving drugs for long periods of time to 
the patient dulls the immune response and increases susceptibility to 
disease (Menasché et al., 2014). 
 There are ethical issues associated with sourcing ESCs from the early 
embryo (Elnakish et al., 2012).  
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1.5.2: Adult stem cells for cardiac therapy  
Adult stem cells are found in the adult tissue and they can either make more 
copies of themselves or differentiate into specific lineages, usually the one from 
the tissue they are sourced from. In addition, they do not pose the risk of being 
rejected by the body because of their immunological compatibility and they can 
be extracted from an individual’s fat or bone marrow hence avoiding ethical 
concerns. These advantages make them desirable for application in ischemic 
cardiac regeneration.  
 
1.5.2.1: Skeletal myoblasts 
Skeletal myoblasts are committed progenitors of skeletal muscle cells with a high 
proliferative potential, commitment to a myogenic lineage, and resistance to 
ischemia which made them desirable for applications in cardiac regeneration 
(Dowell et al., 2003). These were the first cells to be used in clinical trials for the 
treatment of the injured myocardium (Menasché et al., 2003). Previous work 
showed that when the skeletal myoblasts were injected into the infarcted 
myocardium of rats, there was the formation of islands of cells of different sizes 
that maintained characteristics of both skeletal and cardiac cells which led to 
improved cardiac function (Taylor et al., 1998; Dowell et al., 2003). However, 
despite their potential for heart therapy, previous clinical work showed that the 
cardiomyocytes derived from the skeletal myoblasts fail to integrate and work in 
complete synchrony with the native tissue, which can lead to life-threatening 
ventricular arrhythmias (Menasché, 2008). Moreover, the reported positive effect 
of skeletal myoblasts on the function of the left ventricle was only short-term 
(Menasché, 2008). Therefore there is still the need to carry out extensive in vitro 
and in vivo studies to confirm their safety and feasibility for clinical studies. 
 
1.5.2.2: Haematopoietic stem cells (HSCs) 
Hematopoietic stem cells (HSCs) are obtained from the bone marrow and they 
are multipotent stem cells that can undergo lymphoid and myeloid lineages 
meaning that they can give rise to all of the blood cell types (Bryder et al., 2006). 
The first study that proved the existence of HSCs involved the injection of a cell 
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suspension sourced from the bone marrow into irradiated mice. Following this, 
colonies constituting various differentiated cells of multiple blood lineages were 
observed in their spleens. Because the bone marrow suspension included 
several cell types, these cells were initially referred to as colony-forming units 
(Till and McCulloch, 1961). 
 
HSCs can be recognised by the expression of CD90 and CD34, and by the lack 
of expression of lineage markers such as CD14 (monocyte/macrophage) and 
CD38 in humans (Bryder et al., 2006; Ishikawa et al., 2006). CD34-/CD38+ 
expression has been reported in mice. Hence, there is a need to carefully assess 
the results from animal studies and these differences should be taken into 
account in clinical work (Balsam et al., 2004; Bryder et al., 2006). Early studies 
using HSCs have shown that they have a positive impact on neovascularization 
and cardiac regeneration (Jackson et al., 2001). Contrastingly, Balsam and 
colleagues reported that when HSCs were injected into the infarcted heart of 
mice, they failed to express cardiac-specific tissue markers and instead they 
differentiated into blood cells and failed to induce myocardial regeneration 
(Balsam et al., 2004).  
 
More recently, a study by Lemcke and colleagues showed that HSC-MSC co-
transplantation could be more beneficial for promoting heart regeneration 
(Lemcke et al., 2017). Similarly, to Balsam and colleagues, this study showed 
that HSCs are associated with blood vessel formation. Additionally, it also 
demonstrated that MSCs communicate via gap junctions with the surrounding 
cardiac cells, which favour their differentiation into cardiac cells. Gap junctions 
are specialized cell-cell contacts that enable the transfer of molecules between 
adjacent cells. Overall this study confirmed that both HSCs and MSCs act 
through different mechanisms to promote heart regeneration even though there 
was not a clear benefit on MI-treated hearts upon co-transplantation (Lemcke et 
al., 2017). For this reason, it may be beneficial to study the MSC-HSC possible 
synergistic actions by performing in vitro studies that could look at separate 
aspects of angiogenesis (Staton et al., 2007). 
 
Pre-stimulation strategies could also be adopted on to enhance the recruitment 
of bone marrow cells in disease and to promote cardiac regeneration. 
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For example, it has been reported that the mobilization of HSCs towards the 
ischemic injured heart can be enhanced in response to granulocyte-colony 
stimulating factor which inhibits the CXCR4/SDF-1α signalling (pathway involved 
in stem/progenitor cell trafficking) and is involved in the retention of HSCs in the 
bone marrow (Pitchford et al., 2009).  
 
1.5.2.3: Endothelial progenitor cells (EPCs) 
Endothelial progenitor cells (EPCs) are CD34+ mononuclear cells residing in the 
bone marrow (Kamei et al., 2017). Evidence suggests that tissue ischemia 
mobilizes EPCs to the ischemic site where they differentiate into endothelial cells 
and form blood vessels (Kawamoto et al., 2003; Rosenstrauch et al., 2005). 
Moreover, several studies showed that when ECs were transplanted into the 
ischemic areas in vivo they were able to reduce ischemia and enhance 
neovascularization in the infarcted zone (Kawamoto et al., 2003; Liao et al., 
2017). It was shown that the mobilization of EPCs can be enhanced through 
VEGF pre-treatment in response to inhibition of CXCR4 signalling which is 
involved in stem/progenitor cell trafficking (Pitchford et al., 2009). Moreover, 
several studies agreed on the importance of ECs in the formation of new blood 
vessels through integration to the ischemic area and the release of 
proangiogenic factors including VEGF, angiopoietin-1, hepatocyte growth factor 
and platelet-derived growth factor (PDGF). All of this mechanisms provide 
nutritional support and attenuate apoptosis for the resident EPCs and cardiac 
cells (Kamei et al., 2017; Liao et al., 2017). EPCs may also increase ischemia-
induced inflammatory factors such as interleukin-8 and worsen the ischemic 
injury (van der Strate et al., 2007; Liao et al., 2017).  
 
1.5.2.4: Cardiac stem cells (CSCs) 
The mammalian heart houses one or several clusters of an endogenous 
population of cardiac stem cells (CSCs) (Basciano et al., 2011). CSCs have been 
shown to differentiate into cardiomyocytes and to improve cardiac function 
through paracrine signalling after they have been transplanted into the ischemic 
heart (Chimenti et al., 2010; Nguyen et al., 2016). Similarly, it has been reported 
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that cardiosphere-derived cells, which are cells migrating out of cardiac tissue 
fragments to form spheres, can differentiate into CMs this was observed in both 
in vivo and in vitro studies. However, the drawback of both cardiac stem cells and 
cardiosphere-derived cells is that their isolation involves the harvesting of cardiac 
tissue through percutaneous endomyocardial biopsies or surgical extraction, 
followed by digestion, expansion, and purification of the wanted cell types this 
process is time-consuming as it takes over a month to acquire a clinically 
relevant number (Makkar et al., 2012). In addition, it has been previously shown 
that the ability of CSCs to promote cardiac regeneration may be hindered by the 
low oxygen environment and inflammatory response around the ischemic tissue 
(Kubo et al., 2008).  
 
1.6: Overview of MSCs 
Mesenchymal stromal cells (also termed mesenchymal stem cells or 
multipotent stromal cells) are multipotent non-hematopoietic stem cells that have 
the ability to differentiate into a variety of tissues including osteoblasts and 
chondrocytes (Williams and Hare, 2011).  
 
Recent work has put forward various hypotheses to uncover the ontogeny of 
MSCs, and the most accepted is that MSCs originate from pericytes (Huang 
et al., 2011; Herrmann et al., 2016). For every blood vessel in the body 
mesenchymal cells are observed in perivascular locations (Caplan and Correa, 
2011). Several studies reported that both pericytes and smooth muscle cells 
tend to transdifferentiate into a variety of cell lines including osteocytes, 
chondrocytes, and neural lineages. In addition, pericytes were shown to 
express MSC markers such as CD146 and NG2 (Crisan et al., 2008, 2012). 
CD146+ pericytes (negative for CD34, CD45, and CD56) have been shown to 
possess the same multipotential capacity of MSCs (Crisan et al., 2012, 2008; 
Huang et al., 2011). Similarly to MSCs, pericytes also act through 
paracrine/juxtacrine signalling to recruit host stem cells to the site of injury.  
 
MSCs are a promising therapy for many diseases because of their 
immunosuppressive and immune privilege roles. For this reasons, they have 
been widely studied for the treatment of damaged tissue such as bone, 
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muscle, and ligaments. Their immunosuppressive role indicates that they have 
the ability to suppress the functions of cells of the immune system such as T 
cells and B cells. Whilst, immune privilege indicates that they do not trigger 
the immunological defence mechanisms observed with allogeneic cells. The 
immunosuppressive and immune privilege properties of MSCs make them ideal 
for the treatment of graft-versus-host disease which is a lethal complication in 
allogeneic HSC transplantation recipients (Amorin et al., 2014; Hass et al., 
2011).  
 
Not all MSCs possess immune privilege features and this can result in 
contradictory results between research groups. In fact, conflicting results 
showed that MSCs are not immune privileged and that their immunosuppressive 
role in vivo causes graft rejection (Le Blanc et al., 2004, Nauta et al., 2006). 
For example, in a study carried out by Nauta et al., (2006), allogeneic bone 
marrow with or without the presence of host or donor MSCs was introduced into 
sub-lethally conditioned mice recipients. This study showed that the addition of 
host MSCs led to a longer engraftment that resulted in less rejection of donor 
BM cells. On the other hand, the co-transplantation with allogeneic donor 
MSCs was followed by the rejection of the allogeneic donor BM cells (Nauta et 
al., 2006). Some more recent findings have shown that the immune privilege 
state of MSCs is not stable (Hass et al., 2011). In support of this theory, some 
in vitro and in vivo studies observed that when MSCs differentiate they adopt an 
immunogenic phenotype that leads to immune rejection (Hass et al., 2011). 
These findings suggest that there is a need to develop potency assays, which 
can better characterize MSCs. These data inconsistencies could be due to 
several factors, including heterogeneity between primary cells from different 
sources (e.g. bone marrow and umbilical cord), poor characterization methods 
(i.e. use of surface markers) and population diversity within cell cultures (Hass 
et al., 2011). 
 
MSCs can be sourced from adult tissue such as bone marrow and adipose 
tissue or foetal tissue such as Wharton’s jelly, placenta, and umbilical cord 
blood. MSCs from different origins have some similarities but they may also 
present different proliferation profiles, differentiation potential and gene 
expression profiles (Eckert et al., 2013). Typically, mesenchymal cells are 
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sourced from the bone marrow where they support hematopoietic 
differentiation in vitro. Here they only represent a small population of less than 
0.01% (Fortier and Travis, 2011; Le Blanc et al., 2003).  
 
1.6.1: Biological differences between BM-MSCs and umbilical 
cord MSCs (UC-MSCs) 
Currently the bone marrow and the adipose tissue are the main sources for 
clinical work; however, their collection involves invasive methods of cell 
extraction (Jin et al., 2013). In addition, comparative studies between younger 
(<35 years) and older (<60 years) donors showed that adult stem cells derived 
from elderly donors may not be effective in clinical work (Alves et al., 2012; 
Scruggs et al., 2013; Bruna et al., 2016). Hence, there is a need to use other 
alternative sources such as neonatal tissues including the placenta and the 
umbilical cord (Jin et al., 2013). Several studies have shown that the umbilical 
cord (UC) is abundant in MSCs compared to other sources such as the bone 
marrow (Acosta et al., 2013). Moreover, the mesenchymal cells from the UC 
do not pose any ethical or practical objections and they can be easily isolated 
using non-invasive methods. However, Kern and colleagues showed that the 
success rate of isolating MSCs for the bone marrow and adipose tissue was 
100% compared to only 63% for UCB (Kern et al., 2006). 
 
Evidence suggests that UC-MSCs possess greater proliferation capacity and 
faster population doubling in vitro than BM-MSCs (Jin et al., 2013; Chen et al., 
2014). Furthermore, in one study it was observed that the faster population 
doubling of UC-MSCs against BM-MSCs remained constant after 30 passages. 
On the other hand, the bone marrow MSCs in this study not only showed a slower 
population doubling than umbilical cord-derived MSCs but their doubling time 
became longer after passage 6 (Lu et al., 2006; Kern et al., 2006; Maglieri et al., 
2010). Similarly, Mennan and colleagues, who compared MSCs from various 
compartments of the umbilical cord against BM-MSCs, reported that all UC-
derived MSCs displayed a faster proliferation capacity than BM-MSCs, with mean 
doubling times of 2-3 from P0 to P3 (Mennan et al., 2013). On the other hand, the 
mean doubling time for the BM-MSCs in this study was of ~5 days (P1-P2) and 
~11-12 days (P2-P3) (Mennan et al., 2013). 
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Umbilical cord blood cells can be harvested in different ways, for example by 
puncturing the umbilical vein with a syringe for blood extraction following 
cryopreservation and storage in a blood bank for future use (Acosta et al., 
2013). Cryopreservation was shown to not impact on the proliferation 
potential of these cells which means that they remain viable even after long 
periods of time (Acosta et al., 2013). For example, an early study assessed 
the expansion potential and engraftment of UCB derived cells previously 
stored frozen for 15 years compared to freshly sourced cord blood cells. The 
study indicated the cells that were previously cryopreserved maintained their 
extensive proliferative, self-renewal and ex vivo expansion capabilities. This 
study also showed that UC derived cells display higher engraftment capabilities 
compared to the bone-derived cells (Broxmeyer et al., 2003; Acosta et al., 
2013).  
 
UC-MSCs have been reported to possess “immature immunogenicity” which 
suggests that they are less likely to cause graft-versus-host disease during 
allogeneic transplantations (Acosta et al., 2013). In support of this 
hypothesis, a recent study carried out by Jin and colleagues showed that UC-
MSCs present higher anti-inflammatory effects compared to MSCs from other 
sources. The study was carried out by measuring the number of secreted 
factors during inflammation and it demonstrated that UC-MSCs secrete the 
highest amount of angiopoietin-1, an inflammatory factor that modulates 
anti-inflammatory responses (Jin et al., 2013). 
 
Earlier studies reported that hUC-MSCs display low levels of human leukocyte 
antigens-ABC (HLA-ABC) which have been shown to be an obstacle for 
allogeneic transplantation. Therefore, the lower expression of these markers 
makes UC-MSCs favourable for allogeneic cell transplantations (Maglieri et al., 
2010). In addition, Wegmeyer and colleagues showed that compared to BM-
MSCs, UC-MSCs secrete a higher level of hepatocyte growth factor (HGF), 
monocyte chemoattractant protein 1 (MCP-1), and macrophage colony-
stimulating factor (M-CSF) cytokines (Wegmeyer et al., 2013). In particular, 
these proteins have been shown to have a role in MSC differentiation and 
inhibition of T-cell proliferation. However, BM-MSCs were shown to secrete 
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higher levels of interleukin-1 receptor antagonist (IL-1ra) which is mainly linked 
to anti-inflammatory and anti-fibrotic responses (Wegmeyer et al., 2013). 
 
UC-MSCs share a range of neural markers, differentiating markers and 
extracellular adhesion molecules with BM-MSCS including CD13, CD29, CD44, 
CD73, CD90, CD105 and CD146. This means that they have similar 
differentiation capacity, cell cycle status, haematopoietic supportive function 
and cytokines to BM-MSCs (Maglieri et al., 2010; Lu et al., 2006). However, 
some studies have also reported contradictory data in regards to the expression 
of CD105 which is one of the markers required for MSC verification as outlined 
by the ISCT (Dominici et al., 2006). Although, most studies showed that CD105 
is expressed by UC-MSCs even at later passages (> passage 16; Shi et al., 
2015), some studies have also reported that UC-MSCs either do not express 
CD105 (Kadam et al., 2009) or they only express it until passage 5 (Bakhshi et 
al., 2008; Arutyunyan et al., 2016). Differently from the bone marrow cells, UC-
MSCs have also been shown to express genes associated with embryonic 
stem cells (Kowsari et al., 2017). However, the expression of such markers was 
only observed under specific conditions. For example in early passage or post 
oxygen reduction from 21% to 5% O2 (Arutyunyan et al., 2016).  
 
In terms of differentiation potential, no differences were reported in the ability of 
UC-MSCs to undergo chondrogenic differentiation when compared to BM-
MSCs (Nagamura-Inoue et al., 2014). On the other hand, previous work 
showed that UC-MSCs undergo insufficient osteogenic differentiation (even 
though they have been shown to express osteocyte related genes) in 
comparison to BM-MSCs which were able to easily undergo osteogenic 
differentiation (Mennan et al., 2013). Furthermore, differences have also been 
observed between UC-MSCs derived from different regions of the umbilical 
cord, and it has been reported that Wharton’s jelly MSCs and whole UC-derived 
MSCs possess better differentiation abilities than MSCs derived from other 
regions such as those derived from the UC lining (Mennan et al., 2013). As for 
adipogenic differentiation, UC-MSCs were shown to produce small lipid 
vacuoles and less mature adipocytes than BM-MSCs (Mennan et al., 2013). 
Therefore, UC-MSCs may maintain their multipotency for an extended period of 
time compared to BM-MSCs.  
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UC-MSCs have also been shown to have less inter-donor variability compared 
to other MSCs (Wegmeyer et al., 2013). For example, in a study by Wegmeyer 
and colleagues, BM-MSCs, UC-MSCs and amniotic membrane (AM) MSCs 
were compared in terms of their biological functions. The study showed that 
whilst there were no differences in terms of the genetic background between 
AM-MSCs and UC-MSCs, contrasting results were observed in terms of their 
inter-donor variability. In fact, AM-MSCs displayed high inter-donor variability 
since only two of the five AM-MSC preparations met the minimal ISCT criteria 
for MSCs, whilst these differences were not observed between different 
populations of UC-MSCs. Therefore, the superior robustness and evident 
identity of UC-MSC stocks from different donors indicated that cells from the 
umbilical cord can be a reliable alternative for cell therapy applications 
(Wegmeyer et al., 2013).  
 
Hypoxic pre-conditioning was also shown to unveil further differences between 
UC-MSCs and those from other sources. For example, one study compared 
MSCs from the BM, AT and UC that were subject to 1.5% O2. The study 
showed that the levels of lactate production were significantly lower in UC-
MSCs compared to those from other sources and the same was observed 
under normoxic conditions (Lavrentieva et al., 2010).  
 
UC-MSCs have also been shown to have higher angiogenesis abilities than 
BM-MSCs. For example, one study showed that in Matrigel and co-culture 
assays, both BM-MSCS and UC-MSCs were able to undergo endothelial cell 
differentiation and form capillary-like networks. However, the UC-MSCs used in 
this study demonstrated a significantly higher number of total tubule length, 
diameter, and area than differentiated BM-MSCs. In support of these results, 
the RT-qPCR data from this study and immunocytochemical analyses showed 
that there was a higher expression of endothelial specific markers in UC-MSCs 
(Chen et al., 2009). Recent studies have also reported that the use of UC 
conditioned medium increased the lengths of the tubes formed in UC-MSC and 
HUVEC angiogenesis assays in vitro which are more representative of the 
capillaries formed in vivo (Shen et al., 2015).  
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In terms of migration, some studies have shown that BM-MSCs have higher 
migration abilities than UC-MSCs as observed in migration and scratch assays 
in vitro (Huang et al., 2015). 
 
Overall, umbilical cord and bone marrow-derived MSCs share many similarities. 
However, UC-MSCs have been shown to possess several advantages over 
BM-MSCs including higher immunomodulatory abilities, proliferation and easier 
isolation, which makes them an excellent replacement to BM-MSCs for the 
treatment of several diseases.  
 
1.6.2: Characterization of MSCs 
In order to be able to compare results from different research groups using 
hMSCs from different sources, different methods of expansion and isolation and 
different characterization protocols, the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cell Therapy (ISCT) proposed a 
standard minimum criteria to define hMSCs for in vitro and pre-clinical studies 
(Dominici et al., 2006). Three specifications were proposed:  
 
1. hMSCs must display adherence to plastic when maintained in standard 
culture conditions (Dominici et al., 2006). 
 
2. hMSCs must express high levels (≥ 95% positive) of CD73, CD90 and 
CD105, and lack expression (≤ 2% positive) of CD11b or CD14, CD19 or 
CD79α, CD34, CD45 and HLA-DR (unless stimulated by interferon-γ (IFN-γ) 
surface molecules (Dominici et al., 2006)).  
 
3. hMSCs must be able to undergo tri-lineage differentiation which is the ability 
of the cells to differentiate into osteoblasts, adipocytes, and chondroblasts 
when using the standard in vitro tissue culture-differentiating conditions 
(Caplan, 2007).  
 
1.6.3: Effect of cell age on the potency of MSCs 
Several studies have looked into the effects of sequential passaging on the 
functional characteristics and morphology of MSCs (Dominici et al., 2006; Ullah 
et al., 2015; Choi et al., 2015). The long-term passaging of MSCs (>5 passages) 
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leads to less spatially organized, bigger in size and more heterogeneous cell 
cultures (Lo Surdo and Bauer, 2012; Whitfield et al., 2013, Jin et al., 2013).  
 
Earlier studies compared BM-MSCs from three different passage numbers (P3, 
P5, and P6) and showed that younger and older cells meet the ISCT guidelines 
highlighted in section 1.6.2 (Dominici et al., 2006). In support of these results, a 
more recent study showed that following long-term expansion (up to passage 12), 
BM-MSCs and UC-MSCs display a decrease in proliferation capacity over time 
whilst still expressing MSC markers. In addition, cell age contributes to a 
decrease in immunosuppressive properties, this has been reported for both UC-
MSCs and BM-MSCs (de Witte et al., 2017).  
 
However, some studies showed that the effect of cell age on bone marrow MSCs 
is more significant. For example, Beane and colleagues demonstrated that old 
BM-MSCs display impaired proliferation, senescence, and chondrogenic 
response, whilst this was not observed in muscle-derived and adipose-derived 
MSCs (Beane et al., 2014). 
 
Overall cell age affects cell proliferation but there is still need to confirm whether 
serial passaging has a significant impact on cell functionality or not. These 
contrasting results suggest that there is a need to standardize techniques 
between research groups to obtain comparative results.  
 
1.7: Potential of MSCs for MI in clinical trials  
Currently, there are over 493 clinical trials that are looking at the therapeutic use 
of MSCs with a focus on safety and efficacy of the cell product (Squillaro et al., 
2016). Moreover, much of this work shows that the infusion of bone marrow stem 
cells has a positive impact on cardiac function (Wollert et al., 2004; Lunde et al., 
2006; Wen et al., 2011; Acosta et al., 2013; Cashman et al., 2013). The positive 
results from animal studies have led to the initiation of phase I and phase II trials 
using BM-MSCs in humans. An indicator of prognosis in AMI patients is the left 
ventricular ejection fraction (LVEF) and the lower the LVEF the poorer is the 
patient’s survival (Nair et al., 2015). 
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LVEF can be calculated using the following formula: 
 
 
 
Where: 
 
EF = Ejection fraction  
SV = Stroke volume (volume pumped from left ventricle per beat) 
EDV = End-diastolic volume (volume of blood in a ventricle immediately before a 
cardiac contraction begins) 
ESV = End-systolic volume (volume of blood in a ventricle at the end of 
contraction/systole) 
 
The majority of clinical trials have used autologous bone marrow cells since it 
avoids the potential of rejection hence graft versus host disease (GvHD) which 
would require the patients being immunosuppressed (Wolf et al., 2009). 
However, using allogeneic therapies is a more attractive option as it can lead to 
the treatment of a larger number of patients. 
 
1.7.1: Clinical outcomes of stem cells looking at LVEF 
Several phase I and phase II trials have investigated the use of stem cells as a 
regenerative strategy to treat acute myocardial infarction (AMI) with LVEF being 
the most common endpoint, even though the results have been modest. 
 
One of the first randomised trials looking at the use of progenitor cells for the 
treatment of AMI was the TOPCARE-AMI trial in which either bone marrow-
derived progenitor cells (n = 29) or circulating progenitor cells (n = 30) were 
administered to the patients 5 days after percutaneous coronary 
intervention. The trial indicated an increase in LVEF (50 ± 10% to 58 ± 10%; 
p < 0.001) and no significant differences between the two cell types 
however, no appropriate control was available for comparison (Schachinger 
et al., 2004). Similarly, Yousef and colleagues studied the long-term benefits 
of bone marrow cells into the infarct zone of patients who suffered an AMI. 
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The study was performed on 62 patients who were administered BMCs 7 ± 2 
days after AMI and with a control group of 62 patients who had similar LVEF 
and diagnosis. The benefits of BMCs were investigated after 3, 12 and 60 
months. The results from this study, showed an improved EF with an 8% 
reduction in infarct size and with a significant reduction in mortality after 5 
years in comparison to the control groups (Yousef et al., 2009).  
 
The BOOST trial also looked at the effect of bone marrow stem cells 
(BMSCs) in patients following injection 5-7 days after AMI. The study 
showed a 6.7% increase in LVEF after 6 months when compared to the 
control groups. However, the benefits of the BMSCs were not observed after 
18 months (Wollert et al., 2004). Similarly, the REPAIR-AMI trial which had 
204 participants, showed that the administration of BMCs to the infarct zone 
led to improvement in LVEF compared to placebo (+5.5% versus +3.0%) at 
4 month follow-up (Marenzi and Bartorelli, 2007; Nait et al., 2017). The 
largest phase II trial of autologous bone marrow mononuclear cells is the 
BAMI study which showed a 2.5% increase in EF against the control group. 
The ongoing BAMI trial is a phase III trial with a 20 year follow-up which 
would give further insights into the benefits of cell therapy in patients 
suffering from AMI (Mathur et al., 2017). Furthermore, because these trials 
used heterogeneous populations it is difficult to attribute the positive effects 
on LVEF to a specific set of cells. Overall most studies using bone marrow 
stem cells have shown an improvement in LVEF ranging from 3% in the 
REGENT trial (n = 200) to 13.1% observed in the CARDIAC study (n = 38) 
(Pinepoli et al., 2010; Maglieri et al., 2010, Hare et al., 2012). 
 
The Cochrane review examined 33 randomised clinical trials (1765 patients) 
which showed a consistent improvement in left ventricular function in 
patients who were administered stem cells in comparison to those who 
underwent existing medical treatments. The conclusion from this review was 
that there is a lot of heterogeneity between studies (Martin-Rendon et al., 
2008). However, various studies have also failed to show the presence of bone 
marrow cells in the myocardium after 1 to 3 months of infusion with some not 
detecting MSCs post 2 weeks of injection (Chin et al., 2003; Kurtz, 2008) which 
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indicates that there is a need to find an agreement in terms of delivery method, 
administration and cell preparation.  
 
Some of the studies that showed a positive outcome following BM-MSC 
administration include the POSEIDON trial which looked at the effect of 
autologous and allogeneic BM-MSCs in patients suffering ischemic 
cardiomyopathy. This study was only performed on 5 patients per 
experimental group with no placebo controls. However, the results were 
encouraging and this was evidenced by a 1.96% increase in EF in both 
groups although not statistically significant (Hare et al., 2012). Similarly, 
Yang and colleagues transplanted autologous BM-MSCs in 16 patients with 
anterior MI and reported approximately a 9% increase in left ventricular 
ejection (after six months) from baseline (Yang et al., 2010). Whilst, in 
another study cardiac improvement following BM-MSC injection was 
observed after 3 months (Chen et al., 2004). Contrarily from the data in 
these clinical trials, other studies showed no improvement in LVEF upon 
infusion of BM-MSCs (Janssens et al., 2006).  
 
A recent randomised clinical trial reported that UC-MSCs can be used as a 
replacement to BM-MSCs for the treatment of patients with heart failure and 
reduced ejection fractions (Bartolucci et al., 2017). 15 patients were used for 
each experimental and placebo groups. The study indicated a significant 
increase in LVEF after 12 months between the experimental and placebo 
groups (7.07 ± 6.2% versus 1.85 ± 5.6%; p = 0.028).  
 
In another study, 116 patients with acute MI were randomly chosen to 
receive infusion of Wharton’s jelly derived MSCs or placebo into the zone of 
injury. The patients were monitored over time in which there was a 
significant increase in perfusion at the infarct site with a 7.8% increase in 
LVEF in the MSC group at 18 months over the baseline compared to a 2.8% 
increase in the placebo group (Gao et al., 2015). 
 
The majority of these clinical studies have small sample size as well as a high 
degree of heterogeneity in terms of cell product, the methodology used and 
cell dosing (Hare et al., 2012; Nair et al., 2015). Other treatments for heart 
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disease include using adipose tissue (AT) regenerative cells which have many 
similarities with MSCs. However, a clinical study performed on 14 patients 
administered with AT cells showed that there were no improvements in LVEF 
compared to the control group (Houtgraaf et al., 2012). Granulocyte-colony 
stimulating factors (G-CSF) were also shown to improve MI. G-CSFs are 
glycoproteins that stimulate the bone marrow to release granulocytes and stem 
cells into the blood-stream. In the MAGIC trial it was observed that when G-CSFs 
were infused together with BMSCs, LVEF increased from 46.4% ± 8.1% at 
baseline to 54.3% ± 11% after 6 months (Steinwender et al., 2006).  
 
ACE inhibitors have been long shown to improve survival in AMI patients. 
For example, the SOLVD trial compared the administration of the ACE 
inhibitor enalapril (2.5-20 mg/day) to placebo for a year. The results showed 
a significant increase in LVEF from 0.25% to 0.29% (p < 0.01) in the 
enalapril group (Konstam, 1992). Currently, there are not many studies 
comparing the effect of pharmaceutical drugs used for the treatment of AMI 
and stem cells. However, pharmaceutical drugs are only used to subsidise 
symptoms and they do not aim to regenerate the heart tissue.  
 
A recent phase III randomised multicentric trial compared the improvements 
in LVEF of patients with AMI who were infused with bone marrow stem cells 
in comparison to standard medical therapy. This study compared 125 
patients who received 5-10 x 108 autologous bone marrow stem cells in 
addition to standard medical therapy and 125 patients that only received the 
standard medical therapy but no stem cells. The follow-up results after 6 
months showed that in both groups there was an increase in mean change 
in LVEF of 7.05% in the stem cell groups and 4.1% in the non-stem cell 
groups which indicated a benefit in using stem cells for AMI (Nair et al., 
2015). It is notable that the type of standard medical therapy used in this trial 
was not specified (Nair et al., 2015).  
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1.8: Clinical and pre-clinical outcomes of therapeutic 
angiogenesis and engraftment  
Therapeutic angiogenesis and engraftment are strategies used to promote 
reperfusion to tissue and organs through the formation of new vessels and/or 
repair of existing vessels to affected ischemic tissue. MSCs have been shown to 
have pro-angiogenesis features and contribute to the formation of vasculature in 
vivo in a variety of vascular diseases (Tao et al., 2016).  
 
The engraftment of MSCs is mediated by the interaction between cell surface 
receptors and glycoproteins found in the extracellular matrix (ECM) of the cells. 
The lack of cell engraftment is known to lead to anoikis (Ezquer et al., 2017). 
This is apoptosis induced by the loss of anchorage-dependent attachment to the 
ECM which results in cell death (Ezquer et al., 2017). 
 
MSCs are known to improve cardiac function in patients with MI through their 
direct engraftment and integration at the site of injury. For example, in a pre-
clinical study in swine, it was observed that the robust engraftment of BM-MSCs 
at the zone of injury attenuated the degree of contractile dysfunction at 4 weeks 
(5.4% ± 2.2% versus − 3.37% ± 2.7% in control) and reduced the extent of wall 
thinning which might have resulted from increased angiogenesis and perfusion at 
the zone of injury (Shake et al., 2001). Next, a phase I clinical study looked at the 
effect of infusing 1 x 106 cells/kg of allogeneic MSCs for the first infusion and 5 x 
106 cells/kg for the second infusion into 5-6 children with osteogenesis imperfecta 
(Horwitz et al., 2002). This is a condition where the bones break easily due to a 
detective type I collagen. The data from this study indicated that the engraftment 
of mesenchymal cells at the site of injury resulted in clinically measurable 
benefits. In fact, cell engraftment was observed in different sites including bone 
and marrow stroma. Furthermore, striking benefits were observed in two of the 
patients where there was a significant improvement in bone growth ranging from 
67% to 94% of the predicted median values over the first 6 months after MSC 
therapy. The data from this study, also indicated that the fraction of donor-
derived osteoblasts in the biopsies was less than 1% and this suggests that low 
levels of MSC engraftment can result in clinical benefits (Horwitz et al., 2002). 
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Even though cell adhesion appears to have clinical outcomes and improve 
cardiac function, the engraftment of the MSCs is too low to account for the 
benefits observed in clinical trials (Becker et al., 2016). In fact, in most studies, 
MSCs only show limited engraftment or no engraftment at all which indicates that 
these cells may also be acting through other mechanisms for therapeutic effect 
(Becker et al., 2016). 
 
MSCs are known to secrete several paracrine factors including fibroblast growth 
factor (FGF) and vascular endothelial growth factor (VEGF) which have been 
reported to promote local angiogenesis in pre-clinical and clinical studies 
(Schumacher et al., 1998, Prasajak et al., 2013; Lu et al., 2016). For example, in 
one study it was observed that when bone marrow mononuclear cells (BM-
MNCs) were administered to the ischemic myocardium of swine, the cells 
expressed bFGF, VEGF and angiopoietin-1 as well as levels of TNF-alpha which 
was previously shown to increase cell engraftment (Prasajak et al., 2013). The 
results from this study showed that after 3 weeks following the injection of the 
BM-MNCs into the ischemic tissue, there was an increase in capillary density and 
blood flow at the zone of injury. Therefore, the data from this study suggested 
that the release of these factors might have promoted angiogenesis at the infarct 
site (Kamihata et al., 2001). In another study, which used a mouse aortic ring 
assay, BMC conditioned medium was shown to promote the formation of a 
significant number of tubes (p < 0.01; almost two-fold increase) which stimulated 
cell sprouting. Therefore, the increase in capillary density observed in this study, 
was associated with a reduction in necrotic and apoptotic cell death confirmed 
through staining assays (Korf-Klingebiel et al., 2008).  
 
The importance of angiogenesis/branching in vivo is also evidenced by the 
clinical results from phase I trials. Clinical trials using pro-angiogenic factors have 
been limited to phase I studies and involved small sample sizes.  
 
In an early pre-clinical study it was observed that the intracoronary injection of 
FGF-2 in 21 dogs with ischemia led to significant improvements in left ventricular 
function and 40% increase in transmural collateral flow (i.e. alternate circulation 
around a blocked artery or vein via nearby minor vessels). These improvements 
were observed as a result of vessel sprouting and capillary network formation 
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from the original coronary vessels with 6.7 ± 1.4 vessels/mm2 capillary density for 
the experimental group versus 3.5 ± 0.7 vessels/mm2 for the control group (p < 
0.05; Unger et al., 1994).  
 
Using genes encoding angiogenic cytokines such as VEGF is also another 
strategy used on patients who suffer from MI to promote the formation of 
collateral blood vessels which would allow for re-perfusion around the ischemic 
area (Losordo et al., 1998). For example, in an early phase I trial, naked plasmid 
DNA encoding VEGF (phVEGF165) was administered to 5 patients (aged 63.8 ± 
3.4 years) who were unsuccessful with conventional therapy and who suffered 
angina (no placebo group). When phVEGF165 was injected at the site of injury, 
2/5 patients showed an LVEF improvement of 5% and reduced ischemia in 5/5 
patients. Myocardial perfusion was improved by the positive change in the mean 
number of normally perfused segments per patient which increased from 6.0 ± 
1.1 before gene transfer to 8.0 ± 0.7 (p < 0.05) at day 60 after gene transfer, and 
a reduction of irreversibly ischemic segments from 2.4 ± 0.2 to 1.2 ± 0.4 (p < 
0.05) at day 60 follow-up examination (Losurdo et al., 1998). Similarly, in a phase 
II clinical trial (with placebo controls, 27 patients), phVEGF-2 was administered to 
three treatment groups at 200 μg, 800 μg, or 2000 μg. The results from this 
study, indicated that there was an improvement in Canadian Cardiovascular 
Society (CCS) angina class in phVEGF2-treated versus placebo-treated patients 
(-1.3 versus -0.1, p = 0.04). The improvements observed in the angina class and 
in the other endpoints of the study, were associated with a significant increase in 
vessel formation (5.9 ± 1.0% to 13.2 ± 1.3% in phVEGF-2 patients; p = 0.004) 
which followed a reduction in ischemic site from 6.4 ± 2.2 cm2 before gene 
transfer to 2.6 ± 1.4 cm2 after gene transfer (Losurdo et al., 2002).  
 
Overall the results from these studies indicate that increasing the number of 
blood vessels in ischemic areas via pro-angiogenic factors is desirable for 
optimal therapeutic effect in AMI. Therefore, it can be concluded that future 
biological assays should also be aiming to improve angiogenesis and cell 
engraftment as endpoints.  
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1.9: Mode of action of MSCs for cardiac repair 
Evidence suggests that there are various mechanisms (listed below) by which 
MSCs can repair the infarcted myocardium. 
 
Mode of action References 
MSCs induce the reprogramming of 
CMs into cardiac progenitor cells 
that can repair the heart. 
Acquistapace et al., 2011 
MSCs transdifferentiate into CMs 
and restore cardiac function. 
Tomita et al., 1999; Yoon et 
al., 2005 
MSCs trigger cardiac repair 
through paracrine signalling. 
Koninckx et al., 2009; Wollert 
et al., 2004; Cashman et al., 
2013 
MSCs trigger tissue repair by 
reacquiring a pericyte phenotype. 
Kean et al., 2013; Melero-
Martin et al., 2008; Gnecchi et 
al., 2012; Au et al., 2008 
Electrophysiological MSC-CM 
coupling may improve functionality 
of cardiac tissue. 
Mayourian et al., 2016 
Table 1-2: Mode of action of MSCs. 
 
Several studies showed that the co-culture of MSCs with cardiomyocytes 
triggers their reprogramming into cardiac progenitor cells. A study from 
Acquistapace and colleagues supported this theory and demonstrated that 
the MSC-CM co-cultures led to the increase in cardiac progenitor markers 
and proliferation (Acquistapace et al., 2011). MSCs have also been reported to 
transdifferentiate into cardiomyocytes in the injured cardiac tissue of animal 
models in vitro and in vivo thus leading to cardiac repair (Tomita et al., 1999; 
Yoon et al., 2005). 
 
However, it has been shown that only <2% of the transplanted MSCs 
transdifferentiate into cardiomyocytes (Arnous et al., 2012). Further evidence 
has suggested that perhaps MSCs do not transdifferentiate but instead fuse 
with the CMs (Kouris et al., 2012). In opposition to this finding, Tsuji et al. 
(2010), carried out an experiment which involved the staining of human amniotic 
membrane-derived mesenchymal cells (hAMCs) with MitoTracker Red 
(Invitrogen, M7512), a red fluorescence dye, followed by co-culture with 
enhanced green fluorescent protein (EGFP) murine CMs. The study showed 
that MitoTracker positive cardiomyocytes were EGFP negative so there was 
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no cell fusion between the CMs and the hAMCs (Tsuji et al., 2010). Hence, this 
work disproved the MSC-CM cell fusion mechanism of action. 
 
Of particular interest is the conclusion by Koninckx and colleagues, who 
stated that although transdifferentiation of MSCs may take place, paracrine 
effects do play a much bigger role in cardiac repair. The basis for 
Koninckx’s conclusion was that the immature cardiomyocytes would most 
likely induce a minor effect in cardiac repair (Koninckx et al., 2009). On the 
other hand, paracrine factors secreted by the stem cells could improve the 
functionality of mature cardiomyocytes. 
 
Various clinical trial studies showed that the beneficial effects of transplanted 
MSCs are transient. For example, in a study carried out by Wollert and 
colleagues which involved the transplantation of autologous derived BM stem 
cells it was observed that the effects only lasted for six months. Follow-up 
work showed that after 18 months the beneficial effects of MSCs were severely 
reduced (Wollert et al., 2004; Cashman et al., 2013). Although these data 
suggest that MSCs do repair the injured heart by releasing paracrine factors, 
the results also suggest that, as the stem cells differentiate or disappear by 
apoptosis, the concentration of the paracrine factors decreases hence 
affecting their beneficial effects (Wollert et al., 2004; Cashman et al., 2013).  
 
MSCs have been shown to trigger angiogenesis by also assuming a 
“perivascular-like” phenotype in the basement membranes of newly forming 
capillaries where they favoured and contributed to their stabilization (Kean et al., 
2013). Melero-Martin and colleagues performed a study which involved the 
co-implantation of endothelial progenitor cells and hMSCs into 
immunodeficient mice, and vascular network formation was observed within a 
week (Melero-Martin et al., 2008; Gnecchi et al., 2012). Similarly, Au et al. 
(2008) showed that when MSCs were co-transplanted with HUVECs they 
enhanced blood vessel assembly and adopted a perivascular phenotype (Au 
et al., 2008). However, it has also been previously reported that although 
pericytes are a subpopulation of bone marrow MSCs with vasculogenic 
potential, not all MSCs display a pericyte-like behaviour (Blocki et al., 2013). 
As multiple modes of action have been proposed for MSCs, there is a need to 
56 
 
develop assays that can precisely give information on their functional 
characteristics and speed the translation of MSC-based therapies into the 
clinical setting. 
 
1.10: Preconditioning MSCs for clinical efficacy 
A major challenge in the clinical efficacy of MSCs is the low viability of the 
engrafted cells in the zone of injury due to anoikis. Decreased cell survival can 
also be attributed to the hostile environment in the injured myocardium where a 
highly inflammatory and cytotoxic process takes place to remove anything 
unnecessary in the injured myocardium and leads to oxidative stress (Ezquerchen 
et al., 2017). Various research groups are now looking into strategies to improve 
cell survival for therapeutic efficacy. 
 
1.10.1: Hypoxia pre-conditioning of MSCs in vitro  
Several studies have shown that hypoxia (1-7% oxygen) positively impacts on 
migration, metabolism, angiogenesis, and cell stemness (Moriyama et al., 2014; 
De Becker and Riet, 2016) and that normoxia may hinder the therapeutic potential 
of hMSCs (Basciano et al., 2011). For example, Lan and colleagues showed that 
when BM-MSCs were subject to 1% O2 for 24 hours, the cells were able to 
engraft in an animal model of idiopathic pulmonary fibrosis four times better than 
the untreated cells (Lan et al., 2015). The benefits of MSCs subject to hypoxic 
conditions were also observed in an acute myocardial infarction murine model. In 
this study, the authors reported a 2.5 fold increase in engraftment after one day 
of intravenous injection which led to a decrease in myocardial infarct site (Ezquer 
et al., 2017).  
 
The results from different research groups have been difficult to compare due to 
differences in oxygen tension ranging from 0.1 to 5%, and different culture times 
ranging from a few minutes to 2 months (Bain et al., 2014; Basciano et al., 2011). 
For example, it was shown that when BM-MSCs were subject to 2% oxygen 
tension for 20 min there was an increase in their migration and a decrease in 
adhesion abilities (Bain et al., 2014). In another study it was observed that cells 
subject to 5% O2 display increased level of adhesion and extracellular matrix 
molecules in MSCs (Basciano et al., 2011).  
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Many studies assessed whether levels of oxygen below 5% O2 have an effect on 
the MSC function such as their differentiation abilities and angiogenesis potential. 
Holzwarth and colleagues showed that levels of oxygen between 3% and 5% 
(after 3 weeks in culture) did not impact on the differentiation of MSCs whilst the 
cells that were cultured in <1% O2 showed impaired differentiation abilities 
(Holzwarth et al., 2010). In another study it was demonstrated that culturing 
MSCs at 5% O2 (after 21 days in culture) inhibits osteoblast differentiation (Raheja 
et al., 2010). Whilst in a study by Zhang and colleagues hUC-MSCs were 
cultivated in 1%, 3% and 5% oxygen tensions following their induction to 
cardiomyocyte-like cells. However, it was observed that only when hUC-MSCs 
were pre-conditioned in 3% O2 there was an enhanced proliferation and 
differentiation to cardiomyocyte-like cells, and no significant differences were 
observed at 1% O2 and 5% O2 (Zhang et al., 2015). Hypoxia was also shown to 
increase the secretion of HIF-1 in MSCs leading to a two-fold up-regulation of 
VEGF and a higher angiogenetic ability than normoxic MSCs (Zhang et al., 2012). 
 
The effect of hypoxia is also source-specific. For example, in a study by 
Lavrentieva and colleagues, it was observed that hypoxic hUC-MSCs displayed 
much lower lactate levels than hBM-MSCs and adipose-derived MSCs 
(Lavrentieva et al., 2010). Moreover, low oxygen also appeared to impact 
differently on MSCs at different passages. For example, Basciano and colleagues 
observed that until passage 1, MSCs grew more slowly when subject to 5% O2 
than in normoxic conditions, whilst as they were expanded further they displayed 
a growth rate advantage compared to the cells cultured in ambient oxygen 
(Basciano et al., 2011). Overall, these studies indicate that hypoxia may be an 
optimal pre-conditioning strategy to increase the beneficial effects of MSCs and to 
investigate their mechanism of action in an environment that closely mimics the 
physiologic injury sites. However, there is a need to carry out further studies 
looking at the impact of different ‘low-oxygen’ conditions on the potency of cells 
and to compare the effects that it has on differently-sourced cells. 
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1.10.2: Engraftment strategies to increase angiogenesis, 
adhesion and migration  
Two major contributors to the successful engraftment of MSCs at the site of 
tissue injury are cell adhesion and migration. In fact short adhesion times are 
required to avoid post-surgical complications (Chang et al., 2015). A recent study 
showed that it takes a minimum of 30 minutes for multi-layered MSC sheets to 
adhere to the heart tissue (Chang et al., 2015). As a result, various studies have 
investigated the effect of regulating key molecules involved in cell attachment 
such as integrin receptors (Lee et al., 2015; Veevers-Lowe et al., 2011).  
 
A study carried out on the infarcted myocardium of a rat, showed that when 
MSCs were induced to overexpress tissue transglutaminase a co-receptor for 
fibronectin in cell adhesion associated with integrins, there was an increase in 
the ability of MSCs to attach, spread and migrate, leading to improved heart 
function. In this study, it was also reported that MSCs overexpressing tissue 
transglutaminase, showed a 20% increase in adhesion on FN and a 4.75% and 
2.52% increase in spreading and migration (Song et al., 2007). FN is an ECM 
protein which contains the site for integrin α5β1 that MSCs express and during an 
MI it accumulates in the injured sites of the heart to stop the bleeding (Van Dijk et 
al., 2008; Veevers-Lowe, 2011). FN has been shown to increase the adhesion 
properties of BM stem cells in vitro (Van Dijk et al., 2008).  
 
Recent studies showed that microRNAs may also have a role in enhancing MSC 
survival and adhesion (Lee et al., 2015). For example, Yu and colleagues 
showed that the expression of one microRNA, miR-125b, achieved through the 
knockdown of beta5 integrin protects MSCs from anoikis (Yu et al., 2012). The 
modulation of MSC pro-angiogenic factors gives insights on the activation of 
other signalling pathways involved in cell migration, proliferation, and network 
formation. For example, in one study it was observed that the knockdown of 
Neuropilin-1, a pro-angiogenic receptor, decreases cell proliferation and hinders 
platelet-derived growth factor receptor signalling which is involved in the 
mobilization of MSCs in neovascularization and tissue remodelling (Ball et al., 
2010).  
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1.10.2.1: Engraftment of MSCs and Notch pathway  
The Notch signalling pathway is highly conserved and plays an important role in 
regulating EC function during sprouting and angiogenesis by aiding 
communication between adjacent cells (Benedito et al., 2009; Lu et al., 2016). 
The Notch pathway can be triggered via the Notch ligands binding to their 
receptors. In mammals, these ligands are encoded by the Jagged (Jag1 and 
Jag2) and Delta-like (Dll1, Dll3, and Dll4) gene families (Gridley, 2010). The 
primary targets of the this signalling pathway are the Hes and Hey genes, the 
latter plays a key role in the development of the cardiovascular system (Rizzo et 
al., 2014). 
 
Several studies showed that targeting the Notch signalling pathway may enhance 
responses relevant to cardiovascular regeneration using MSCs (Xie et al., 2013). 
For example, Semon and colleagues showed that when MSCs were pre-
stimulated with tumour necrosis factor alpha, a key cytokine known to up-regulate 
Jagged1-mediated Notch signalling in EC tip cells, there was an increased cell 
adhesion to the endothelium (Johnston et al., 2009; Semon et al., 2010). The 
overexpression of Jag1 enhances angiogenesis whereas the opposite is 
observed in mutants that lack this gene (Benedito et al., 2009). Jagged1 was 
also shown to enhance the differentiation of MSCs into cardiomyocytes. For 
example, Li and colleagues showed that the addition of Jag1 in MSC-CM co-
cultures enhanced the differentiation of the mesenchymal cells into 
cardiomyocytes (Li et al., 2006). Whilst in another study it was observed that the 
proliferation of cardiomyocytes is increased by direct co-culture with MSCs which 
act through paracrine mechanisms to up-regulate the Notch1-Jag1 pathway 
(Sassoli et al., 2011). Evidence also suggests that blocking Notch signalling in 
BM-MSCs promotes cell migration in vitro and up-regulates the cell receptor 
CXCR4 which is beneficial for cell survival and homing (Cao et al., 2013; Xie et 
al., 2013). Various studies have also looked into the effect of hypoxia on Notch 
signalling. For example, in one study it was observed that culturing human 
adipose progenitor cells in 5% O2 increased their proliferative capacity and 
maintained their stemness. These benefits were linked to an increase in the levels 
of activated Notch1 by hypoxia and the expression of its downstream gene Hes1 
(Moriyama et al., 2014). Similarly, Ciria and colleagues showed that cultivating 
MSCs in 1% O2 for 4 hours leads to the overexpression of HIF-1 which induces 
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Notch-dependent migration and spreading of MSCs through the overexpression 
of the ligands Jagged 1-2 and Dll1, Dll3, and Dll4 (Ciria et al., 2017). Overall 
Notch signalling plays a key role in MSC cardiac differentiation, migration, 
proliferation and angiogenesis, all of which contribute to the recovery of the 
myocardium after cardiac injury (Li et al., 2010; Rizzo et al., 2014). Hence further 
work investigating the effect of MSC pre-stimulation by Notch ligands could be 
beneficial to speed their clinical application as a therapy to treat myocardial 
injury.  
 
 
Figure 1-2: Notch signalling pathway- Notch receptors can be found on the cell surface. When 
Notch ligands bind to the Notch receptors (Notch1, Notch2, Notch3, and Notch4), two 
proteolytic cleavages take place leading to the release of the active form of Notch (NIC). NIC 
then migrates to the nucleus and binds to the transcription factor RBP-jk (recombination signal 
binding protein for the immunoglobulin kappa j region) and controls the transcription of 
specific genes (Rizzo et al., 2014). 
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1.11: In vitro angiogenesis assay methods 
This section will give an overview of the methods used to carry out in vitro 
tubule formation assays. In addition, it will include a comparison of in vivo 
versus in vitro angiogenesis assays. Of interest to this work is endothelial cell-
based assays seeded on Matrigel. 
 
1.11.1: ECs for in vitro studies 
In vitro assays are often used to study the regulatory role of angiogenic 
factors particularly on endothelial cells (Arnaoutova and Kleinman, 2010). 
Tubule assays use a range of ECs including human microvascular endothelial 
cells (HMECs), ECs sourced from mice and primary human umbilical vein 
endothelial cells (HUVECs). The last are the most widely used for in vitro 
assays because they are primary cells which can be easily isolated in the lab 
(Smith and Staton, 2007). However, the problem with primary cells is that 
they have limited function and replicative lifespan, with studies showing that 
ECs experience significant senescence after a sequence of ten serial 
passages (Smith and Staton, 2007; Suh et al., 2015). Moreover, Skinner and 
colleagues showed that ideally primary ECs should be used between P2 and 
P6, whilst it was observed that using the cells below P2 and above P10 is not 
beneficial for maximum tube formation, with a decrease in network formation 
observed after the sixth passage (DeCicco-Skinner et al., 2014).  
 
Another problem encountered with primary cells is that they are sourced from 
various donors using different cell extraction techniques which hinders data 
comparison for in vitro assay work (Smith and Staton, 2007; Staton et al., 
2009). This has increased the demand of well-characterized cell lines such as 
immortalised cells, which due to mutation can undergo indefinite division. 
However, immortalization involves changing cell characteristics and therefore it 
will affect the angiogenic potential of the cells and gene expression. Moreover, 
it may lead to subsequent cell phenotypic changes after several passages. For 
example, Nisato et al. (2004) showed that HMEC-1, a cell line established by 
Ades and colleagues, stopped forming tubules after 12 years (Nisato et al., 
2004). Also, because of the higher cell maintenance costs and availability of 
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HMCE-1 cells, HUVECs will always be the preferred choice for regular in vitro 
studies (Ades et al., 1992; Nisato et al., 2004; Staton et al., 2009). 
 
1.11.1.1: HUVECs 
The majority of in vitro tubule assays have been performed using HUVECs 
because they are primary cells, they can be easily isolated in the lab and they are 
commercially available (Smith and Staton, 2007; Cao et al., 2017). HUVECs have 
also been shown to express more important endothelial markers than other 
endothelial cells e.g. vascular cell adhesion molecule 1 and signalling molecules 
which have a role in vascular physiology (Cao et al., 2017). Also, compared to other 
types of endothelial cells, HUVECs have been shown to respond to a variety of 
physiological stimuli such as shear stress, high glucose and hypoxic pre-
conditioning (Zhang et al., 2012; Cao et al., 2017). For example, in one study it 
was observed that when HUVECs were subject to hypoxic pre-conditioning, there 
was a reduction in apoptosis. In addition, when the endothelial cells were co-
cultured with MSCs in hypoxic conditions for 12, 24, 48 and 72 hours there was 
an increase in survival, migration, and angiogenesis (Zhang et al., 2012). 
Therefore, HUVECs can be used to test different factors on the endothelium 
through in vitro tube formation assays and to also give an insight on the function 
of other cell types in neovascularization (Zhang et al., 2012). Furthermore, when 
performing experiments it is important to recognise the differences between 
HUVECs and other types of endothelial cells. For example, palmitic acid can 
activate human microvascular endothelial cells in vitro, whilst no response is 
observed with HUVECs (Cao et al., 2017). 
 
The growth of HUVECs in vitro is limited to a few passages even in optimal 
conditions which include the use of heparin, endothelial cell growth supplements 
and high serum concentrations (O’ Donnell et al., 2000). The limited life-span of 
primary ECs is an issue for long term-studies (Smith and Staton, 2007). 
Therefore, recent studies have looked into the use of stem cells as a potential 
source of primary ECs (Cao et al., 2017). For example, it was shown that 
fibroblasts can be reprogrammed into iPSCs and then differentiated into 
functional endothelial cells (Margariti et al., 2012; Cao et al., 2017), hence 
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allowing for the production of large number of ECs and making iPSCs derived 
endothelial cells a potentially good model as primary ECs (White et al., 2013). In 
conclusion, whilst further work is needed to be carried out on stem cells to 
overcome the limited supplies of ECs, HUVECs will be the best option for in vitro 
vascular assays for the study angiogenesis (Smith and Staton 2007; Cao et al., 
2017). 
 
1.11.1.2: Heterogeneity of ECs 
Endothelial cells have the ability to adapt to the needs of different tissues within 
the body. For this reason, they present a high degree of heterogeneity. ECs can 
differentiate based on their size, shape, thickness and the vascular bed they are 
derived from. The microenvironment is a deciding factor in endothelial cell 
phenotypic differences (Jackson and Nguyen, 1997). Jackson and Nguyen (1997) 
observed different secretion levels of angiogenic factors between HUVECs and 
human endothelial cells derived from neonatal foreskin (Jackson and Nguyen, 
1997). Furthermore, a study by Gallery and colleagues showed that decidual 
microvascular endothelial cells need high concentrations of serum for growth 
(Gallery et al., 1991). Contrary to this conclusion, Jackson & Nguyen, 1997 
showed that endothelial cells derived from the umbilical vein are not affected by 
the absence of serum (Jackson and Nguyen, 1997). These data suggest that 
different culture conditions may be required for cells derived from different 
tissues.  
 
1.11.2: Endothelial cell tubule formation assays 
In vitro tubule formation assays by endothelial cells can give valuable information 
on a particular step in vascular network formation such as proliferation, 
migration, or differentiation. Tubule formation can be achieved using a variety 
of substrates including but not limited to fibrin clots, collagen and Matrigel 
(Donovan et al., 2001; Gambino et al., 2017). The type of matrix used in these 
assays strongly affects the rate of tubule formation. For example, seeding cells on 
interstitial collagen (collagen I and collagen III) results in cell proliferation but 
very limited tubule formation. On the other hand, it was previously reported that 
when cells were plated on collagen from the basement membrane (collagen 
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IV and collagen V), there was not much proliferation occurring but the rate of 
tubule formation was high. 
 
Both collagen and fibrin have been used to carry out 3-D in vitro assays since the 
1980’s and not so much for 2-D studies (Montesano et al., 1993; Calderon et al., 
2017; Gambino et al., 2017). Tubule formation on collagen in 2-D tubule assays 
takes several days to be performed and they are difficult to quantify since not 
all of the cells form vessel-like networks (Arnaoutova and Kleinman, 2010). 
Instead, tubule formation on Matrigel only takes 4-12 hours, for this reason this 
has ultimately become the preferred matrix for this type of assay. Matrigel is a 
mixture of extracellular basement membrane proteins including collagen IV and 
laminin that is sourced from the mouse Engelbreth–Holm–Swarm sarcoma 
proteins (Faulkner et al., 2014).  
 
Matrigel assays are easy to carry out and to quantify. For example tubule 
networks can be imaged through an inverted microscope and quantified 
based on their length, number of branch points and tubule area (Arnaoutova 
and Kleinman, 2010). Many companies including BD Biosciences have now 
developed a growth factor reduced (GFR) form of Matrigel. This GFR form 
contains very low levels of growth factors thus avoiding over-stimulation of 
endothelial cells observed with the standard Matrigel which interferes with 
efficacy studies of proangiogenic factors (Staton et al., 2004; Xie et al., 2016). 
One key disadvantage in using Matrigel is variability lot-to-lot which can 
majorly affect tubule formation activity as well as data robustness and reliability. 
For this reason, it is strongly recommended to purchase high quantities of the 
matrix and carry out experiments in triplicate wells (Arnaoutova and Kleinman, 
2010).  
1.11.2.1: Co-culture functional assays 
Another type of tubule formation assays involves the co-culture of endothelial cells 
with stromal cells, such as fibroblasts, smooth muscle cells and blood vessel 
explants. These types of assays were developed to better mimic the in vivo 
capillary structures. In addition, they can be carried out with/without the aid 
of a matrix. Co-cultures performed without the aid of a basement membrane 
take 12-14 days compared to when the cells are co-cultured on Matrigel 
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(Donovan et al., 2001). This is because they require the fibroblasts to initially 
secrete extracellular matrix (ECM) components which act as a platform for tubule 
formation (Bishop et al., 1999). 
 
The capillary-like structures in co-culture usually form in two-dimensional 
planes thus facilitating assay quantification and they also resemble more the 
capillary bed in vivo (Donovan et al., 2001; Smith and Staton, 2007). Co-culture 
assays where MSCs are co-cultured with ECs in conditions that mimic the 
physiological environment have been used to study the effect of MSCs in 
angiogenesis and to compare different cell types (Zhang et al., 2012; Ma et al., 
2014). For example, Ma and colleagues co-cultured either adipose-derived MSCs 
or BM-MSCs with HUVECs concluding that they both had equal angiogenic 
potential (Ma et al., 2014). 
 
1.12: In vivo angiogenesis assays 
The table below summarizes the most widely used in vivo angiogenesis assays. 
Table 1-3: Summary table of in vivo angiogenesis assays. 
 
Assays Procedure Quantification References 
Chick  
chorioallantoic 
membrane 
(CAM) assay 
The CAM embryo of the chick is 
used as a physiological 
environment for in vivo analysis of 
cells, pathogens and 
pharmacological reagents. 
Microscopy, 
determining 
content and 
synthesis of 
DNA, protein 
and basement 
membranes 
(Norrby, 
2006; Staton 
et al., 2009) 
Corneal 
micropocket 
assay 
Given that the cornea is the only 
avascular transparent tissue in 
the body, it is optimal for 
assessing neovascularization. 
Usually, micropockets are made 
in the stroma of the cornea 
following implantation of slow 
release polymers. 
 
Transmission 
and scanning 
electron 
microscopy 
(Norrby, 
2006; Staton 
et al., 2009) 
Dorsal air sac 
model 
Involves implantation of a 
chamber ring loaded with tumour 
cells on the mouse dorsal air sac 
to induce angiogenesis.  
Microscopy- or 
photographs of 
the skin  
(Oikawa et 
al., 1997; 
Staton et al., 
2009)  
Zebrafish 
assay 
Involves implantation of cells in 
the zebrafish developing embryo 
followed by monitoring of 
vasculature development and 
angiogenesis after 
transplantation. 
Microscopy  (Staton et al., 
2004, 2009, 
Taylor et al., 
2009) 
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1.13: In vitro versus in vivo angiogenesis assays 
The table below summarizes the key comparison points between in vitro and in 
vivo angiogenesis assays. 
 
 In vitro References In vivo References 
Advantages -quick and 
easy to 
perform. 
Staton et 
al., 2004; 
Smith and 
Staton, 
2007; 
Tahergorabi 
and 
Khazaei, 
2012 
-Allows for the 
study of the 
complex 
physiological 
processes that 
occur in vivo. 
 
Staton et al., 
2009 
Disadvantages -Can behave 
differently 
depending 
on the 
culture 
conditions 
(i.e. still vs. 
flowing) and 
when 
seeded onto 
different 
matrices. 
 
-May not 
show 
comparable 
results to the 
in vivo work. 
Staton et 
al., 2007 
-Expensive, not 
easy to perform 
and time-
consuming. 
 
-Difficult to 
quantify. 
 
-Involves using 
non-human 
tissue. 
 
Guedez et 
al., 2003; 
Staton et al., 
2007; 
Tahergorabi 
and 
Khazaei, 
2012; Chen 
et al, 2013 
 
 
Table 1-4: Summary of advantages and disadvantages of in vitro and in vivo angiogenesis 
assays. 
 
Overall, all of these observations suggest that in vitro models of vasculogenesis 
and angiogenesis can give initial information on cell function. In vivo assays 
can then validate the results from the in vitro tests. Moreover, since in vitro 
assays are less time consuming, it is possible to carry our more tests whereas 
there are only a limited number of tests that can be carried out using in vivo 
assays (Auerbach et al., 2003; Tahergorabi and Khazaei, 2012). 
 
1.14:  Quantification of release assays 
According to the guidelines set by the EMA, the measured biological function of 
a product from a potency assay should closely relate to the product’s clinical 
response (European Medicines Agency, 2016). The type of assays performed, 
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can be either in vitro or in vivo. In vitro assays are usually used for short time 
scale experiments and examples include the enzyme-linked immunosorbent 
assay (ELISA) and microarray technology (Stroncek et al., 2007). Although in 
vivo animal models can directly measure the biological function of the product, 
there is an inherent variation between the results. Additionally, the testing of 
animal models is less cost-effective than experiments in vitro. This section will 
give a quick overview of three in vitro release tests: ELISA, transcriptome-
based screening and metabolite screening. 
 
1.14.1: ELISA for growth factor release 
The enzyme-linked immunosorbent assay technique is commonly used for cell 
product characterization. This test quantifies the concentration of the protein of 
interest in a solution, by using antibodies specific to the particular protein. 
The reaction product is then detected through colour change of the solution and 
measured by using a spectrophotometer (Gan and Patel, 2013; Leng et al., 
2008). ELISA has often been used as a surrogate for potency testing during the 
initial phase development of a biological product (Stroncek et al., 2007; Thej et 
al., 2017). This is because it is easy and quick to carry out and it allows for the 
processing of several samples in parallel. This test can be used to measure 
growth factor release and protein expression that are necessary for 
understanding cell function. However, it cannot confirm whether the product will 
display the desired potency (effect) in vivo or not and for this reason, there is a 
need to develop better assays that can address the complexity of cellular 
therapy products.  
 
In the case of cytokine release by the inflammatory response, this simple test 
cannot give a full evaluation of the complexity and dynamic response of such 
process (Leng et al., 2008). Also, its performance is very much dependent on 
the user’s skills, the manufacturer and the quality of the antibody (Aziz et al., 
1999). This could lead to differences in cytokine levels when comparing the 
data of two different ELISA assays carried out in slightly different conditions. 
Moreover, ELISA-based assays have a dynamic range (range of linearity 
between cytokine concentration and absorbance reading in the standard 
curve) over which the samples will need to be diluted. This dilution lowers the 
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concentration of the cytokine to be quantified, and it may affect the 
concentration of other molecules contained in the solution such binding 
proteins. Additionally, it can lead to the amplification of differences in readings 
between samples that require dilution and samples that do not because they fit 
within the dynamic range (Leng et al., 2008). Overall, there is a need to look 
at technologies that can more directly determine the biological function of a cell 
product and overcome some of these drawbacks. 
 
1.14.2: Gene expression microarrays and qPCR 
The quantification of genes associated with a specific cell function could be used 
as a surrogate to in vitro potency testing. For example, quantitative real-time 
PCR has been used to quantify the expression of specific cytokines triggered by 
T-cell activation and to study other cell related processes including angiogenesis, 
cell-cycle, and apoptosis (Stroncek et al., 2007). qPCR can be used to screen 
single genes as well as groups of genes but it is not sufficient to screen a broader 
range of gene transcripts. Moreover, gene expression microarrays have been used 
to simultaneously measure the expression of more than a thousand genes 
(Stroncek et al., 2007). Microarray technology can screen all the gene expression 
profiles related to cell function and other cell characteristics such as stability and 
purity. Because this technology gives an indication of the signals that lead to cell 
death, it could be particularly useful for cell viability studies. The gene expression 
profiles can also detect the presence of other cell subpopulations thus giving 
an indication of cell purity (Stroncek et al., 2007).  
 
Ultimately, because microarray screening gives a better insight in cell 
function compared to other techniques, it would be particularly beneficial to 
use it in the context of stem cell research. However, there are limitations 
associated with such technology for lot release testing. For example, there is 
a need to carry out several steps before gathering the data which means that 
until further technology advances are developed, it is very unlikely to carry 
out these steps in just a few hours (Stroncek et al., 2007). 
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1.14.3: Metabolomics screening 
Metabolomics screening tests are generally used to quantify the presence of 
metabolites in biological specimens such as body tissues and body fluids 
(Dettmer et al., 2007). For this reason, it has found application in many disease-
related studies including cardiovascular diseases (Dettmer et al., 2007). The 
advantage that metabolomics has over other analytical methods is that there 
are only a small number of human metabolites (≈7000) compared to the 
approximate 25 000 genes, 100 000 transcripts, and 1 000 000 proteins. The 
human metabolome is composed of a variety of compounds belonging to 
different compound classes, such as lipids, proteins, and nucleotides. These 
different compounds display not only a significant chemical diversity but are 
also found at different concentrations (Dettmer et al., 2007). Although there has 
been significant technological advancement during the past few years, the 
current analytical instruments available can measure only a limited number of 
analytes simultaneously in one single analysis. This suggests that there is a need 
to develop high throughput protocols that can profile a wider range of 
metabolites in a given biochemical pathway, in particular in the case of cell 
therapies. In this way, the data gathered would allow for a better understanding 
of metabolic perturbations, and could be integrated with other omics data (e.g. 
genomics and proteomics) to give a complete picture of biological function 
(Dettmer et al., 2007).  
 
1.15: QbD for process standardization 
In 2002, the Food and Drug Administration (FDA), decided to make improvements 
to the systematic and risk-based approach used in industry with the “cGMP for 
the 21st Century: A Risk-based Approach” initiative (FDA, 2004). This initiative 
involved the use of quality by design (QbD) and the publication of the process 
analytical technology (PAT) guidance (FDA, 2004). Furthermore, three guidance 
documents followed as part of the International Conference on Harmonization 
(ICH): Q8 Pharmaceutical Development and Q9 Quality Risk Management, in 
2005, and ICH Q10 Pharmaceutical Quality System, in 2008. According to ICH 
Q8, QbD can be defined as a holistic approach to development that allows for 
predefined product specifications through the understanding of the products and 
processes, process control and quality risk management. Quality in itself is then 
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related to the suitability of a product to its intended use which includes attributes 
of identity, strength, and purity (FDA, ICH Q8 2009). 
 
The aim of QbD is to make processes more cost-effective and improve the 
quality of the process or the product. This approach involves the interaction 
between product knowledge and process understanding for continuous 
improvement (Figure 1-3), which according to ICH Q8 can be gained through 
design of experiments (DOE), process analytical technology (PAT) and/or 
previous knowledge. Quality risk management can also be used to recognise 
the studies required to acquire such knowledge. 
 
 
Figure 1-3: Quality by design (QbD) concept as presented by the FDA 
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QbD processes and product development should include the following elements 
(FDA, ICH Q8 2009):  
 
 Defining the quality target product profile (QTPP) which is obtained from 
the desired product information such as safety and efficacy. 
 Identifying potential critical quality attributes (CQAs) of the drug/cell 
product to study and control the product characteristics that affect product 
quality. 
 Choosing appropriate manufacturing processes.  
 Designing and implementing control strategy. 
 
1.15.1: Development of cell-based potency assays  
The cell-based therapy industry is faced with several bottlenecks, which 
include the intrinsic variability between cells, the lack of robust standard 
reference analytes and the difficulty in accurately measuring function. For this 
reason, there is a need to identify the sources of variation that affect the product 
and reduce/eliminate them. The difficulty in controlling the factors associated with 
cell quality has led to the failure of many cell-based bioprocesses (Ratcliffe et al., 
2011). Along with other tests that are required for product quality and 
reproducibility, cell-based potency assays are integral to effective QbD as they 
ensure that only products that meet a specific requirement are given to patients 
(Porat et al., 2015). Potency can be defined as the mode of action of the cell 
product, as indicated by predefined laboratory tests or data from clinical studies, 
to achieve a given result (Porat et al., 2015). The optimization of cell-based 
potency assays is fundamentally important for cell-based therapy 
bioprocessing especially considering the biological complexity of cells, as well as 
variations between lots. As part of good manufacturing practice regulations, 
potency assays used for release testing are required to (Porat et al., 2015): 
 
 Measure identity and strength (activity) of the product e.g. the indication of 
biological activities specific to the product with results that correlate to an 
effect in a relevant animal model and human trials. 
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 Provide quantitative data. 
 Include appropriate reference materials, replicates and controls to make 
sure that the assays perform as expected. The controls selected for the 
assays will then be chosen based on the product being analysed and the 
assays used. 
 Identify and establish the accuracy, sensitivity, specificity, and 
reproducibility of the assays used. 
 Adhere to pre-defined acceptance and/or rejection criteria. 
 Provide data to establish dating periods. 
 Meet labelling requirements. 
 
As part of QbD, a typical approach is to identify the key process input variables 
(KPIV) and key process output variables (KPOV) and have a range of 
acceptability in order to achieve good product standards. KPIVs can then be 
studied through a combination of design of experiments, mathematical models, 
or studies that lead to mechanistic understanding to gain a better understanding 
of the process. 
 
Traditional pharmaceutical approaches involve a one-factor at a time approach 
where only one variable is tested per experiment. On the other hand, DOE 
involves the use of statistical designs to understand the product. Therefore, the 
output from the DOE can then be used to confirm CQAs and critical process 
parameters (CPPs) that need to be controlled (FDA, ICH Q8 2009). Typically 
DOE will divide the input variables into three categories: statistically 
controlled variables, variables that are not controlled but for which there is the 
possibility to control and those that cannot be controlled (Ratcliffe et al., 2011; 
Williams et al., 2012). In this way, it is possible to characterize and identify 
KIPVs, gather an understanding of how much variation there is in each process 
and determine the relationships between the different parameters.  
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1.16: Research aims 
Currently, there are no potency assays in the clinical setting that give a reliable 
measurement of MSC mode of action other than simple surface marker 
expression that does not predict function. For this reason, there is a need to 
develop in vitro assays that can robustly predict the functional activity of the MSC 
product. In addition, the use of bone marrow MSCs can be potentially limiting as 
cells may lose functionality after a few passages and mesenchymal cells from 
other sources may differ in their engraftment abilities. The current work aims to:  
 
 Carry out comparative studies between slightly-younger and slightly-older 
bone marrow (BM) and umbilical cord (UC) derived MSCs. This will be 
achieved by assessing the adhesion, migration and vascular support abilities 
of Notch ligand-primed bone marrow and umbilical cord MSCs on biologically 
relevant matrices. 
 
 Use a methodological approach to determine key functions of HUVEC tubule 
formation. 
 
 Explore strategies to improve the engraftment and angiogenic properties of 
differently-sourced MSCs. For example, by subjecting the cells to process 
conditions which mimic the physiologic environment.  
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Chapter 2: Materials and methods 
The materials and methods described in this chapter apply generally to all the 
results sections reported later. Some detailed aspects of materials and methods 
will be described within the specific results chapter concerned.  
Note: As the earlier data to convert the hUC-MSCs from passage number to PDL 
was not available, individual donor hBM-MSCs that were available in both PDL 
and passage number were compared with hUC-MSCs (only available in passage 
number) and commercial low-serum hBM-MSCs (only available in PDL). In this 
way, it was possible to use the same parameters to study the effect of cell source 
and different growth medium on MSC functionality.  
 
2.1: Culture of human mesenchymal stromal cells 
(hMSCs) 
2.1.1: Culture and expansion of human bone marrow MSCs (hBM-
MSCs) and human umbilical cord MSCs (hUC-MSCs)  
hMSCs from the bone marrow of individual donors (Dr Mike Watts, Department of 
Haematology, University College London Hospital, London UK) or from the 
umbilical cord (Dr John Girdlestone, NHS Blood and Transplant, London UK) 
were cultured in a humidified incubator under normal conditions (20% O2, 5% CO2 
and 37 oC) at 4500 cells/cm2 in a volume of either 7 ml (for T25 flasks) or 12 ml 
(for T75 flasks) of complete medium. The complete medium consisted of low 
glucose (1 g/l) Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Invitrogen, 
Paisley UK) supplemented with 10% v/v foetal bovine serum (FBS, Sera 
Laboratories International, West Sussex UK) and 1 ng/ml of recombinant basic 
fibroblast growth factor (bFGF, R&D Systems, Minneapolis USA). The complete 
hMSC growth medium was stored at 2 – 8 oC and used within two weeks of 
preparation. Cells were provided with fresh media after every 2 days and they 
were observed every day under an inverted light microscope (Evos FL Cell 
Imaging System, Thermo Scientific, Loughborough UK) to record morphology and 
check for contamination. hMSCs were passaged after reaching 80-90% 
confluency following washing with 1% Phosphate-Buffered Saline (PBS) and 
trypsinization with 1 ml and 2 ml of 0.25% Trypsin-EDTA (Invitrogen, Paisley UK) 
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for each T25 and T75 flask respectively. The flasks were placed back in the 
incubator for 3 minutes at normal conditions and the cell detachment was 
confirmed under the inverted light microscope. Following this, complete medium 
(double the amount of Trypsin/EDTA solution) was added into each flask to 
inactivate Trypsin. The cell suspension was then transferred to a 15 ml Falcon 
tube and centrifuged at 300 g for 3 minutes at room temperature. After discarding 
the supernatant, the cell pellet was resuspended in 5 ml of complete medium with 
a 5 ml Pasteur pipette. Cell density was then measured using the Trypan Blue 
exclusion method (explained in section 2.1.3:) and the hMSCs were seeded in 
either T25 or T75 flasks at 4500 cells/cm2. Cell expansion for individual donor 
hBM-MSCs was carried out until passage 5 (P5) and cell expansion for hUC-
MSCs was carried out until passage 12 (P12).  
 
2.1.2: Culture and expansion of low serum commercial hBM-MSCs  
Commercially available hBM-MSCs (RoosterBio Inc, Frederick Maryland US) 
were maintained in culture with their own High Performance Medium (low-serum 
<5%, SU003, and SU005, RoosterBio Inc) in T75 flasks for 5 days. The High 
Performance Medium was prepared according to the manufacturer’s instructions. 
This involved bringing the hBM-MSC High Performance Medium Kit to room 
temperature and then adding 1 vial of hBM-MSC Medium Booster GTX (SU003) 
to 500 mL hBM-MSC Basal Medium (SU005). After reaching 80-90% confluency 
cells were detached from the flasks using 5 ml of TrypLE Express (Gibco, Life 
Technologies, 12604-021, Paisley UK) and incubated in a humidified incubator at 
normal conditions for 5 minutes. Cell detachment was assessed using an inverted 
light microscope and the cell suspension was then transferred to a 15 ml Falcon 
tube, followed by pelleting at 300 g for 3 minutes at room temperature. After 
discarding the supernatant, the cells were resuspended in the High Performance 
Medium and counted using the Trypan Blue exclusion method as described 
below. Cells were then seeded at 4500 cells/cm2 in T75 flasks containing 12 ml of 
High Performance Medium. The RoosterBio Inc hBM-MSCs will be referred to as 
commercial hBM-MSCs throughout the thesis. 
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2.1.3: Cell counting  
Cells were counted using the Trypan Blue exclusion method. Initially, cells were 
trypsinized, centrifuged and resuspended in complete medium. 100 µl aliquot of a 
single cell suspension was mixed in a 1:1 ratio with Trypan Blue by pipetting up 
and down, and 10 µl of the resulting cell suspension was pipetted inside the 
chamber between the haemocytometer glass slip and the haemocytometer. The 
cells present in the four corner primary squares of each grid (16 squares per 
corner) were counted under an inverted light microscope at X10 magnification 
(Evos FL Cell Imaging System, Thermo Scientific, Loughborough UK). Counts 
were carried out in duplicates and averaged. Only the cells that were not shown in 
blue under the light microscope and therefore did not stain with Trypan Blue were 
counted as viable cells. Cell viability was calculated by dividing the number of 
viable cells over the total number of dead and viable cells. The volume in of each 
of the counted squares of a haemocytometer is 0.1mm3 (or 10-4 ml). Therefore the 
number of viable cells/ml was calculated by taking the average number of cells 
per square and multiplying by the dilution factor and 10,000 to obtain the number 
of cells per ml of diluted sample. 
 
2.1.4: Cell banking  
Working cell banks were created for each differently-sourced MSC (P3 (PDL4) to 
P5 (PDL7) individual-donor hBM-MSCs, PDL10-PDL15 commercial hBM-MSCs 
and P9-P12 hUC-MSCs) to have enough material for the experiments outlined in 
this thesis. hMSCs were expanded in either T25 and then in T75 flasks until they 
reached 80-90% confluency. Following this, they were detached from the flasks 
and pelleted as described in section 2.1.1: and section 2.1.2:. hBM-MSCs and 
hUC-MSCs were resuspended respectively in a solution containing 10% Dimethyl 
sulfoxide (D5879, DMSO, Sigma Aldrich, Poole UK) and 90% FBS and gently 
mixed. Commercial hBM-MSCs were resuspended in CryoStor cryopreservation 
solution (C2999-100 ml, Sigma Aldrich, Poole UK). The cell concentration of each 
suspension was calculated as described in section 2.1.3 and adjusted to 1x106 
cells/ml using a 5 ml Pasteur pipette; 1 ml of cell solution was added into each 
cryovial (Nalgene, Invitrogen, Paisley UK). Cryovials were then placed into a 
freezing container within 2 min (Mr Frosty, Nalgene and Invitrogen, Paisley UK) 
with isopropan-2-ol and then moved to a -80 oC freezer overnight to gradually 
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reduce the temperature by 1 oC per minute so that the cells were not shocked. 
The following day, the freezing containers were moved into liquid nitrogen (-196 
oC) for long term storage.  
2.1.5: Cell thawing  
1x106 cells/ml of either individual donor hBM-MSCs, hUC-MSCs or commercial 
hBM-MSCs were thawed at 37 oC for 3 minutes. Following this, the cell 
suspension was added drop by drop (using a p1000 Gilson pipette) into a 15 ml 
Falcon tube containing 4 ml of pre-warmed growth medium. Cells were then 
pelleted at 300 g and 21 oC for 3 minutes and the supernatant discarded. 
Following this, the cell pellets were resuspended in 5 ml of their respective growth 
medium. Cells were counted, seeded in tissue culture flasks (T-flasks) at 4500 
cells/cm2 and maintained in a humidified incubator at normal conditions until they 
were ready to be passaged.  
 
2.2: Characterizing the growth kinetics of hMSCs 
To determine the growth kinetics of MSCs, cells were cultured in T25 and T75 
flasks until they reached 80-90% confluency. After 5 to 7 days, cells were 
harvested from the flasks and counted using the Trypan Blue exclusion method. 
 
2.2.1: Fold increase 
Fold increase is a measure describing how much the cells grow from one 
passage to another. Fold increase was calculated using the following formula: 
Fold increase = C(n)/C(n-1)  
 
Where: C(n) = cell number output at each given passage  
C(n-1) = cell number output from previous passage 
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2.2.2: Population doubling level (PDL)  
PDL represents the number of times of two-fold increase (doubling) in the total 
number of cells in culture. PDL number was calculated as follows:  
 
PDL= X + 3.32 log10 (UCY/l) 
Where: 
X = initial population doubling level 
UCY = final cell yield or number of cells at the end of growth period 
l = initial cell number seeded into the flask 
 
2.3: Characterization of human MSCs (hMSCs)  
2.3.1: Tri-lineage differentiation of hMSCs 
hMSCs were tested for their ability to undergo trilineage differentiation to 
osteoblasts, adipocytes and chondroblasts using the StemPro differentiation kits 
from Invitrogen. Control wells containing hMSCs cultured in standard growth 
medium were run in parallel to the experimental wells and each condition was 
performed in triplicate. 
 
2.3.1.1: Adipogenic differentiation 
hMSCs were seeded on 12 well plates at 1 x 104 cells/cm2 in growth medium and 
incubated at 37 oC for 3 days. After 3 days the growth medium was replaced with 
complete adipogenic differentiation medium (StemPro Adipogenesis 
Differentiation Kit, GIBCO and Invitrogen, Paisley UK) and cells were refed every 
4 days. After 14 days in culture, cells were washed once with 1x PBS (without Ca 
and Mg), fixed with 4% paraformaldehyde (PFA) solution for 30 minutes and 
rinsed with 2 ml distilled water. Following fixation, 2 ml of 60% of Isopropanol was 
added to each well, left for 5 minutes and then removed. Cells were then stained 
with 2 ml of 3% w/v Oil-Red-O/isopropanol in distilled water and incubated at 
room temperature for 5 minutes. After removing the Oil-Red-O dye from the wells, 
cultures were rinsed with distilled water until the water rinsed off clear. Wells were 
visualized under a microscope (Nikon Eclipse Ti, Kingston UK).  
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2.3.1.2: Osteogenic differentiation 
hMSCs were seeded on 12 well plates at 5 x 103 cells/cm2 in growth medium at 
37 oC for 3 days. The growth medium was then replaced with 1 ml of complete 
osteogenic differentiation medium (StemPro Osteogenesis Differentiation Kit, 
GIBCO and Invitrogen, Paisley UK) every 3 days. After 30 days cultures were 
rinsed with 1x PBS, fixed with 4% PFA solution for 30 minutes and washed with 
distilled water. Following fixation, cells were stained with 2% Alizarin Red solution 
(pH 4.2) for 5 minutes. Cells were then carefully washed with distilled water and 
visualized under the Nikon microscope. 
 
2.3.1.3: Chondrogenic differentiation 
hMSCs were trypsinized, centrifuged and resuspended in an appropriate volume 
of pre-warmed standard growth medium to generate a cell solution of 1.6 x 107 
cells/ml. Micromass cultures were generated by seeding 5 µl droplets of the cell 
solution in the centre of a 6 well plate. Cultures were then incubated in normal 
conditions for 2 hours. After 2 hours, cultures were fed with 2 ml of pre-warmed 
chondrogenesis medium (StemPro Chondrogenesis Differentiation Kit, GIBCO 
and Invitrogen, Paisley UK). The chondrogenesis medium was replaced every 2 
days and after 23 days in culture, the micromassess were washed once with 1x 
PBS and fixed with 4% PFA solution for 20 minutes at room temperature. 
Following fixation, cells were rinsed with distilled water and stained with 1% 
Alcian Blue (Sigma Aldrich, Poole UK) in 0.1 N Hydrochloric Acid (HCL) for 30 
minutes. Cultures were then washed 3 times with 0.1 N HCL followed by x1 wash 
with distilled water to dilute the acidity. Stained cultures were imaged under the 
Nikon microscope. 
 
2.4: Immunophenotype profile of hMSCs 
Flow cytometry was carried out using the BD Stemflow™ Human MSC Analysis Kit 
(BD Bioscience, Oxford, UK). hMSCs were characterised for the expression of the 
positive markers CD105-PerCP, CD73-APC and CD90-FITC and the negative 
markers CD34-PE, CD45-FITC and CD11b-PE. Cells were cultured for 5-7 days 
followed by trypsinization and resuspension in 1 ml of 3% bovine serum albumin 
(BSA, Sigma Aldrich, Poole UK) in PBS for 30 minutes. 
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Each cell sample was then split between three 15 ml tubes (one untreated tube, 
one treated tube, two negative control tubes and one isotype control tube). 
Following this, cells were pelleted at 300 g for 4 minutes and resuspended in 200 
µl of conjugated antibody solution for 20 minutes at 4 oC. hMSCs were then 
washed with 20 ml of 1x PBS and pelleted twice at 300 g for 4 minutes. Each 
pellet was resuspended in 1 ml PBS solution and processed with the BD Accuri™ 
C6 Flow Cytometer (BD Biosciences, Maryland USA). 
 
Isotype  Fluorochrome  Vendor Cat. 
number   
Dilution ratio of 
antibody for 
staining 
Mouse IgG1 , κ PerCP-Cy5.5 BD Biosciences 550795 1:200 
Mouse IgG1 , κ FITC BD Biosciences 555748 1:200 
Mouse IgG1 , κ PE BD Biosciences 555749 1:200 
Mouse IgG1 , κ APC BD Biosciences 555751 
 
1:200  
Table 2-1: list of isotype controls used for the staining of hMSCs. 
 
Specificity   Fluorochrome  Vendor Cat. 
number   
Dilution ratio 
of antibody 
for staining 
Mouse anti-
human CD11b 
PE BD Biosciences 555388 1:100 
Mouse anti-
human CD34 
PE BD Biosciences 555822 1:100 
Mouse anti-
human CD45 
FITC BD Biosciences  555482 1:100 
Mouse anti-
human CD73 
APC BD Biosciences  560847 1:100 
Mouse anti-
human CD90 
FITC BD Biosciences 555595 1:100 
Mouse anti-
human CD105 
PerCP-Cy™5.5 BD Biosciences 560819 1:80 
Table 2-2: List of negative and positive antibodies used for the staining of hMSCs. 
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2.5: Priming of hMSCs by soluble Notch ligands 
hMSCs were grown until they reached 80-90% confluency. Cells were then 
trypsinized and resuspended in 1% FBS/DMEM or High Performance Medium at 
1.8 x 105 cells/ml. hMSCs were pre-stimulated for 45 minutes in the presence of 
3.6 nM of either soluble recombinant human Jagged 1 (sJag1, 277-JG, R&D 
Systems, Minneapolis USA) or soluble recombinant human Delta-Like 4 (sDll4, 
1506-D4, R&D Systems, Minneapolis USA). Hence, either 500 ng of sJag1 or 200 
ng of sDll4 were added for each ml of hMSC suspension. 
 
2.6: RNA extraction and quantitative polymerase chain 
reaction (qPCR) for gene expression analysis 
2.6.1: RNA extraction 
qPCR was performed to quantify the sJag1/sDll4 preconditioning effects on cells 
seeded on fibronectin coated wells. 1 x 106 hMSCs were seeded on fibronectin 
coated 6-well plates and incubated at 37 oC for 45 minutes. Following this, the 
non-adherent cells were washed away and the cells that remained attached were 
trypsinized, pelleted at 300 g for 4 minutes and left at -80 oC for qPCR analysis. 
RNA was extracted from the frozen cell pellets using the Qiagen RNeasy kit 
(Qiagen, Manchester UK). In brief, cells pellets were lysed using RTL buffer and 
homogenized by being centrifuged in Qiashredder columns (Qiagen, Manchester 
UK) at 10,000 RPM for 2 minutes. The RNA was extracted according to the 
manufacturer’s instructions and collected in 40 µl RNase-free water, following 
quantification using a NanoDrop (ND1000; NanoDrop Products, Wilmington 
USA). 
 
2.6.2: gDNA elimination 
Before proceeding to cDNA synthesis, RNA samples must be free of 
contaminating genomic DNA (gDNA) which can be achieved through an 
elimination step. gDNA elimination was performed using the QuantiTect Reverse 
Transcription kit (Qiagen, Manchester UK) according to the manufacturer’s 
instructions. Briefly, 2 µl gDNA wipeout buffer was added to 1 µg of template RNA 
and the volume was made to 14 µl using RNase-free water. The mix was then 
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centrifuged for a couple of seconds and placed in a thermocycler set at 42 oC 
heating for 2 min and then left to cool at 4oC. 
 
2.6.3: cDNA synthesis 
A master mix was then prepared for cDNA synthesis. Briefly, a reaction 
containing 1 μl Quantiscript reverse transcriptase (RT), 4 μl RT buffer 5x, 1 μl RT 
primer mix and 14 µl of template RNA was prepared and placed in a thermocycler 
set at 42 oC for 15 min, followed by 95 oC heating for 3 min and then left to cool at 
4oC. 
 
2.6.4: Two-step qPCR 
qPCR was performed using 10X QuantiTect Primer Assay (Qiagen, Manchester 
UK) and a summary of the primers used can be found in table 2-6. Before the 
beginning of the experiment primers were reconstituted at room temperature in 
Tris-EDTA buffer to obtain a 1X working stock solution. A master mix was 
prepared for each gene to be analysed based on the number of reactions 
required. Each master mix included 12.5 µl 2X QuantiTect SYBR green (Qiagen), 
1.5 µl 1X QuantiTect primers (Qiagen) and 6µl RNAse-free water for each gene. 
Afterwards, 20 µl of each master mix was aliquoted into each well of the 96-well 
plates. Following this, 5 µl of cDNA was ejected into each well according to the 
manufacturer’s instructions. Gene expression was then detected using a CFX 
Connect Real time PCR Detection system (Bio-Rad, Hemel Hempstead UK). 
Each condition was run in duplicate and experiments were run independently 
three times using a CFX-Connect thermocycler (Bio-Rad Laboratories, Watford 
UK). No template controls (NTCs) were run in a single well for each gene to 
enable detection of contamination and no reverse transcriptase controls (NRT) 
were run in triplicate wells to detect DNA contamination. Refer to Table 2-3 for the 
RT-PCR cycling. 
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Table 2-3: Summary of cycling conditions for qPCR. 
 
2.6.4.1: Calculation of expression fold change 
Gene expression was calculated manually by extracting the Cq values from the 
Bio-Rad CFX Manager software (Bio-Rad Laboratories, Watford UK) after which 
Cq values for each gene were averaged.  
The relative quantification (RQ) for each gene was obtained by using the following 
formula: 
Relative quantification = 2-(ΔCTE - ΔCTC) 
 
Where: 
ΔCTE = average of experimental Cq values 
ΔCTC = average of control Cq values 
 
The normalised RQ value (NRQ) for each gene was obtained by normalizing the 
RQ value from each gene to the RQ value of the house keeping gene 18S. 
Table 2-4: List of qPCR primers used. 
 
Step  Temperature  Duration  
1 –PCR initial heat 
activation  
95 ⁰C  15 min  
2 –Denaturation  94 ⁰C  15 s  
3 –Annealing  55 ⁰C  30 s  
4 –Extension  72 ⁰C  72 s 
5 –Go to Step 2 45X    
6 –Data Acquisition  65 ⁰C  5 s  
Gene  Supplier Supplier Product Code  Location 
18S  Qiagen  QT00199367  Manchester UK 
HES1  Qiagen  QT00039648 Manchester UK 
HEY1  Qiagen  QT00035644  Manchester UK 
JAG1  Qiagen  QT00031948  Manchester UK 
DLL4  Qiagen QT00081004  Manchester UK 
HIF1 Merck Millipore  MAB5382 New Jersey USA 
HIF3 Qiagen  QT00059157 Manchester UK 
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2.7: Macro design to quantify staining  
The following script was created using ImageJ (ImageJ software, National 
Institutes of Health, Maryland USA) to quantify the area, the integrated density 
and the mean intensity of the integrin β-1 staining in Chapter 3. The ImageJ batch 
processing tool was used to automate the analysis of all of the staining images. 
The ImageJ macro was generated by recording a series of commands using the 
command recorder. The units of pixels were converted to micrometres by 
measuring the length of the scale bar on the image and using the “set scale” 
command to input the measured length. Each image was first converted to 8-bit 
grayscale to allow the use of the “thresholding” tool which only works with 
grayscale images. Following this, the thresholding tool was run for each image to 
select the stained regions. In order to tell imageJ what to measure, the “set 
measurements” dialog was opened and the wanted outputs selected e.g. 
integrated density. The “analyze particles” command was run to select the particle 
size range and to show the regions of interest using the “overlay mask” option. 
Following this, the “roi manager show all” command was selected to display all of 
the stained regions and the number of stained cells per image simultaneously.  
 
run("Set Scale...", "distance=439 known=200 pixel=1 unit=um global"); 
run("8-bit"); 
run("Median...", "radius=2"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
setThreshold(7, 255); 
run("Set Measurements...", "area mean standard integrated display redirect=None 
decimal=3"); 
run("Analyze Particles...", "size=200-Infinity show=[Overlay Masks] display exclude add"); 
roiManager("Show All with labels"); 
roiManager("Show All"); 
 
2.8: Hypoxic chamber oxygen measurements 
A low oxygen environment was achieved by purging a mixture of oxygen, carbon 
dioxide and nitrogen (2% O2/5% CO2/93% N2 balanced) into an air-tight chamber. 
To quantitatively confirm that a low oxygen environment for the cells was 
achieved, sensors were attached to the top of the chamber and the bottom of 96-
well plates (containing cell growth medium) that were put inside the chamber. 
Three measurements were taken because the oxygen profile in the liquid phase 
of the 96-well plates can be different from the air phase in the chamber. Oxygen 
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profiles were monitored over a period of 24 hours. In this way, it was possible to 
confirm that a low oxygen environment was maintained for more than 18 hours. 
 
 
Figure 2-1:A) Set up for oxygen chamber measurement B) oxygen sensors were attached to 
the chambers C) the partial pressure of oxygen (PO2) in the chambers was measured in a 
5%CO2/20% O2 incubator to ensure optimum growth environment for the cells. 
 
2.9: Cell culture techniques of primary human umbilical 
vein endothelial cells (HUVECs)  
2.9.1: Thawing, culture and expansion of HUVECs 
HUVECs were obtained from Dr Enca Martin-Rendon’s lab at the University of 
Oxford. The cells were thawed at 37 oC for 3 minutes and resuspended in a 15 ml 
Falcon tube containing 4 ml of pre-warmed growth medium. The growth medium 
consisted of Endothelial Growth Medium-2 (EGM-2, Lonza, Slough UK) including 
Bullet-kit (Lonza; containing FBS, human epidermal growth factor, hydrocortisone, 
vascular endothelial growth factor, human bFGF, insulin like growth factor-1, 
ascorbic acid and heparin). The cell solution was then centrifuged at 300 g and 21 
oC for 3 minutes. The supernatant was discarded and the cell pellet was 
resuspended in 3 ml of pre-warmed EGM-2 medium. HUVECs were expanded in 
T75 flasks and the medium was replaced every two days. Cells were then 
passaged after reaching 80-90% confluency following washing with 1x PBS and 
trypsinization with 0.25% Trypsin-EDTA (Invitrogen) for 3 minutes at 37oC. EGM-
2 (double the amount of Trypsin/EDTA solution) was added into each flask to 
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inactivate Trypsin. Cells were always seeded in a 1:3 ratio. Tubule assay 
experiments were carried out on early passage 7 HUVECs (P7), passage 10 
HUVECs (P10), passage 13 HUVECs (P13) and passage 15 HUVECs (P15). 
 
2.9.2: Characterization of HUVECs 
HUVECs were tested for the expression of vWF and CD31. The endothelial cells 
were seeded on 12-well plates at 10000 cells/cm2 and cultured in EGM-2 medium. 
After 2 days the medium was removed from each well and the cells were washed 
once with 1x PBS, fixed for 15 minutes in 4% PFA followed by 3 washes with 
PBS. Cells were then permeabilized using 0.25% Triton X-100 (BDH, Poole UK) 
in PBS solution for 10 minutes, washed 3 times with PBS and incubated for 1 
hour at room temperature in 1% BSA/PBS. Cells were then incubated overnight at 
4 oC with either Von Willebrand Factor (vWF, A0082, Dako, Ely UK) or CD31 
(ab28364, Abcam, Cambridge UK) at 1:200 dilution in blocking solution. For the 
negative controls, the primary antibody was omitted. The following day each well 
was washed 3 times with PBS and incubated with the appropriate secondary 
antibodies at 1:200 dilution in PBS for 1 hour at room temperature. After x2 wash 
with 1x PBS, nuclei were counterstained with DAPI (1:2000 dilution in PBS) for 10 
minutes, followed by x3 wash with PBS. The cells were left in PBS for imaging. 
 
2.9.3: Cell banking of HUVECs 
In order to have a sufficient number of HUVECs to carry out the experimental 
work, a working cell bank (P5-P12 HUVECs) was created. P3 HUVECs were 
expanded in T25 flasks and when they reached 80-90% confluency they were 
detached trypsinized, pelleted and resuspended in 5 ml EGM-2. Cells were then 
counted using the Trypan Blue exclusion method (section 2.1.3:), pelleted and 
resuspended in the appropriate volume of FBS to obtain 3x105-5x105 cells/ml. 
10% DMSO was added to the cell suspension drop by drop and gently mixed 
using a 5 ml pipette. Cells were then transferred to 1 ml cryovials and carefully 
placed in Mr Frosty freezing containers. The containers were then placed 
overnight in a -80 oC freezer and on the following day the cryovials were stored in 
liquid nitrogen. 
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2.10: In vitro vascular assays 
2.10.1: Gel coating 
The in vitro vascular assays were all performed in 96-well plates. Aliquots of 
Growth factor reduced Matrigel (GFR Matrigel, BD Biosciences, Maryland USA) 
and growth factor reduced Geltrex (GFR Geltrex, Life Technologies, Paisley UK) 
previously stored at -20 oC were thawed overnight on ice at 4 oC. The following 
day, 96-well plates were cooled on ice and each well was coated with either 35 μl 
or 55 μl of GFR Matrigel or GFR Geltrex using pre-cooled pipette tips. The plates 
were then incubated in an incubator set at 37 oC and 5% CO2 for at least 30 
minutes. Following this, cells were seeded on top of the gel coatings as described 
below. 
 
2.10.2: Tubule assay formation on Matrigel and Geltrex 
HUVECs were seeded into each of the wells at the desired concentrations 
(cells/ml) and a total volume of 150 µl suspension of cells in pre-warmed EGM-2 
was gently mixed and seeded on either Matrigel-coated or Geltrex-coated wells of 
x2 96-well plates. Each condition was repeated in triplicate. One of the 96-well 
plates was first placed in a hypoxic chamber purged with 2% oxygen (2% O2/5% 
CO2/93% N2 balanced) and then put together with the other plate in a humidified 
incubator set at 37 oC, 5% CO2 and ambient oxygen (20% O2). The networks 
formed were observed after 18-19 hours. Tubules were imaged using phase 
contrast imaging and branches were quantified manually and also by using the 
ImageJ angiogenesis analyser (ImageJ software, National Institutes of Health, 
Maryland USA).  
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Figure 2-2: Diagram summarizing experimental setup for vascular tubule assays. 
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2.10.3: In vitro vascular assay quantification 
Counts were performed on either whole well representative images taken at x2 
magnification (2000 µm) or on whole well images taken at x4 magnification (1000 
µm) and merged (PanoramaStudio2Pro software, Sulzfeld EU). The number of 
branch points was measured as the number of sprouts originating from a single 
tubule. Measurements were made based on 1 branch point = junction of 3 
branches, 2 branch points = junction of 4 branches and 3 branch points = junction 
of 5 branches. Counts were performed either manually or using the automated 
counting technique using the ImageJ angiogenesis analyser. However, the 
ImageJ analyser was also used to quantify number of meshes (small areas 
enclosed by the tubules), average tubule length and cumulative tubule length of 
the branches (total length of all the branches in a given field) as these type of 
measurements would have been more time-consuming and more difficult to 
measure using the manual method (Staton et al., 2007). It is notable that in 
Chapter 4 the comparison between manual and automated counting technique 
was based on the number of branch points. In fact, whilst in the co-culture assays 
there were evident differences in branch length between the co-culture assays 
and the endothelial tubule assays, this was not the case for the data in Chapter 4 
where only one type of assay was performed and therefore the average length of 
the branches was similar. 
 
2.11: Statistical analysis  
All experimental conditions were tested in triplicate. Experiments were performed 
independently at least two times. Results were presented as standard error of the 
mean (SEM) when comparing across three independent experiments or more, or 
standard deviation (SD) of the mean when comparing data within an experiment. 
Statistical significance was determined by Analysis of Variance (ANOVA) with 
Bonferroni post-hoc correction to obtain the adjusted p values for multiple 
comparisons. Data with p values less than 0.05 were considered statistically 
significant. GraphPad Prism v7 (GraphPad Software, La Jolla USA) was used to 
perform statistical analysis.  
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Chapter 3: A comparative analysis of cell retention 
responses of differently-sourced hMSCs 
3.1: Introduction  
The following section will summarize the relevant literature which was previously 
discussed in Chapter 1.  
 
To understand how MSCs might behave when they are in the injury site, it is 
beneficial to consider the environment that they will experience and how this 
might affect them. Fibronectin (FN) is expressed after a myocardial infarction (MI). 
This protein is known to play a fundamental role in cell adhesion and migration 
(Van Dijk et al., 2008). During an MI, fibronectin deposits in the infarcted zone of 
the heart and forms a blood clot to stop the bleeding (Van Dijk et al., 2008). FN 
fragments also contain the site for integrin α5β1 that MSCs express and therefore 
the FN fragments may increase the adhesion of α5β1-expressing cells which 
could potentially improve engraftment (Van Dijk et al., 2008; Veevers-Lowe, 
2011). For example, it was shown that MSCs induced to overexpress 
transglutaminase which is a co-receptor for fibronectin, showed increased 
adhesion and migration properties in the infarcted myocardium of a rat hence 
leading to improved heart function (Lee et al., 2015; Song et al., 2007). Moreover 
studies could be carried out to compare the effect of different FN concentrations 
on the adhesion abilities of MSCs. Fibronectin has also been shown to perform 
better than other types of extracellular matrix (ECM) molecules in enhancing the 
adhesion properties of bone marrow-derived stem cells in vitro (Van Dijk et al., 
2008). 
 
One of the main limitations in determining the mode of action of MSCs in vivo is 
their poor engraftment at the site of injury (Amado et al., 2005; Cheng et al., 
2008). Several studies reported that targeting the Notch signalling pathway may 
enhance responses relevant to cardiovascular regeneration of MSCs (Xie et al., 
2013). The Notch pathway is highly conserved and it has a fundamental role in 
cardiac development (Li et al., 2010). There are many molecules involved in 
Notch signalling. For example, tumour necrosis factor alpha, a key cytokine 
involved in inflammation and a potent regulator of the migration of MSCs in vivo, 
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is known to modulate key ligands involved in the Notch pathway (Benedito et al., 
2009). Recent studies demonstrated that when MSCs were pre-stimulated with 
tumour necrosis factor alpha, cells remained engrafted in the endothelium for 
longer (Lu et al., 2016). In another study it was reported that blocking Notch 
signalling in bone marrow MSCs (BM-MSCs) promoted cell migration in vitro and 
up-regulated the cell receptor CXCR4 (Xie et al., 2013); the up-regulation of 
CXCR4 was shown to be beneficial for cell survival and homing (Cao et al., 
2013). 
 
To date bone marrow has been the main source of MSCs for clinical use. 
However, they are limited because their harvesting involves invasive methods 
and the number and differentiation potential as well as the maximum life span of 
BM-MSCs significantly declines with the age of the donor (Bruna et al., 2016). On 
the other hand, human umbilical cord MSCs (UC-MSCs) can be easily isolated 
using non-invasive methods (Jin et al., 2013). Moreover, they have been shown 
to have greater proliferation capacity and faster growth in vitro than BM-MSCs 
(Chen et al., 2014). The media used for cell culture is another challenge in the 
clinical application of MSCs (Chen et al., 2013). Even though serum containing 
medium allows for robust cell expansion, traditional formulations carry the risk of 
viral, bacterial and mycoplasma contamination from the serum as well as 
variations between batches which affect the reliability of experimental data 
(Witzeneder et al., 2013). Generally high amounts of foetal bovine serum (FBS) 
are added as a supplement to the culture media in which the cells grow, typically 
5-15% (Chen et al., 2013). Current research is focused on reducing/eliminating 
the dependence on serum (Chen et al., 2013).  
 
With the understanding that there is a need to reduce dependence on serum in 
MSC cultures and that MSCs from different origins may behave differently, the 
current study compared bone marrow-derived MSCs (expanded in complete 
DMEM medium) with hUC-MSCs as well as hBM-MSCs that came with their own 
low-serum medium (<5%, Rooster Bio, Maryland US). These comparative studies 
were performed to investigate differences in cell attachment and migration 
responses via priming with Notch factors, phenotype, and expression levels of 
MSC positive and negative markers. 
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3.2: Aim and hypotheses 
3.2.1: Aim 
 
 To test the functional abilities of hMSCs primed with Notch ligands and to 
compare differences in surface marker expression, proliferative capacities 
and differentiation patterns of differently-sourced hMSCs. 
 
3.2.2: Hypotheses  
 
 Differently-sourced MSCs will exert differences in functional abilities. 
 
 The adhesion and migration ability of hMSCs can be enhanced by Notch 
ligand preconditioning. 
 
 Stimulation of commercial hBM-MSCs with PDGF-BB will increase their 
migration potential. 
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3.3: Materials and methods  
Adhesion assays were carried out on individual donor hBM-MSCs, commercial 
low-serum hBM-MSCs and hUC-MSCs at different passage (P) numbers or 
population doubling level (PDL). Individual donor hBM-MSCs were also referred 
to as gx11 hBM-MSCs, gx11 being the name arbitrarily given to the batch of 
hMSCs isolated from one specific donor. Migration assays were carried out on 
commercial hBM-MSCs expanded in their own low-serum high performance 
medium. All the general materials and methods are described in Chapter 2. 
 
3.3.1: Adhesion assay 
hMSCs were cultured until they reached 80-90% confluency. Cells were starved 
in 1% FBS/DMEM (no growth factors added) for 24 hours before the experiment. 
Meanwhile, 48-well plates were coated overnight at 4 oC, or at room temperature 
(in the biological safety cabinet) for 2 hours, with 200 µl of 10 µg/ml of human 
plasma FN (1 mg; Tebu Bio, Peterborough; UK). The excess FN was then 
removed from the wells followed by one wash with 1x PBS. Cells were then 
blocked for 1 hour with sterile 3% BSA/PBS. Meanwhile, MSCs were trypsinized 
and resuspended in 1% FBS/DMEM (no growth factors added). Viable cells were 
then counted using a haemocytometer and diluted to a concentration of 1.8 x 105 
cells/ml. The cell suspension was then split between three tubes. In two of the 
tubes the MSCs were pre-stimulated respectively with soluble Jagged 1 (sJag1) 
at a concentration of 500 ng/ml and soluble Delta-like 4 (sDll4) at a concentration 
of 200 ng/ml, cells were then gently mixed and pre-stimulated for 45 minutes in a 
humidified incubator set at 37 oC and 5% CO2. The third tube was used as a 
control (UT) with non-pre-stimulated hMSCs and it was run in parallel at the same 
conditions as the other two tubes. 1 ml of 1 x 104 per well was seeded into each 
of the well plates, the assays were performed in triplicate for each condition. Cells 
were incubated for the desired time before being washed once with PBS to 
remove the non-adhered cells. The attached cells were then fixed with 500 µl of 
4% paraformaldehyde (PFA) and left in the hood for 15-20 minutes. Following 
fixation, the adhered cells were washed twice with PBS and stained with 1:3000 
dilution of 4',6-diamidino-2-phenylindole (DAPI) for 3 minutes. Wells were then 
washed once or twice with 1x PBS and left in PBS for imaging under the Nikon 
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Eclipse TE2000-U microscope (Nikon, UK) for assessment of adhesion at 4x 
magnification (four random fields of view per well). The number of attached cells 
was quantified with the ImageJ software Cell Counter plugin. Experiments were 
performed independently at least two times.  
 
3.3.1.1: Adhesion ligand expression analysis  
Fixed cells from the adhesion assays were washed once with 1x PBS and 
permeabilized with 0.25% TRITON X-100/PBS for 10 min. After a three times 
wash with PBS, cells were blocked for 1 hour with 3% BSA/PBS at room 
temperature (RT). Cells were then incubated overnight at 4 oC with the primary 
antibody at the desired concentration and on the following day they were washed 
three times with PBS. The attached cells were then incubated with the secondary 
antibody (previously diluted at the desired concentration in 1x PBS) for 1 hour 
following a three times wash with PBS. Fluorescence images were taken using 
the Nikon Eclipse TE2000-U fluorescence microscope (Nikon UK Limited, 
Kingston, UK). 
Table 3-1: List of antibodies used to assess the adhesion of MSCs on FN surfaces.  
 
3.3.2: Hypoxia 
To mimic the environment within an ischemic heart, plates containing the cell 
solutions were placed in a modular in house manufactured chamber (Mondragon-
Teran et al., 2009) purged with a gas mixture of 2% O2/5% CO2/ 93% N2 balanced.  
Host  Antibody Reactivity Type Catalogue no. Dilution 
Rabbit IgG  Human   Primary AB52971; Abcam 
(total integrin β-1) 
1:50 
Mouse IgG Human   Primary 556048; BD 
Bioscience (active 
integrin β-1) 
1:250 
Goat  IgG Alexa 
Flur 448 
Rabbit IgG Secondary A-21428; 
Thermofisher 
1:200 
Goat IgG Alexa 
Flur 595 
Mouse IgG Secondary A-11001; 
Thermofisher 
1:200 
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Cell age 
(passage 
number/PDL) 
Cell type  Oxygen 
tension 
 
Number of 
independent 
experiments 
(n) using 
same donor 
cells 
Attachment time  Well plates used  Variables being 
investigated  
P4 (PDL 5) gx11 hBM-MSCs 20% O2 n = 3 20 min & 45 min 48-well plates 
Effect of attachment time 
and priming of MSCs with 
Notch ligands. 
P6 (PDL 8) gx11 hBM-MSCs 20% O2 n = 3 20 min & 45 min 48-well plates 
Effect of attachment time 
and priming of MSCs with 
Notch ligands. 
P11 hUC-MSCs 
20% O2  and 
2% O2 
n = 4 20 min & 45 min 48-well plates 
Effect of attachment time 
and priming of MSCs with 
Notch ligands. 
P13 hUC-MSCs 
20% O2  and 
2% O2 
n = 4 20 min & 45 min 48-well plates 
Effect of attachment time 
and priming of MSCs with 
Notch ligands. 
PDL15 
Commercial hBM-
MSCs 
20% O2 n = 5 20 min & 45 min 48-well plates 
Effect of attachment time 
and priming of MSCs with 
Notch ligands. 
PDL 15 
Commercial hBM-
MSCs 
20% O2 n = 3 & n = 2 20 min & 45 min 96-well plates 
Effect of different 
concentrations of FN and 
Notch ligands (sJag1 and 
sDll4) on cell adhesion. 
Table 3-2: Summary of attachment assays.  
 
Note: Experiments were carried out using different hMSC batches isolated from the same donor for each condition, and (n) represents the 
number of times (i.e. different days) the experiments were performed using same donor cells. 
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3.3.3: Transwell migration assay 
Low-serum hBM-MSCs were cultured for five days in their own medium (Rooster 
Bio Inc, Maryland, US), following their adaptation in 1% FBS/DMEM for 24 hours 
prior to the migration experiment or left in their low-serum medium. Migration 
assays were performed in 24-well plates (BD; Oxford, UK) using 8-µm pore cell 
culture inserts (BD; Oxford, UK). Transwell inserts were coated overnight with 10 
μg/ml of FN in 1x PBS. On the day of the experiment, inserts were washed with 
1x PBS and transferred into new 24-transwell plates. 300 µl of serum free 
medium/low-serum medium containing 2 x 104 cells was loaded to the upper 
chamber of the inserts, whilst 800 µl of serum free medium/low-serum medium 
with or without 50 ng/ml Recombinant Human platelet-derived growth factor BB 
(PDGF-BB; R & D Systems, Abingdon, UK) was added to the lower chamber; the 
assays were performed in triplicate for each condition. After 3 hours of incubation at 
37ºC, 5% CO2, cells which adhered to the membrane were fixed with 4% PFA for 
10 minutes, washed once with distilled water and then stained with 0.5% (w/v) 
crystal violet in 5% ethanol filtered solution for 30 minutes. Following this, the 
inserts were washed serially twice with PBS and any remaining cells were once 
more removed by gently scraping the upper surface of the membrane with cotton 
swabs. Transwell inserts were left to dry, mounted onto microscope slides and 
counted in four to five random fields of view at 10X magnification. The migrated 
cells were counted using the ImageJ software Cell Counter plugin. 
 
Cell age 
(PDL) 
Cell type  Supplier for 
cells and 
culture medium 
Number of 
independent 
experiments 
using same 
donor cells 
Migration 
time   
Oxygen 
tension 
PDL 15 hBM-MSCs Rooster Bio Inc; 
Maryland, US 
n = 3  4 hours  20%  
PDL 15 hBM-MSCs Rooster Bio Inc; 
Maryland, US 
n = 3 4 hours 2% 
Table 3-3: Summary of transwell migration assays. 
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3.4: Results 
3.4.1: Characterization of hMSCs 
3.4.1.1: Cell morphology  
The morphological characteristics of hMSCs were observed using an inverted 
light microscope. hMSCs from different sources were seeded at 4500 
cells/cm2. All three differently-sourced hMSCs maintained their proliferative 
and plastic adherent abilities after being frozen down from liquid nitrogen and 
this was also observed for the older cells (Figure 3-1 A-F). No significant 
morphological differences were observed between the three differently-
sourced hMSCs, in fact they all displayed a homogeneous monolayer with the 
cells adopting a small spindle-shaped morphology (Figure 3-1 A-F).  
 
Figure 3-1: Cell morphology characterization of hMSCs after 5 days in culture. (A) Individual 
donor gx11 P4 (PDL 5) hBM-MSCs and (B) Individual donor P6 (PDL 8) gx11 hBM-MSCs 
were expanded in complete medium (C) PDL 14 commercial hBM-MSCs (D) and PDL 17 
hBM-MSCs were expanded in their low-serum medium (E) P11 hUC-MSCs and (F) P13 hUC-
MSCs were expanded in complete medium. Scale bars = 400 µm. 
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3.4.1.2: Tri-lineage differentiation  
Osteogenic differentiation ability was determined by Alizarin Red staining of 
mineralization (Figure 3-2 4, 5 and 6) after culturing cells in osteogenic 
medium for 30 days. Adipogenic differentiation was determined using Oil-Red-
O, which stains small lipid vacuoles in the cytoplasm of mature adipocytes, 
following 14 days culture in adipogenic medium (Figure 3-2 7, 8 and 9) and 
chondrogenic differentiation was evaluated using the pellet culture system 
(Figure 3-2 10, 11 and 12). Cells undergoing chondrogenic differentiation 
appeared blue when stained with Alcian Blue dye (Figure 3-2 10, 11 and 12). 
However, cells cultured in their standard medium displayed their usual 
morphologic characteristics (Figure 3-2 1, 2 and 3).  
 
Figure 3-2: All different source hMSCs successfully underwent osteogenic, adipogenic and 
chondrogenic differentiation. hMSCs were stained with Alizarin Red for osteogenesis after 30 
days in culture (4, 5 and 6), Oil-Red-O for adipogenesis after 14 days in culture (7, 8 and 9) 
and Alcian Blue for chondrogenesis after 23 days in culture (10, 11 and 12) respectively. 
Scale bars = 200 μm (1, 2, 3 and 4, 5 and 6), 50 µm (7, 8 and 9) and 100 µm (10, 11 and 12). 
 
3.4.1.3: Immunophenotype  
Flow cytometry was carried out on cell pellets of no less than 5 x 105 cells, to 
quantify the percentage of cells expressing positive MSC surface markers (>95% 
according to the ISCT guidelines, CD105, CD90 and CD73) and lacking the 
expression of the negative markers CD45 (pan-leukocyte marker), CD34 (labels 
primitive hematopoietic progenitor and endothelial cells), and CD11b (expressed 
on monocytes and macrophages) (<2% according to the ISCT guidelines) 
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(Domini et al., 2006). A cocktail of isotype controls was also used to detect 
background staining. The flow data was displayed using histogram plots which 
plotted a single parameter (FITC, PE or PercP intensity, x-axis) against the 
number of events (cells) detected (y-axis) by the machine. An event is a unit of 
data which represents a cell. The isotype controls for the differently-sourced 
hMSCs indicated low levels or the absence of non-specific interactions (0%-3.7%; 
see Figure 3-6 A, Figure 3-7 C, Figure 3-4 E, Figure 3-5 G and Figure 3-3 I). As 
seen in Figure 3-6 H and Figure 3-7 J, the slightly-younger and slightly-older 
hUC-MSCs highly expressed the positive markers (>95%) and showed no 
expression (<2%) of the negative markers; similarly individual donor hBM-MSCs 
also displayed a near pure population (Figure 3-3 A and B). Furthermore, old and 
young commercial low-serum hBM-MSCs (Figure 3-4 D and Figure 3-5 F) highly 
expressed the positive markers (>95%) and lacked the expression of MSC 
negative markers (<2%). However, the PDL17 commercial hBM-MSCs displayed 
a decrease in expression of CD105 (82.2%; Figure 3-5 F, 2). CD105 was 
observed to be consistently lower in expression than the other positive markers 
CD73 and CD90 which consistently showed expression levels of above 99%.  
 
 P6 (PDL 8) 
hBM-MSCs 
Low-serum 
PDL 14 
hBM-MSCs 
Low-
serum PDL 
17 hBM-
MSC 
P11 
hUC-
MSCs 
P13 
hUC-
MSCs 
CD90 99.8% 99.8% 99.8% 99.6% 99.5% 
CD73 99.5% 99.6% 99.6% 99.5% 99.1% 
CD105 95.2% 94.4% 82.2% 96.9% 96.4% 
CD45 0.1% 0.6% 0.3% 1.4% 1.9% 
CD34 0.1% 1.1% 0.2% 1.2% 0.9% 
CD11b 0.0% 0.3% 0.1% 1.1% 1.0% 
Table 3-4: Immunophenotypic data for differently-sourced hMSCs. 
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A     Isotype controls  
 
B       P6 (PDL 8) Individual donor hBM-MSCs  
 
Figure 3-3: Immunophenotype by flow cytometry analysis of individual donor P6 (PDL 8) hBM-
MSCs expanded in complete medium. (A) isotype controls were run in parallel to the 
experimental samples. (B, 1) results reported positive expression of hMSC markers (CD90, 
CD73, and CD105); (B, 2) less than 1% of hMSCs expressed negative markers (CD45, CD34, 
and CD11b). The red horizontal line on each histogram represents the percentage of positive 
cells for each surface protein. 
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C     Isotype controls  
 
 
D      PDL 14 low-serum commercial hBM-MSCs  
 
Figure 3-4: Immunophenotype by flow cytometry analysis of low-serum PDL 14 hBM-MSCs. 
(C) isotype controls were run in parallel to the experimental samples. (D, 1) results reported 
positive expression of hMSC markers (CD90, CD73, and CD105); (D, 2) less than 1% of 
hMSCs expressed negative markers (CD45, CD34, and CD11b). The red horizontal line on 
each histogram represents the percentage of positive cells for each surface protein. 
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E     Isotype controls  
 
F      PDL 17 low-serum commercial hBM-MSCs  
 
Figure 3-5: Immunophenotype by flow cytometry analysis of low-serum PDL 17 hBM-MSCs. 
(E) isotype controls were run in parallel to the experimental samples. (F, 1) results reported 
positive expression of hMSC markers (CD90, CD73, and CD105); (F, 2) less than 1% of 
hMSCs expressed negative markers (CD45, CD34, and CD11b). The red horizontal line on 
each histogram represents the percentage of positive cells for each surface protein. 
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G    Isotype controls  
 
H     P11 hUC-MSCs  
 
Figure 3-6: Immunophenotype by flow cytometry analysis of low-serum P11 hUC-MSCs. (G) 
isotype controls were run in parallel to the experimental samples. (H, 1) results reported 
positive expression of hMSC surface markers (CD90, CD73, and CD105); (H, 2) less than 1% 
of hMSCs expressed negative markers (CD45, CD34, and CD11b). The red horizontal line on 
each histogram represents the percentage of positive cells for each surface protein. 
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I     Isotype controls  
 
 
J       P13 hUC-MSCs  
 
Figure 3-7: Immunophenotype by flow cytometry analysis of low-serum P13 hUC-MSCs. (I) 
isotype controls were run in parallel to the experimental samples. (J, 1) results reported 
positive expression of hMSC surface markers (CD90, CD73, and CD105); (J, 2) less than 1% 
of hMSCs expressed negative markers (CD45, CD34, and CD11b). The red horizontal line on 
each histogram represents the percentage of positive cells for each surface protein. 
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3.4.2: Attachment Assays 
3.4.2.1: Cell attachment quantification  
Attachment assays were carried out after the hMSCs reached 80-90% 
confluency. Three differently-sourced hMSCs were tested at the following 
passage numbers or PDL: P4 (PDL 5) individual donor gx11 hBM-MSCs, P6 
(PDL 8) individual donor gx11 hBM-MSCs, PDL 15 commercial low-serum hBM-
MSCs, P11 hUC-MSCs and P13 hUC-MSCs. In order to measure the effect of 
priming hMSCs with Notch ligands wells were imaged using an inverted light 
microscope at X4 magnification (five random fields of view per well). Following 
this, the number of cells that attached to the fibronectin surfaces was quantified 
automatically by using the ImageJ “analyse particles” tool. An example of 
triplicate wells of adhered P11 hUC-MSCs is shown in Figure 3-8, which suggests 
that the number of adherent cells for the sJag-1-primed cells was higher than that 
of the UT and the sDll4 samples. This observation was confirmed in the 
quantification data in Figure 3-11 A. 
 
Figure 3-8: Sample phase contrast images of P11 hUC-MSCs after 20 min of adhesion on FN 
coated wells. Cells were quantified using the ImageJ cell plugin software. Scale bars = 1000 
µm. 
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3.4.2.2: Attachment of differently-sourced hMSCs  
The data for the individual donor gx11 hBM-MSCs showed that there were no 
marked differences between adhesion at 20 min and 45 min, this trend was 
observed for both P4 (PDL 5) and P6 (PDL 8) hBM-MSCs (Figure 3-9). The data 
also revealed that there were no evident differences in adhesion observed as a 
result of cell pre-stimulation by sJag1 and sDll4 over the untreated cells. 
However, as shown in Figure 3-9 A, there was a constant trend for both P4 (PDL 
5) and P6 (PDL 8) hMSCs at both 20 min and 45 min where cells preconditioned 
with sJag1 exhibited a modestly higher cell adhesion when compared to the UT 
groups. This trend was more evident in the P6 (PDL 8) hBM-MSC groups at 45 
min (Figure 3-9 A). In addition, the error bars for the P4 (PDL 5) gx11 hBM-MSCs 
were tighter than those observed for the P6 (PDL 8) cells.  
  
Figure 3-9: (A) Quantification of cell count adhesion of P4 (PDL 5) gx11 hBM-MSCs and P6 
(PDL 8) gx11 hBM-MSCs on FN coated surfaces at 20 min and 45 min. The data indicated the 
mean ± SEM of triplicate samples from 3 independent experiments. (B) Raw data from (A) of 
the three independently repeated experiments.  
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Similarly to the gx11 cells (Figure 3-9), no noticeable difference in cell attachment 
was observed between the commercial hBM-MSCs that were primed with sJag1 
and sDll4 over the UT cells (see 20 min and 45 min; Figure 3-10). 
   
Figure 3-10: (A) Quantification of cell count adhesion of PDL 15 commercial hBM-MSCs on 
FN coated surfaces at 20 min and 45 min. The data indicated the mean ± SEM of triplicate 
samples from 5 independent experiments. (B) Raw data from (A) of the four independently 
repeated experiments.  
 
Comparative adhesion studies were also carried out for P11 hUC-MSCs and P13 
hUC-MSCs at 20 min and 45 min. The results showed that the adhesion of P11 
hUC-MSCs primed with sJag1 at 20 min and 45 min and 20% O2 and 2% O2 
respectively was approximately two-fold higher than that observed for the UT cells 
(Figure 3-11 A). However, this trend was not observed for the P13 hUC-MSCs 
where pre-stimulation by sJag1 appeared to have no marked effect on attachment 
(see Figure 3-11 B, 20 min and 45 min at 20% and 2%). On the other hand, sDll4 
priming did not appear to benefit cell adhesion and this trend was evident in both 
slightly-older and slightly-younger cells (Figure 3-11 A and B).  
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Furthermore, the data revealed no marked differences between adhesion at 20% 
O2 and 2% O2, this trend was observed for both P11 and P13 hUC-MSCs for all 
conditions (see Figure 3-11 A and B, 20 min and 45 min, 20% O2 and 2% O2 for 
UT, sJag1 and sDll4). Next, the comparative data in Figure 3-11 C revealed that 
the P11 hUC-MSCs showed at least a two-fold increase in adhesion to fibronectin 
than the P13 hUC-MSCs at 20 min for 20% O2 and 2% O2 respectively, these 
differences were more obvious in the sJag1 groups. At 45 min the differences in 
cell adhesion between the P11 and the P13 hUC-MSCs for the UT and the sDll4 
groups were not as obvious as those observed at 20 min. However, for the sJag1 
groups at 20 min and 45 min, it was evident that the P11 hUC-MSCs performed 
noticeably better than the P13 cells with at least a two-fold increase in adhesion 
to fibronectin. Overall these results indicated that increase in cell age may 
decrease the adhesion properties of hUC-MSCs (Figure 3-11 C). However, 
further work will need to be carried out with more hUC-MSC donors. 
 
 
Figure 3-11: Comparison of cell adhesion using P11 (A) and P13 (B) hUC-MSCs at 20% and 
2% oxygen tensions for 20 min and 45 min time points. (C) Comparison of P11 and P13 hUC-
MSCs at different conditions. The results in (A), (B) and (C) indicated the mean ± SEM of 
triplicate samples from n = 4 independent experiments.  
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3.4.2.3: Comparing the effect of different sJag1 and sDll4 
concentrations on the adhesion of commercial hBM-
MSCs 
In the present study commercial hBM-MSCs were treated with various 
concentrations of Notch ligands (sJag1 or sDll4 priming at 200 ng/ml, 500 ng/ml 
and 800 ng/ml) and two different concentrations of FN (5 µg/ml and 20 µg/ml) 
were also investigated.  
 
The data revealed that there were no noticeable differences in cell adhesion at 20 
min between the different concentrations of FN and of Notch ligands (Figure 3-12 
A). In addition, no evident trends were observed between the sJag1, sDll4, and 
UT groups at 20 min (Figure 3-12 A). Next, the hMSCs primed with 800 ng/ml 
sJag1 consistently showed the lowest adhesion to FN (Figure 3-12 A and B), and 
this difference in adhesion became more evident with increase in incubation time. 
In fact, at 45 min the values for the 200 ng/ml sJag1 were almost double that of 
the cells primed with 800 ng/ml sJag1 (Figure 3-12 A and B).  
 
Furthermore, it was also observed that the sDll4 cells exhibited a concentration-
dependent trend. In fact, with the increase in sDll4 concentration, the adhesion of 
the cells to FN decreased. However, the cells primed with 800 ng/ml sDll4 did not 
follow this trend (Figure 3-12 A and B). 
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Figure 3-12: Effect of different sJag1 and sDll4 concentrations on the adhesion of PDL 15 
commercial hBM-MSCs. Cells were seeded on FN coated plates at 5 µg/ml and 20 µg/ml 
respectively. The data in (A) indicates the mean ± SEM of triplicate samples from 3 
independent experiments. The data in (B) indicates the mean ± SD of triplicate samples from 
2 independent experiments.  
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3.4.2.4: Beta integrin staining for commercial hBM-MSCs 
Cell adhesion is mainly mediated by integrin protein heterodimers formed by non-
covalently assembled α and β subunits (Veevers-Lowe et al., 2011). This study 
investigated the expression of the active and inactive form of integrin β-1 in 
sJag1-primed hMSCs upon seeding to FN surfaces. PDL15 commercial hBM-
MSCs were cultured on FN surfaces for 45 min, washed and stained with 
antibodies against total integrin β-1 (recognizes both active and inactive form of 
integrin β-1) and active integrin β-1 (also known as CD29). Total and active 
integrin β-1 were used to determine whether any differences in attachment were 
apparent between the UT groups and the groups of cells primed with the different 
concentrations of sJag1 (Figure 3-13). An intensity analysis was carried out to 
investigate differences in integrin β-1 activation between sJag1-primed cells and 
untreated samples.  
 
The immunofluorescence results indicated that in the UT groups fewer cells 
expressed the active integrin β-1 in comparison to the cells that were primed with 
sJag1 (Figure 3-13 A). On the other hand, the total integrin β-1 levels seemed to 
be equal in all of the conditions (Figure 3-13 A). Furthermore, the normalized 
mean intensity was quantified by developing an ImageJ script that automatically 
measured values for integrated density (sum of the intensity of pixels), area 
(number of pixels) and mean intensity (integrated density/area). Images were 
scaled in µm by obtaining the value in pixels of the scale bar on the image. 
 
The data indicated that the overall active integrin β-1 / total integrin β-1 mean 
intensity (ratio of sum of intensity of pixels that are positive in the red channel / 
area, and then sum of the intensity of pixels that are positive in the green channel 
/ area) was higher in sJag1 treated cells over the control groups (Figure 3-13 D). 
In particular, cells primed with 500 ng/ml sJag1 showed nearly double the values 
of mean intensity than that of the untreated samples, however it was not possible 
to carry out statistical analysis as only one independent experiment was carried 
out (Figure 3-13 D).  
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Figure 3-13: (A) Positive staining for total (stained red) and active integrin β-1 (stained green) 
using commercial low-serum PDL15 hBM-MSCs primed with different concentrations of sJag1 
after 45 min adhesion at 20% O2. DAPI stain (in blue) was performed to visualize the nuclei of 
the cells. Scale bars = 200 µm. (B) Quantification of cell fluorescence using ImageJ, where 
mean intensity represented integrated density/area occupied by integrin β-1. The data 
indicated the mean ±SD of five pictures of a well for sJag1 at 300 ng/ml, 500 ng/ml and 800 
ng/ml respectively, and triplicate values for UT with each value representing five pictures per 
well.  
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3.4.3: Effect of low oxygen on the migration abilities of commercial 
low-serum hBM-MSCs  
The phase contrast images for the normoxic hBM-MSC experiments showed that 
there was stronger migration across FN when PDG-BB was present (Figure 3-14 
A). This was expected, as PDGF-BB is an important chemoattractant for 
mesenchymal cells as previously reported in other studies (Veevers-Lowe et al., 
2011). The results also showed that there were no obvious differences in 
migration between UT (+PDGF-BB), sJag1 (+PDGF-BB) and sDll4 (+PDGF-BB) 
groups.  
 
Figure 3-14: (A) Representative transwell migration phase contrast images of normoxic PDL 
15 commercial hBM-MSCs. Assays were performed in ambient oxygen conditions. Scale bars 
= 200 μm. (B) Quantification of the number of migrated cells across fibronectin. The data in 
indicated the mean ± SEM of triplicate samples from 3 independent experiments.  
 
The phase contrast images for the normoxic hBM-MSC experiments showed that 
there was high variability between the independently repeated experiments that 
were mainly introduced by the values in experiment 3 (Figure 3-15 A and C). The 
data showed there were no obvious differences in migration between the sJag1 
pre-conditioned groups and untreated groups + or - PDGF-BB (Figure 3-15 B). 
However, the values for the sDll4 groups showed approximately a two-fold 
decrease in migration compared to the untreated groups and also against the 
cells treated with sJag1 (Figure 3-15 B). Based on the mean data of experiment 
2, the values for sJag1 and sDll4 might have been considered as outliers since 
there was less variability between experiment 1 and experiment 3 (Figure 3-15 B 
and C). However, as experiment 2 performed best and it followed the expected 
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trend of higher migration across fibronectin in the presence of a chemoattractant 
(PDGF-BB), there is a need to carry out further experiments to draw conclusions. 
 
 
Figure 3-15: (A) Representative transwell migration phase contrast images of hypoxic PDL 15 
commercial hBM-MSCs for each independently Assays were carried out in ambient oxygen 
conditions. Scale bars = 200 μm. (B) Quantification of the number of migrated cells across 
fibronectin. The data in indicated the mean ± SEM of triplicate samples from 3 independent 
experiments. (C) Raw data from (B) of the three independently repeated experiments. 
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The results also indicated that there were no obvious differences in the number of 
migrated cells between the normoxic and the hypoxic hBM-MSCs for the sJag1 
groups (Figure 3-16). On the other hand, the number of migrated cells for the 
normoxic hMSCs primed with sDll4 were at least two-fold higher than those 
observed for the hypoxic hMSCs (see sDll4 groups; Figure 3-16). This result 
suggested that hypoxic pre-conditioning may not be beneficial for cell migration 
on cells primed with sDll4. Next, there was a higher number of migrated cells in 
the UT groups when using the normoxic hMSCs in comparison to the hypoxic 
groups however, differences were not as marked as it was observed in the sDll4 
groups. It is notable that there was a much tighter distribution for normoxic hMSC 
groups in comparison to that observed for the hypoxic hMSC groups. Therefore, 
more experiments will need to be performed to validate these trends. 
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Figure 3-16: Quantification of number of migrated cells using either normoxic hMSCs or 
hypoxic hMSCs. Experiments were carried out at ambient oxygen conditions. The data 
indicated the mean ± SEM of triplicate samples from 3 independent experiments. 
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3.5: Discussion 
Previous literature showed that hMSCs from different sources exhibit different 
proliferation and growth abilities (Chen et al., 2014). In fact, even though hUC-
MSCs have been shown to have similarities to hBM-MSCs (Hass et al., 2011), 
evidence suggests that they exhibit greater proliferation capacity and faster 
growth in vitro than bone marrow-derived MSCs (Jin et al., 2013; Chen et al., 
2014). For example, hUC-MSCs have been shown to have doubling times of 2-3 
days from P0 to P3 in comparison to ~5 days (P1-2) and ~11-12 days (P2-3) 
observed for BM-MSCs (Mennan et al., 2013). 
 
In this work, first tri-lineage differentiation studies were performed to confirm that 
UC-MSCs underwent differentiation in response to chemical stimuli similar to BM-
MSCs. Next, the second aim was to assess whether there were any differences in 
cell attachment between UC-MSCs and those isolated from bone marrow. Since 
cell age has also been shown be another factor impacting on the potency of 
MSCs (Ullah et al., 2015), comparative studies were carried out between slightly 
earlier and slightly later passage hMSCs. All of the cells used in this study 
displayed a spindle-like morphology typical of hMSCs (Figure 3-1). However, with 
the increase in cell age, the MSCs became less spatially organized and they 
appeared to increase in size (Figure 3-1). As observed in other studies, the 
morphological changes observed in older MSCs (e.g. increase in size) due to cell 
age may not be necessarily associated with a decrease in positive MSC surface 
marker expression (Dominici et al., 2006; Lo Surdo and Bauer, 2012; Whitfield et 
al., 2013). For example, in one study hBM-MSCs from two different donors and 
three different passage numbers (P3, P5, and P6) were compared in terms of 
marker expression and cell morphology. The study showed that the cells from the 
two different donors and three different passage numbers maintained over 95% 
expression of all the positive markers described in the ISCT paper (Dominici et 
al., 2006). The results from the characterization studies were also in line with the 
work of Chen et al. where it was shown that old hUC-MSCs (passag15) were still 
able to meet the surface expression standards set by the ISCT (Chen et al., 
2014).  
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The immunophenotype analysis indicated that positive marker expression of the 
slightly earlier and slightly older passage hMSCs was in line with the guidelines 
set by the ISCT (>95% positive expression; Caplan, 2007). However, the 
expression of CD105 for the PDL17 hBM-MSCs was lower (82.2%) compared to 
that of the PDL 14 hBM-MSCs (94.4%) and gx11 P6 (PDL 8) hBM-MSCs (96.2%) 
(Figure 3-3 B1; Figure 3-4 D1; and Figure 3-5 F1). The evident decrease in 
CD105 expression for commercial PDL17 hBM-MSCs indicated a loss of 
differentiation potential. Contrasting results have been reported in the literature in 
relation to the expression of CD105 by UC-MSCs. In fact, whilst some studies 
reported the expression of CD105 even at later passages (> passage 16; Shi et 
al., 2015), other studies showed that either CD105 is not expressed by these cells 
or that it is expressed only in early passage UC-MSCs (Kadam et al., 2009; 
Bakshi et al., 2008). Overall, the data from the phase contrast images together 
with the immunophenotype results showed that the PDL 17 hBM-MSCs were able 
to proliferate in culture and to express high levels of the positive markers (>95%) 
as well as negligible levels of the negative markers (<2%) (Figure 3-2; Figure 3-5 
F1).  
 
Next, all of the differently-sourced MSCs were able to undergo tri-lineage 
differentiation with positive osteogenic, adipogenic and chondrogenic staining 
(Figure 3-2). The results from this study were line with previous work that showed 
that UC-MSCs are able to undergo tri-lineage differentiation (Mennan et al., 
2013). Differently from previous studies, there were no marked differences in 
terms of osteogenic and adipogenic differentiation between UC-MSCs and BM-
MSCs. In fact, both umbilical-derived and bone-marrow derived cells were able to 
form mature adipocytes and the size of the vacuoles in these cells appeared to be 
the same. Furthermore, in agreement with previous work, the microscopy images 
also showed no obvious differences in chondrogenic differentiation between the 
differently-sourced cells (Figure 3-2; Mennan et al., 2013). 
 
The current work demonstrated that all of the hMSCs used in this study (slightly 
earlier and slightly later passage) were able to attach to the FN-coated surfaces. 
However, only P11 hUC-MSCs showed a significant adhesion response to sJag1 
priming, with the adhesion values for the sJag1 groups being approximately two-
fold higher than those of the UT groups. Furthermore, no evident difference in 
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adhesion was observed when cells were pre-stimulated with sDll4 in comparison 
to the untreated samples. Following this, P11 hUC-MSCs appeared to perform 
better than the gx11 hBM-MSCs (Figure 3-9) and the older P13 hUC-MSCs 
(Figure 3-11 B); this trend was observed for all of the conditions (UT, sJag1, and 
sDll4). This data is in line with previous in vivo work which showed that UC-MSCs 
have higher engraftment abilities in comparison to bone marrow cells hence 
resulting in the lower numbers of UC cells required (Broxmeyer et al., 2013). 
However, as this study only used one donor for either UC-MSCs or BM-MSCs, 
the positive results observed for the UC-MSCs, can only be attributed to the 
specific cell populations used. Therefore, further work will need to be carried out 
using a bigger number of donors to confirm these results. However, previous work 
also showed that UC-MSCs have less inter-donor variability compared to other 
MSCs sources (Wegmeyer et al., 2013), hence suggesting that the positive 
outcomes in this study could be observed in other UC-MSC cell populations. 
 
Next, no evident differences were observed for the individual donor gx11 hBM-
MSCs (earlier and late passage/PDL) and in the P13 hUC-MSCs. However, all of 
the UC-MSC and gx11 B-MSCs showed a constant trend where sJag1 primed 
cells displayed higher adhesion to FN-coated wells. It is odd that there were no 
apparent differences with sJag1-priming or between younger and older individual 
donor hBM-MSCs because other research showed that they did. For example, 
contrarily to the results from this study (Figure 3-9), it was shown that slightly later 
passage (P5) bone marrow MSCs adhered to FN surfaces at a significantly faster 
rate than slightly earlier passage (P3) cells. Previous work also demonstrated that 
at 40 min adhesion sJag1-primed hBM-MSCs showed a significant higher 
adhesion to FN surfaces than untreated cells and these differences were not 
observed/obvious in this work (Figure 3-9). On the other hand, the data for the 20 
min adhesion (Figure 3-9) was in line with the work of Detela (2014) which 
showed that the adhesion of sJag1-primed cells to fibronectin was not 
considerably higher than that of the untreated cells.  
 
The work of Detela (2014) also demonstrated that hBM-MSCs exhibit donor-
dependent variability which could have resulted in different outcomes in this study 
119 
 
(Bain et al., 2014; Detela et al., 2018). Future work, could focus on comparing the 
adhesion abilities of hBM-MSCs from different donors to investigate inter-donor 
variability and to further confirm the data obtained in this study.  
 
The higher heterogeneity observed in the gx11 hBM-MSCs may have played a 
role in the increased variability observed in the P6 (PDL 8) experiments in 
comparison to the P4 (PDL 5) experiments. Therefore, from a manufacturing 
perspective using the later passage hBM-MSCs would decrease process 
consistency. The increased cell heterogeneity of hBM-MSCs expanded in culture 
for longer times (>5 passages) has also been reported in the literature (Whitfield 
et al., 2013). Cell age also seemed to affect the hUC-MSCs, as the later passage 
cells displayed less adherence post pre-stimulation and did not show the 
significant adhesion in response to sJag1 observed in the younger cells (Figure 
3-11 A, B and C).  
 
This study also showed that when P13 hUC-MSCs were primed with sDll4 and 
incubated at ambient oxygen, there was a two-fold decrease in the number of 
cells adhering to fibronectin at 20 min in comparison to the 45 min adhesion 
(Figure 3-11 B). This result suggested that effective cell adhesion was not 
achievable at lower time points when pre-stimulating P13 hUC-MSCs with sDll4 
and that therefore it may not be beneficial to use hUC-MSCs older than P11 for 
clinical application. However, the variability encountered within experiments 
(Figure 3-11 A and B) which can be associated with the use of biological reagents 
such as the serum and other components from animal origin, as well as the 
manual errors that can come from the intensive manipulation of cells to achieve 
specific concentrations affects the reliability of the system.  
 
Another major challenge is the tracking of cells by the passage number. This is 
not a reliable way of quantifying cell age, as it only represents how many times 
the physical act of harvesting and re-plating takes place. The seeding density, 
time in between splits, and harvest density would then affect the true age or PDL 
of the harvested cells. In addition, performing the experiments at different times 
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brings in its own right different outcomes and therefore comparing across different 
cells processed at different times can be a huge challenge. Therefore, in order to 
improve the reliability of these assays, there is a need to eliminate/reduce serum 
where possible, track cell age by PDL instead of passage number, minimise 
operator error and variability when culturing cells and setting up experiments by 
including automated processing systems. These would be a less-time consuming 
option and it would increase data robustness.  
 
A recent study showed that low oxygen environment enhanced the proliferation 
and differentiation of MSCs to cardiomyocyte-like cells when these were 
cultivated at 3% O2 but this was not observed at 1% and 5% O2 (Zhang et al., 
2015). It has also been reported that bone marrow MSCs subject to 5% O2 
displayed higher adhesion and increased levels of extracellular matrix molecules 
(Basciano 2011). However, Bain and colleagues showed that when bone marrow 
MSCs were subject to 2% oxygen tension for 20 min there was a decrease in 
adhesion abilities (Bain et al., 2014). Differences in cell source, low oxygen 
conditions and pre-conditioning time make it difficult to make reliable conclusions. 
Therefore, there is a need for different research groups to carry out comparative 
studies on the effect of oxygen concentration for the specific cells used in those 
studies and then make comparisons where possible.  
 
The current work showed that there were no evident differences in adhesion 
between low and ambient oxygen conditions in both the early and late passage 
hUC-MSCs (Figure 3-11 A and B). This result was not in line with previous work 
by Bain and colleagues that showed a decreased attachment to fibronectin after 
only 20 min of priming the MSCs in low oxygen. This outcome may be associated 
with the use of .differently-sourced MSCs (i.e. hBM-MSCs were used in the 
studies of Bain and colleagues).  
 
Additionally to this, most studies showing the enhanced proliferation, 
differentiation and the elevated expression of energy metabolism-associated 
genes with hypoxic pre-conditioning (<5%) used much younger hUC-MSCs (P<5) 
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than those used in this study (Lavrentieva et al., 2010; Zhang et al., 2015). 
However, in the later passage hUC-MSCs there was an evident increase in 
adhesion in the sDll4 groups between the 20 min and the 45 min time points at 
ambient oxygen (see 20% O2, sDll4 at 20 min and 45 min; Figure 3-11 B). On the 
other hand, no differences in cell adhesion were observed between sDll4 groups 
at 20 min and 45 min at low oxygen (see 2% O2; sDll4 at 20 min and 45 min; 
Figure 3-11 B). This result is in line with previous work which showed that low 
oxygen conditions increase the adhesion abilities of MSCs expressing Dll4 (Ciria 
et al., 2017).  
 
Next, it was decided to carry out a titration study investigating the impact of 
different concentrations of sJag1 and sDll4 on the commercial hBM-MSCs. This 
was done because no clear trend in cell adhesion could be determined using 
these cells (Figure 3-10). The results from these experiments showed that hBM-
MSCs primed with 800 ng/ml of sJag1 consistently showed the lowest adhesion 
to FN and this difference in adhesion became evident with the increase in 
incubation time to 45 min (Figure 3-12). This data suggested that a plateau might 
have been reached before 800 ng/ml where any further increase in sJag1 
concentration might have led to a decrease in adhesion efficiency, whilst the 
sDll4-primed cells performed similarly at all concentrations. In contrast to the 
results from the migration studies, the β-integrin staining experiments suggested 
that the presence of sJag1 at the different concentrations of sJag1 is beneficial for 
attachment to FN. However, it was not possible to obtain conclusive answers from 
the staining work as not enough experiments were carried out to test statistical 
significance.  
 
Increasing the number of hMSCs adhering to the infarcted heart has been a major 
goal for clinical applications. Previous work reported that the number of hMSCs 
retained in the heart after 24 hours amounted to less than 1% (Cheng et al., 
2008). For this reason, the current work focused on increasing the retention 
properties of hMSCs in the heart as it is necessary to use cells that can firmly and 
rapidly attach. Furthermore, a study investigating the effect of cell adhesion using 
hMSC sheets reported effective cell adhesion to a porcine heart tissue after 30 
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min whilst adhesion at 15 min was not effective (Chang et al., 2015). Following 
this, the current work investigated the time required for adequate adhesion to FN 
coats. This study revealed that there was no apparent difference in adhesion 
between the 20 min and 45 min experiments for P4 (PDL 5) gx11 hBM-MSCs, P6 
(PDL 8) gx11 hBM-MSCs, P11 hUC-MSCs, commercial PDL15 hBM-MSCs and 
P13 hUC-MSCs for the UT and sJag1 groups only. As a result it was possible to 
conclude that efficient attachment took place within 20 minutes of seeding and 
that cells did not migrate with increase in incubation time. This was a positive 
outcome as it has been previously reported that waiting long for effective cell 
adhesion leads to higher post-surgical complications (Chang et al., 2015).  
 
Previous literature showed that hypoxia pre-conditioning increased the migration 
abilities of MSCs by increasing the protein levels of Jagged 1-2 and Delta-like 
(Dll)1, Dll3, and Dll4 (Ciria et al., 2017) after cultivating the cells in 1% O2 for 4 
hours. For this reason, this study investigated the effect of preconditioning the 
hMSCs in hypoxic conditions for longer times to see whether there were changes 
in the migration MSCs or not. However, no evident differences were observed 
between preconditioned hypoxic and normoxic hMSCs, except in the sDll4 groups 
where using the normoxic hMSCs led to at least a two-fold increase in migration 
(Figure 3-16). Carrying out the migration experiments in ambient oxygen 
conditions might have switched off genes activated by the low oxygen priming. 
Therefore, it may be worth to carry out gene expression analysis on hypoxic 
hMSCs moved to ambient oxygen conditions for a few hours.  
Overall, this study confirmed that hUC-may be were superior in adhesion when 
compared to the gx11 hBM-MSCs especially since they were used at higher 
passages. However, as only one donor was used for each, there is a need to 
perform more experiments testing a bigger range of donors to confirm these 
results.This study, also indicated that 20 min may be a sufficient time to achieve 
effective cell adhesion to FN-coated wells and that sJag1 can be stimulatory to 
earlier passage hUC-MSCs.  
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Chapter 4: Optimization of endothelial cell in vitro 
vascular assays as platforms to examine the 
supportive role of hMSCs in ischemic injury 
 
4.1: Introduction 
In the following section I will summarize the relevant literature which I have 
discussed in Chapter 1.  
Ischemic heart disease is one of the leading causes of mortality in the world 
(Finegold et al., 2013). Multiple clinical trials have explored the use of MSCs for 
therapeutic angiogenesis for the treatment of ischemic cardiac injury (Cashman et 
al., 2013; Eckert et al., 2013; Huang et al., 2015). For example, in one study it 
was shown that when mesenchymal cells were injected into patients with MI, 
there was increase in angiogenesis and perfusion at the site of injury which led to 
a decrease in contractile dysfunction of the myocardium (Shake at el., 2001).  
 
Angiogenesis and vasculogenesis are key processes involved in the de novo 
synthesis of new blood vessels or the formation of blood vessels from existing 
blood vessels e.g. spouting and branching (Jain, 2003). These processes are 
necessary for the supply of oxygen and nutrients for the body’s tissues and 
therefore for the regeneration of the ischemic myocardium. Vascularization is a 
complex process and in order to understand the role of endothelial cells and 
MSCs in promoting angiogenesis, there is a need to create adequate assays that 
can validate their functions. However, there is a lack of biomarkers and potency 
assays that can give a predictive readout of the mode of action of cell products in 
the clinical setting (Galipeau and Krampera, 2015; Ketterl et al., 2015).  
 
For this reason, in vitro cell-based potency assays have been proposed as a 
potential tool to measure the intended therapeutic response of cell therapy 
products (CTPs), other than simple surface marker expression (Galipeau and 
Krampera, 2015; Samsonraj et al., 2015; Thej et al., 2017). Furthermore, there is 
a need to first measure and understand key functions of endothelial cells in 
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tubules assays and then use them as robust platforms to study the mode of action 
of MSCs.  
 
Human umbilical vein endothelial cells (HUVECs) are the most widely used for in 
vitro studies and they are a useful in vitro models that have unveiled major 
insights in angiogenesis and the regulation of endothelial cell function (Smith and 
Staton et al., 2007; Cao et al., 2017). HUVECs are primary cells and therefore 
they are more likely to be chosen over immortalised cell lines as they better 
resemble ECs in vivo (Cao et al., 2017). Furthermore, they can be easily isolated 
in the lab (Smith and Staton, 2007). In addition, they are also commercially 
available (Cao et al., 2017).  
 
HUVECs have been shown to respond to a variety of physiological stimuli such as 
shear stress, high glucose and hypoxic pre-conditioning (Zhang et al., 2012; Cao 
et al., 2017). Furthermore, they can be used to understand the effect of different 
substances and factors (e.g. cell age) on the endothelium through tube formation 
assays (Smith and Staton et al., 2007; Cao et al., 2017). In these assays, cells 
are seeded onto a basement-membrane-like substrate on which the cells are able 
to form capillary-like networks in a short amount of time (Arnoutova et al., 2010). 
In this way, it is possible to study the effect of different factors that have a role in 
angiogenesis.  
 
In vitro vascular assays have many limitations including the undefined chemical 
composition of the reagents e.g. Matrigel (Arnaoutova and Kleinman, 2010) and 
the heterogeneity observed between endothelial cells (Arnaoutova et al., 2009). 
Specific issues associated with tubule formation assays are related to the use of 
Matrigel. This solubilized basement membrane preparation is extracted from the 
Engelbreth-Holm-Swarm (EHS) sarcoma, a type of cancer, and is composed of a 
mixture of extracellular basement membrane proteins such as collagen IV and 
laminin. Matrigel, is the preferred matrix for vascular tubule assays (Khoo et al., 
2011) as it allows for the formation of capillary-like networks in a short time scale (4-
12 hours), whilst other matrices such as collagen take up to five days to show vessel 
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formation (Smith and Staton, 2007). However, the composition of Matrigel is poorly 
characterised as it contains extracellular matrix proteins, growth factors, 
collagenases and many undefined components. The heterogeneity of Matrigel 
and its uncharacterized components creates a key disadvantage for tubule 
formation assays, as it reduces the reproducibility of these assays (Arnaoutova 
and Kleinman, 2010). Therefore, this chapter also focused on measuring key 
functions of HUVEC tubule formation. In the current work a range of matrices 
were assayed- Cell Start, (GFR) Matrigel, and GFR Geltrex. The latter, is also 
derived from mouse EHS tumour and in comparison to Matrigel it offers a 2-fold 
decrease in several growth factors and a consistent manufacturing process. The 
latter ensures a protein concentration with very little variation between batches.  
 
This study also investigated whether lower matrix volumes of Matrigel could be 
used to minimize assay costs. Previous literature indicated that using HUVECs 
older than P10 would reduce tubule network formation (O' Donnell et al., 2000; 
Staton et al., 2007). Therefore, the current work investigated the impact of 
passage number on tubule formation capacity, to determine whether an increased 
number of assays is possible from one single batch of cells. In addition, manual 
quantification was compared to an automated counting technique to measure 
attributes of the branching network. Using the latter would be advantageous as it 
avoids the bias introduced when performing the manual counts as well as the 
difficulty of accurately measuring the length of the branches. 
 
Ultimately the data from this study will give valuable insights into key functions of 
endothelial tubule formation and strategies to reduce assay-costs and increase 
their robustness. 
 
126 
 
4.2: Aims and hypotheses 
4.2.1: Aims 
 To use a methodological approach to determine key functions of 
HUVEC tubule formation. 
 
 To evaluate the ability of old (> P10) HUVECs to efficiently form tubule 
networks. 
 
 
 To investigate if automated counting methods can be used as a 
replacement to manual counting methods. 
 
4.2.2: Hypotheses 
 As cell age impacts on efficient tubule network formation, it is 
hypothesized that cells older than P10 will not be able to form tubule 
networks efficiently. 
 
 It is hypothesized that the automated counting method will follow the 
same trend as the manual counting trend. 
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4.3: Materials and methods 
All the general materials and methods that are not specific to this chapter are 
described in Chapter 2. 
 
4.4: Results 
4.4.1: Cell morphology and immunostaining  
The morphological characteristics of HUVECs were observed using an inverted 
light microscope. HUVECs grew as a homogeneously distributed monolayer of 
polygonal cells (Figure 4-1). In addition, they maintained their cobblestone 
morphology even after they reached 80% confluency (Figure 4-1, day 4).  
 
Figure 4-1: Morphology of P9 HUVECs. Representative phase-contrast images of P9 
HUVECs displaying a cobblestone morphology. Scale bars = 1000 µm. 
The identity of the P7 and P13 HUVECs was confirmed by immunofluorescence 
labelling using antibodies targeting the endothelial cell markers Von Willebrand 
Factor (vWF) and CD31 (Figure 4-2 and Figure 4-3) after one to three days. vWF 
is a glycoprotein which is only produced by endothelial cells (ECs) and it is 
generally used to identify ECs (Zanetta et al., 2000). CD31 is a cell surface 
glycoprotein highly expressed in ECs and it is involved in cell adhesion and 
signalling (Lalor et al., 2006). Negative controls using only the secondary 
antibodies were run in parallel to the stained cells (Figure 4-1 B and D; Figure 4-2 
B and D). Cells stained with the vWF and CD31 confirmed the positive expression 
of the two markers in the older (Figure 4-1 A and C) and the younger (Figure 4-2 A 
and C) cells. On the other hand no staining was observed for the negative controls, 
indicating no cross-reaction from the secondary antibodies (Figure 4-1 B and D; 
Figure 4-2 B and D).  
 
128 
 
 
Figure 4-2: Immunostaining. Characterization of P7 HUVECs. Cells were stained for the 
expression of the endothelial markers: vWF and CD31. After three days in culture, HUVECs 
showed the expression of vWF and CD31 respectively (A and C). Controls for both markers 
were negative for the expression of vWF and CD31 (B and D). Nuclei were stained with 4’, 6-
Diamidino-2-phenylindole (DAPI). Scale bars = 200 µm. 
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Figure 4-3: Immunostaining. Characterization of green fluorescent protein (GFP) stained P13 
HUVECs. Cells were stained for the expression of the endothelial markers: vWF and CD31. 
After one day in culture, HUVECs showed the expression of vWF and CD31 respectively (A 
and C). Controls for both markers were negative for the expression of vWF and CD31 (B and 
D). Nuclei were stained with DAPI. Scale bars = 200 µm. 
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4.4.2: Hypoxic chamber oxygen measurements  
A modular in house manufactured chamber (Mondragon-Teran et al., 2009) was 
used to achieve hypoxic conditions for the assays (Figure 2-2-1). The sealed 
chambers were purged with a gas mixture of 2% O2/5% CO2/ 93% N2 balanced for 
the in vitro angiogenesis assays to mimic the low oxygen environment found in the 
ischemic cardiac tissue (Bain et al., 2014). In order to validate the effectiveness of 
the chamber in achieving relevant physiological oxygen levels, studies were 
conducted to monitor the gas-phase at the top of the chamber, the bottom of the 
chamber and within the liquid in the water dish. The chamber was purged for 5 
minutes, prior to commencing the experiments. Measurements were taken every 
minute, for 24 hours. Figure 4-4 shows a representative trace of the oxygen 
monitoring that was performed and indicates that the oxygen at the top and the 
bottom of the chamber remained constant at 2% oxygen tension. On the other 
hand, the percentage of dissolved oxygen in the water dish although initially high 
(~18%) remained stable at ~3.8 % after one hour. This result was unexpected as it 
was previously reported that it takes > 3 hours for oxygen content in the medium 
present in the plates (no cells present) to achieve equilibrium (Allen et al., 2001). 
This is because oxygen has low solubility in aqueous solutions and therefore, the 
quick drop in oxygen in the medium might have been associated with issues 
relating to the calibration of the 96-well oxygen sensor plates. In addition, different 
oxygen sensors were used to measure the oxygen inside the water dish and that 
at the wall of the chamber. Therefore, another explanation for these results could 
be that the sensors in the 96-well plates were too old and therefore not as efficient 
in measuring dissolved oxygen. 
 
For the purpose of the current work, it was decided to refer to the oxygen tension 
achieved in the chambers purged with 2% oxygen as “low oxygen” or “reduced 
oxygen”, relative to the “ambient oxygen” tension (~ 20% O2).  
 
131 
 
 
Figure 4-4: Hypoxic chamber oxygen measurements. Oxygen tension was measured every 
minute by Oxy-4 using fibre optic transmission. The oxygen measurement was done over 24 
hours. 
 
4.4.3: Branch network formation on gel coated wells 
 
 
Figure 4-5: Branch network formation on gel coated wells. (A) Representative image showing 
network formation after 18 hours under an inverted light microscope. Scale bars = 1000 µm. 
 
4.4.4: Time lapse experiment for vascular tubule formation 
HUVECs were expanded for four days in EGM-2 medium which is composed of a 
basal medium (EBM-2) supplemented with VEGF, human epidermal growth factor 
(hEGF), recombinant 3-insulin-like growth factor-1 (R3-IGF-1) and hFGF-beta, 
which are growth factors known to stimulate angiogenesis (Folkman and D 
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’amore, 1996). Cells were used for experiments after reaching 80-90% 
confluence. Following trypsinization, cells were seeded on top of GFR Matrigel 
and GFR Geltrex coated wells and left to form tubules after 18 hours of incubation 
at low (2% O2) and ambient (20% O2) oxygen tensions (Figure 4-5). Initial 
optimization tests were carried out to examine the kinetics of network formation 
and to identify the best time point at which solid networks formed. P9 HUVECs 
were cultured for four days with medium change after every two days. On day 
five, HUVECs were seeded on 96-well plates with both GFR Matrigel and GFR 
Geltrex respectively at 55 µl and 35 µl. The morphological changes of the 
HUVECs were captured using a phase-contrast inverted microscope. Cells 
aggregated and elongated into tubule-like structures within 3 hours (Figure 4-6, A-
D). After 6 hours, they started forming enclosed areas of vessel-like networks 
which became sparse and wide during the 12 hour period. No obvious 
morphological differences were observed between Matrigel and Geltrex for 
HUVEC tubule formation. Branch networks at 3 hours and 6 hours were difficult to 
quantify as some cells still didn’t make contact and tubule networks appeared to 
be less robust than those formed at 9 and 12 hours (Figure 4-6). Hence from the 
data it was concluded that tubule quantification was not possible until after 6 
hours. The data in Figure 4-6 showed that when cells were seeded on top of the 
basement membranes they would migrate towards each other align and form 
tubes. In the first 3 hours, it was observed that the networks closer to the edges of 
the wells would form faster than those in the middle, perhaps due to the higher 
concentration of cells pooling towards the middle of the 96 wells than at the edges 
(Figure 4-6). 
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Figure 4-6: Time course dynamics of P9 HUVECs after plating on Matrigel at 35 µl (A) and 55 
µl (B) and Geltrex at 35 µl (C) and 55 µl (D). Images were taken every 3 hours. Scale bars = 
1000 µm. 
 
4.4.5: Effect of cell seeding density, passage number and oxygen 
tension on vascular efficiency  
All initial optimization studies were carried out using a range of seeding densities: 
0.67 x 105 cells/ml, 1x105 cells/ml and 1.3 x105 cells/ml respectively, to determine 
the optimal cell seeding density. After being maintained in EGM-2 for three to four 
days, HUVECs (P7 and P10) were trypsinized and seeded on GFR Geltrex, GFR 
Matrigel and xeno-free Substrate Cell Start. The results showed that Cell Start 
allowed cell attachment and proliferation but it did not induce any tubule formation 
(Figure 4-7 A). 
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Figure 4-7: (A-C) Phase contrast representative images showing tubule network formation of 
P9 HUVECs on (A) Cell Start, (B) GFR Matrigel, and (C) GFR Geltrex. Tubule network 
formation was not observed on Cell Start (A). Pictures were taken at 10X (A) and 4X (B and 
C). Scale bars = 400 μm (A), 1000 μm (A and B). 
 
The data also indicated that HUVECs were able to form tubule networks at all 
seeding densities. However, it was observed that there were more connected 
networks at higher seeding densities (Figure 4-8 and Figure 4-9). Branches also 
appeared to be more robust when using 1 x 105 cells/ml and 1.3 x 105 cells/ml 
instead of 0.67 x 105 cells/ml (Figure 4-9).  
 
 
Figure 4-8: Phase contrast representative images of tubule networks formed using P10 
HUVECs in GFR Matrigel (A) and GFR Geltrex (B). Three different seeding densities were 
used: 0.67 x 105 cells/ml, 1 x 105 cells/ml and 1.3 x 105 cells/ml Tubules were imaged after 18 
hours (ambient oxygen 20%). Scale bars = 1000 µm. 
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Figure 4-9: Phase contrast representative images of tubule networks formed using P10 
HUVECs in GFR  Matrigel (A) and GFR Geltrex (B). Three different seeding densities were 
used: 0.67 x 105 cells/ml, 1 x 105 cells/ml and 1.3 x 105 cells/ml. Tubules were imaged after 18 
hours (ambient oxygen 2%). Scale bars = 1000 µm. 
 
4.4.6: Cost comparison of Matrigel and Geltrex at 55 µl and 35 µl 
Assay development involves finding cost effective solutions where there is a 
compromise between good data quality and quantity of reagents required. 
Matrigel and Geltrex were the most costly reagents in the assays (Table 4.1). This 
is why matrix volume was chosen as a key variable for process optimization. A 
basic cost of goods (CoG) analysis was carried out to compare the costs of using 
GFR Geltrex and GFR Matrigel at the lower volumes. The reagent CoG for using 
either Matrigel or Geltrex at 55 µl was found to be £1118 and at 35 µl it totalled to 
£848 (Table 4.1) for 50 tests. Using 35 µl Geltrex reduced the costs of the assays 
by 25%. 
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Reagents Cost 
Date 
of 
purchase 
 
Cost per 
assay  
(55 μl of 
GFR 
Matrigel) 
(£) 
% of 
the 
cost 
Cost per 
assay 
(35 μl of 
GFR 
Matrigel) 
(£) 
% of 
the 
cost 
Cost per 
assay 
(55 μl 
of GFR 
Geltrex ) 
(£) 
% of 
the 
cost 
Cost per 
assay  
(35 μl 
 of GFR 
Geltrex ) 
(£) 
% of 
the 
cost 
Matrix 
0.03 2017 £/μl 14.9 66 9.45 56 14.9 66 9.45 56 
96 well plate 1.5 2017 £/plate 1.5 7 1.5 9 1.5 7 1.5 9 
EGM-2 
Medium 
(EBM-2 
Medium + 
BulletKit) 
0.3 2017 £/ml 6.0 27 6.0 35 6.0 27 6.0 35 
Total per 
assay 
- - - 22.35 100 16.95 100 
22.35 
100 
16.95 
100 
Total for 50 
assays 
- - - 1118 - 848 - 1118 - 848 - 
Table 4.1: Cost comparison for GFR Matrigel and GFR Geltrex using 55 µl and 35 µl matrix volumes. The CoG analysis indicated a 25% reduction in costs 
when using the lower matrix volumes (35 µl). 
 
137 
 
In terms of branch point efficiency, there were no statistically significant 
differences between the three seeding densities for three independently carried 
out experiments per condition. The quantification data in Figure 4-10 A and B, 
indicated that there was also no significant difference in network efficiency when 
using ambient versus low oxygen concentrations for both P7 and P10 HUVECs. 
Following this, higher variability was observed in the 20% O2 P7 HUVECs results, 
whilst the distribution appeared to be tighter at the lower oxygen tensions. 
 
 
Figure 4-10: Branch point quantification for different seeding densities. Effect of cell seeding 
density and oxygen tension on vascular network efficiency using HUVECs at P7 and P10 at 
low oxygen (2% O2) and ambient oxygen (20% O2). The error bars indicate the mean ± SEM 
of n = 3 experiments for each condition performed on different HUVEC donors with triplicate 
wells for each experiment. There were no statistically significant differences between seeding 
densities, 20% O2 versus 2% O2, Matrigel versus Geltrex groups, and 55 µl versus 35 µl group 
means as determined by two-way ANOVA (p > 0.05). 
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4.4.7: Cell morphology and vascular network formation in younger 
and older HUVECs 
Comparative studies were carried out between HUVECs at passage 7, passage 
10, passage 13 and passage 15 to study the effect of cell age on branch network 
formation. HUVECs were grown for 3 to 4 days, trypsinized and seeded on GFR 
Geltrex and GFR Matrigel respectively at two different matrix volumes, 55 µl and 
35 µl. The phase contrast images indicated that ECs were still able to proliferate 
at the higher passage numbers (Figure 4-11 A) as well as consistently forming 
branch networks when seeded at the lower matrix volumes (Figure 4-11 B).  
 
 
Figure 4-11: A) Phase contrast representative images of P7, P10, P13 and P15 HUVECs after 
four days of culture. Scale bars = 400 µm. (B) Effect of passage number on vascular efficiency 
for GFR Matrigel and GFR Geltrex respectively at low (2%) oxygen. Scale bars = 1000 µm. 
The data shows that the endothelial cells are able to still proliferate in culture and form robust 
branches at the higher passage numbers (> P10). 
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4.4.8: Manual versus automated counting techniques  
In order to reduce the time involved in analysing the data, it was decided to carry 
out a comparative study between automated and manual methods. Initially whole 
well images were taken at x2 magnification however, it was difficult for the ImageJ 
program to easily recognize the tubule networks. For this reason, in the next 
couple of experiments, it was decided to perform the counts over a series of 
images taken at x4 magnification using an inverted microscope and merged (x9 
images per whole well; PanoramaStudio2Pro software, Sulzfeld EU). Counts 
were then performed manually and using the automated counting technique. 
Manual counts were performed by quantifying the number of branch points per 
image. On the other hand, automated counts were performed using the 
angiogenesis analyser (ImageJ) to compute the number of branch points and also 
the number of junctions and meshes (Figure 4-12) in a visually user-friendly 
fashion. Comparisons between manual and automated counting techniques were 
performed based on the number of branch points (Figure 4-13). 
 
 
Figure 4-12: Image before (A) and after (B) being processed using the angiogenesis imageJ 
analyser. Branches are shown in yellow. Branch points are shown in pink. Meshes represent 
the enclosed areas between the branches. Images were taken at x4 magnification. Scale bar 
= 1000 μm. 
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The data indicated that both manual and automated counts followed the same 
trend and no statistical differences were observed between the two methods 
(Figure 4-13). This trend was maintained for all of the passage numbers 
investigated in this study (Figure 4-13 A to D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-13: Data comparison between manual and automated counting techniques for A) 
P10 HUVECs B) P13 HUVECs C) P7 HUVECs and D) P15 HUVECs . All conditions were 
carried out using a seeding density 1 x 105 cells/ml. The error bars indicate the mean ± SEM 
of n = 3 experiments for each condition performed on different HUVEC donors with triplicate 
wells for each experiment. One Way ANOVA for each group- Bonferroni post-hoc analysis 
revealed p > 0.05.  
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4.4.9: Multivariate analysis of the effect of passage number, type of 
matrix and matrix volume in tubule angiogenesis assays  
Branch point efficiency between P7 and P13 HUVECs for Geltrex at 55 µl (p = 
0.0006) and 35 µl (p = 0.0009), indicated that Geltrex performed better at higher 
passage numbers. Differences were also observed between P7 and P13 
HUVECs where Matrigel at P13 and 35 µl showed a significantly higher number 
of branch points compared to Matrigel at P7 and 35 µl (p = 0.0486). Also, branch 
point efficiency between P13 and P15 HUVECs for Geltrex at 55 µl (p = 0.0469) 
and 35 µl (0.0452), indicated that Geltrex performed better at P13. Next, the one-
way ANOVA revealed that for the P13 HUVEC groups, Geltrex 35 µl was more 
efficient against the Matrigel 55 µl control group (p = 0.0469).  
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Figure 4-14: Branch point quantification for P7, P10, P13 and P15 HUVECs at high (55 µl) 
and low (35 µl) matrix volumes. The error bars indicate the mean ± SEM of n = 3 experiments 
for each condition performed on different HUVEC donors with triplicate wells for each 
experiment. There were statistically significant differences between group means for passage 
number as determined by two-way ANOVA, Bonferroni post-hoc analysis. One-way ANOVA, 
Bonferroni post-hoc analysis revealed significant differences between Matrigel 55 µl and 
Geltrex 35 µl for the P13 HUVECs (p ≤ 0.05). Matrigel 55 µl was used as a control group for 
comparison. Refer to text for a detailed description of the results. 
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Vascular efficiency was also observed by measuring the number of meshes 
(enclosed areas between branches). The results suggested that there were no 
significant differences between the numbers of meshes formed at the different 
passage numbers (Figure 4-15). However, the trend indicated that there was a 
higher number of meshes formed on Geltrex at both 35 µl and 55 µl when 
compared to network formation on Matrigel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15: Number of meshes quantification for P7, P10, P13 and P15 HUVECs at high (55 
µl) and low (35 µl) matrix volumes. There were no statistically significant differences between 
group means for passage number as determined by two-way ANOVA, post-hoc analysis (p = 
0.9647). Values are mean ± SEM of n = 4 (P7 HUVECs) and n = 3 (P10 to P15 HUVECs) 
experiments performed on different HUVEC donors with triplicate wells for each experiment. 
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4.5: Discussion 
The current study investigated the effect of key input variables on tubule network 
efficiency, to optimize vascular assays for the assessment of angiogenesis. 
Current vascular assays present many challenges, specifically the inherent 
biological variability of the reagents used (Auerbach et al., 2000; Smith and 
Staton, 2007) and the high costs associated with carrying out the assays (Smith 
and Staton, 2007). For this reason, a multivariate screening approach was used 
to systematically optimize key parameters that affect the tubule-formation 
capacity of ECs, with an aim of making the assays more standardized, reducing 
costs and increasing the number of assays that can be performed.  
Initial time-lapse experiments were carried out to observe the dynamics of tubule 
formation. The time lapse experiment showed that ECs were able to form 
quantifiable capillary networks even at 6 hours which further confirmed the ease and 
the rapidity at which tubules are formed on Matrigel and Geltrex. The results in 
Figure 4-5 agreed with previous work which showed that tubule formation on 
Matrigel can vary from 4 to 24 hours (Staton et al., 2004). However, the formation of 
tubules after only 3 hours also revealed the difficulty of Matrigel assays to mimic the 
in vivo situation. In fact, these assays do not measure as many steps in 
angiogenesis as tubule formation on other matrices such as collagen (Arnaoutova 
and Kleinman, 2010). It has been reported that seeding cells on different types of 
collagen affects the rate of tubule formation. For example, it was shown that seeding 
cells on interstitial collagen (collagen I and collagen III) increased cell proliferation 
but severely reduced tubule formation. On the other hand, when endothelial cells 
were plated on collagen from the basement membrane (collagen IV and collagen 
V), there was not much proliferation occurring but the rate of tubule formation was 
high (Calderon et al., 2017; Gambino et al., 2017). Collagen assays are more time 
consuming than Matrigel assays as it takes several days for capillary-like structures 
to form. Branch quantification in these gels is difficult because the tubule 
organization in collagen is in 3-D and requires the sectioning of the gel or 
photography at multiple focal planes (Goodwin, 2007). In addition, not all of the cells 
form tubules which adds to the difficulty in quantifying network formation 
(Arnaoutova and Kleinman, 2010). For this reason, Matrigel 2-D assays, which are 
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easy to quantify seem to be the best option whilst looking for more powerful image 
analysis programs to quantify the angiogenesis potential of collagen.  
The optimized assays from this study showed that lower matrix volumes of 35 µl 
could be used for efficient tubule formation. As reported in the literature, using 
volumes lower than 34 µl per well of a 96 well plate (1.2 µl/mm2) creates a well 
effect which leads to having more cells at the centre of the well than at the edge 
hence making tubule formation difficult (Smith and Staton, 2007). Whilst it was 
reported that using extremely low levels of Matrigel may also avoid the pooling 
effect, there is a risk that the manual spreading required to distribute Matrigel 
around the well could lead to uneven distribution (Staton et al., 2004). The current 
work also investigated the ability of Cell Start and Geltrex to form capillary-like 
networks. The data indicated that Geltrex was able to successfully form branches. 
However, Cell Start still failed to form tubules (Figure 4-7 A); for this reason no 
further work was carried out using this matrix.  
When carrying out in vitro assays it is necessary to use process conditions that 
mimic the physiologic site to which the product will be delivered as closely and as 
reasonably possible. This is done so that the assay measurement reflects the 
anticipated mode of action in the injury site that the cells will be delivered to in 
vivo. The in vivo site is often an extreme environment due to ischemia-reperfusion 
injury and high levels of oxidative stress. Differently from the typical cell culture 
environment that is made of ~20% O2, most tissues in the body experience oxygen 
levels of around 1% to 5%, whilst blood vessels experience 5% to 7% O2 (Kusuma 
et al., 2014). Several studies have also reported that ischemia, which can result 
from lack of nutrients and oxygen, stimulates blood vessel recruitment (Kusuma et 
al., 2014). In the present work, comparative studies were run between vascular 
assays subject to ambient (20%) and low (2%) oxygen tension, to observe any 
differences between the two conditions. However, the initial findings showed that 
hypoxic conditions did not affect the rate of tubule formation in the assays (Figure 
4-10). Future studies could investigate the effect of both oxygen conditions for 
prolonged times (>7 days) instead of imaging the tubules after 18 hours. In this 
way it would be easier to recognize the beneficial effects of low oxygen on the 
stability of the vessels formed. The current study also investigated the effect of 
cell seeding density on vascular efficiency. The findings from the study revealed 
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that an increase in seeding density corresponded with robust branches. These 
findings agreed with previous work where it was reported that high cell seeding 
densities on the basement membranes can lead to large areas of clustered, 
undifferentiated cells, whilst seeding at too low density hinders tubule formation 
as cells do not make contact (Staton et al., 2007). Future work could investigate a 
wider range of seeding densities to find the optimum range for network formation.  
This study adopted a multivariate approach for studying the interactions between 
passage number, type of matrix and matrix volume on vascular efficiency. This 
approach was undertaken to achieve a more robust and cost-effective assay. This 
study showed that Geltrex can work as well or better than Matrigel. Using Geltrex 
as a replacement to Matrigel would account for less assay variability as it is more 
consistent in formulation, making the former a viable option for an optimized tubule 
assay. The CoG analysis showed that the highest costs in the assays came from 
the matrices and that using 35 µl instead of 55 µl would reduce the costs by 25% 
for 50 assays. The possibility of using lower matrix volumes would increase the 
number of assays achievable from a single batch of substrate product and it would 
also reduce assays costs. Future work could assess using much lower matrix 
volumes to further reduce the costs incurred in matrix usage.  
The current work investigated whether HUVECs older than passage 10 could still 
be used to achieve efficient network formation. The findings from this study 
showed an increase in network formation until P13 HUVECs and a decline in 
vascular efficiency at P15 HUVECs. However, P15 HUVECs performed as well as 
P7 HUVECs. Previous studies analysing the effect of cell age in HUVECs showed 
that younger HUVECs were consistently superior in forming vascular vessels than 
those at the later passage numbers (Schechner et al., 2000). However, some 
studies observed that this was not always the case. For example, in one study 
they showed that the vascular efficiency of endothelial cells was best between the 
second and the sixth passage number and that the assay would not work well if 
endothelial cells were used before the second or after the tenth passage 
(DeCicco-Skinner et al., 2014). Similarly, to this study, the findings of the current 
work showed that the assays would work best after P10 and before P15 at which a 
decline in the branching was observed (Figure 4-14 and Figure 4-15). The 
possibility of using older cells means that more experiments could be carried out 
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using the same batch of cells, hence eliminating the issues of donor-to-donor 
variability and reducing costs related to purchasing new cell lines. However, 
increase in cell age may also increase intra-donor variability, as EC monolayers 
will become more heterogeneous with an increase in cell age. This trend was not 
observed in the current work. For example, the error bars for the P15 HUVECs 
appeared to be tighter than those observed for the P10 HUVECs. Furthermore, 
since it was only possible to perform experiments on n = 3 HUVEC donors which 
represents a small sample size, there is a need to perform experiments on a 
greater number of primary cell isolations to confirm these results. In addition, 
since only HUVECs were tested in this study, future work will need to include the 
testing of ECs from different sources and the impact of cell age on each one of 
them. In fact, the difference between HUVECs and other types of endothelial cells 
has been widely reported in the literature and it is one of the main factors 
hindering data comparison between in vitro assays (Cao et al., 2017). For 
example, whilst human microvascular endothelial cells can be activated by 
palmitic acid in vitro, the same is not observed in HUVECs (Cao et al., 2017). 
The present work also investigated whether the automated software was powerful 
enough to quantify the phase contrast images accurately or not. To avoid the 
variability in counts from the meniscus effect in the 96 well plates, it was decided to 
consistently select the large middle region of the well. This study showed that 
automated techniques can be used as a less time-consuming method to the 
manual counts (Zudaire et al., 2011). In addition, the measurements performed 
using this method are more standardised than the manual counts and they avoid 
the variability that is added when different users count the same image. Moreover, 
reducing the time involved in performing the counts by switching to an automated 
method would also bring down the CoG associated with operator time. Overall, this 
study allowed for the understanding of key characteristics of endothelial cells. 
Further work could be done to investigate a wider range for each variable studied. 
In addition, the reliability of the data from the in vitro assays could be confirmed 
using in vivo tests, as the former may not always be representative of the complex 
mechanisms in a living organism (Staton et al., 2004; Xie et al., 2016). 
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Chapter 5: Effect of vasculogenic enhancement 
potential of hMSCs from different sources 
5.1: Introduction  
The following section will summarize the relevant literature discussed in Chapter 
1.  
 
The mechanism of action (MOA) of hMSCs after transplantation into the heart is 
still not well known (Singh et al., 2016). For example, some studies indicated 
that MSCs may rescue the myocardium by differentiating into cardiomyocytes 
(CMs) (Li et al., 2006). However, this would not explain their beneficial effects on 
the myocardium, as it was reported that only <2% of the transplanted MSCs 
transdifferentiate into cardiomyocytes (Arnous et al., 2012). More recently some 
studies reported that MSCs may act through paracrine effects (Zhang et al., 
2012) whilst other studies showed that these cells trigger angiogenesis by 
assuming a “perivascular-like” phenotype in the basement membranes of newly 
forming blood vessels. In this way they were shown to favour and contribute to 
the stabilization of newly formed capillaries (Kean et al., 2013).  
 
In order to improve cellular therapies it is fundamental to understand the mode 
of action of MSCs and to then develop methods to improve their function at the 
site of injury (Bain et al., 2014). To make this possible, it is important to develop 
in vitro assays whose parameters more closely reflect the physiologic 
environment, rather than ambient conditions that do not enable prediction of 
how the cells will work upon transplantation in vivo. For example, by performing 
assays in lower oxygen levels more reflective of the physiologic oxygen tension 
and by measuring cell responses on extracellular matrix rather than directly on 
tissue culture plastic.  
 
Recently one study reported that when BM-MSCs were subject to hypoxic 
conditions (1%) for 24 hrs, the cells were able to engraft in an animal model of 
idiopathic pulmonary fibrosis four times better than the untreated cells (Lan et 
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al., 2015). The benefits of hypoxic preconditioning for myocardial repair were 
also reported in the first-in-man intracoronary administration of hypoxic bone 
marrow mononuclear cells, which led to improved heart function (Hu et al., 
2015).  
 
Another strategy to improve the function of MSCs in cardiac repair has been 
associated with priming MSCs with Notch ligands (Lu et al., 2016). The Notch 
pathway can be triggered via the Notch receptors binding to one of their ligands 
which include Jagged 1 and Delta-like 4 (Gridley, 2010). This pathway was 
shown to cover a fundamental role in regulating the function of endothelial cells 
(ECs) during sprouting and angiogenesis, by aiding communication between 
adjacent cells (Benedito et al., 2009; Lu et al., 2016). The overexpression of 
Jagged 1 was shown to enhance angiogenesis, whereas the opposite was 
observed in mutants lacking Jagged 1 (Benedito et al., 2009). 
 
Given that MSCs have been shown to improve angiogenesis (Zhang et al., 
2012) and that MSCs from different sources may possess different proliferation 
capacities and angiogenesis potential (Hsieh et al., 2013; Chen et al., 2014; 
Singh et al., 2016), it may be beneficial to investigate the angiogenesis 
modulatory effects of hMSCs from different sources. 
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5.2: Aim and hypotheses 
5.2.1: Aim 
 
 To test the vascular support abilities of hMSCs primed with Notch ligands 
in co-culture vascular assays, and to determine the effect of other 
variables such as type of matrix and oxygen tension on vascular network 
formation. 
 
5.2.2: Hypotheses  
 
 Differently-sourced MSCs will exert differences in angiogenic abilities.  
 
 The vascular support ability of hMSCs can be enhanced by Notch ligand 
pre-conditioning. 
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5.1 Materials and methods  
All the general materials and methods are described in Chapter 2. 
 
5.2.3: Cell staining to distinguish hMSCs from HUVECs 
hMSCs were cultured in ambient (20% O2) and low (2% O2) oxygen tensions until 
they reached 80-90% confluency. Live cell staining was performed on hMSCs and 
HUVECs to observe the interaction between the two cell types. HUVECs were 
stained with CellTracker Green CMFDA (1:1000, green fluorescence, Invitrogen, 
Paisley UK) and hMSCs were stained with Vybrant DiI Cell-Labeling solution 
(1:200, red fluorescence, Life Technologies, Paisley UK); cells were incubated 
with the dyes for 1 hour at 37 oC. Following this, both HUVECs and hMSCs were 
washed once in their own pre-growth medium and incubated for a minimum of 30 
minutes at 37 oC to allow the cells to incorporate the dye molecules in the plasma 
membranes. Positive staining was confirmed under a fluorescence microscope. 
 
5.2.4: Co-culture vascular assay  
Following the staining with the red fluorescent dye, the hMSCs were detached 
from the flasks as described in sections 2.1.1 and 2.1.2. Pellets were then 
resuspended in 3 ml of pre-warmed EGM-2 medium and counted using the 
Trypan Blue exclusion method described in section 2.1.3. Following this, cells 
were diluted to 1.8 x 105 total cells/ml in EGM-2 medium contained in 15 ml 
Falcon tubes and preconditioned with soluble Notch ligands as described in 
section 2.5. Meanwhile, HUVECs were detached as per usual when passaging 
and resuspended in EGM-2 medium at 0.67 x 105 cells/ml. For the control groups, 
150 μl of cell suspension was seeded in triplicate on top of the wells coated with 
35 µl of either GFR Matrigel or GFR Geltrex.  
 
Following preconditioning with soluble Notch ligands, hMSCs were diluted at 0.67 
x 105 cells/ml in EGM-2 medium and mixed gently. The HUVEC suspension was 
then added at the desired ratio to each hMSCs-containing tube followed by gentle 
mixing.150 μl of each mix was then seeded on top of the Matrigel-coated and the 
Geltrex-coated wells respectively. Following this, the 96-well plates were placed 
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in a hypoxic chamber purged with 2% O2, and then placed in a humidified 
incubator at 37 oC for 18-19 hrs. Images were visualised using an inverted light 
microscope and then put together using the PanoramaStudio2 software. The 
differences in vascular efficiency between the different conditions (normoxic-
hMSCs/HUVECs vs. hypoxic-hMSCs/HUVECs on either GFR Matrigel or GFR 
Geltrex with hMSCs primed with either sJag1, sDll4 or left untreated) were 
measured by manually counting the number of branch points over the entire well. 
Measurements were carried out by considering one branch point as the meeting 
point between three branches, 2 branch points as the meeting point between 4 
branches and 3 branch points as the junction of 5 branches. Tubule length was 
analysed manually by drawing a line along each tubule and measuring the length 
of the line in µm.  
 
 
Figure 5-1: Diagram summarizing experimental setup for co-culture assay. 
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5.2.5: Vascular support assay  
Following staining with viable dyes, hMSCs were treated with Notch ligands as 
described in section 2.5 and diluted at a concentration of 0.67 x 105 cells/ml. 150 
μl of hMSC suspension was seeded into the 96-well plates in triplicate for each 
experimental condition and incubated at 37 ⁰C for 24 hours. Following this, 
hMSCs were then washed once with EGM-2 medium and 55 µl of either GFR 
Matrigel or GFR Geltrex was carefully pipetted on top of the hMSCs. 
 
Plates were then placed in a humidified incubator at 37 oC for 1 hour. After 
gelation, 150 μl of a HUVEC suspension was added at a concentration of 0.67 x 
105 cells/ml to each well containing the hMSCs/Matrigel or Geltrex stacks. For the 
control groups, 150 µl of HUVEC suspension was seeded on top of the gel-
coated wells in triplicate. Following this, the plates were positioned in a hypoxic 
chamber purged with 2% O2 which was then placed in a humidified incubator at 
37 oC for 18-19 hrs. 
 
 
 
 
Figure 5-2: Diagram summarizing experimental setup for support assay. 
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5.3: Results 
5.3.1: Cell morphology  
Cells were imaged after being cultured in either 20% O2 or 2% O2 (for 5 days) to 
verify morphological differences between the differently-sourced hMSCs. The 
phase contrast images (Figure 5-3 A-F) indicated that the cells tested in this study 
exhibited adherence to tissue culture plastic, active proliferation and a 
homogeneously distributed monolayer of elongated spindle-shaped cells similar 
to those described by Pittenger et al., 1999; this was observed at both 20% O2 
and 2% O2 (Figure 5-3 A-F). The data also showed that the individual donor hBM-
MSCs (Figure 3-1A and B) and the P11 hUC-MSCs (Figure 5-3 E and F) 
appeared to be more confluent than the commercial hBM-MSCs (Figure 5-3 C 
and D). However, as growth rate studies of the cells were not carried out it was 
not possible to quantify these differences. 
 
Figure 5-3: Cell morphology of hMSCs after 5 days in culture. Individual donor gx11 P5 (PDL 
7) hBM-MSCs at 20% O2 (A) and 2% O2 (B) were expanded in complete medium; PDL 14 
commercial hBM-MSCs at 20% O2 (C) and 2% O2 (D) were expanded in their own High 
Performance Medium; P11 hUC-MSCs at 20% O2 (E) and 2% O2 (F) were expanded in 
complete medium. Scale bars = 400 µm. 
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5.3.2: qPCR 
Preliminary experiments of quantitative real-time PCR (qPCR) were carried out on 
hMSCs preconditioned in either low oxygen (2% O2) or in ambient oxygen (20% 
O2) tensions followed by priming with sJag1 or sDll4 or left untreated and let 
attach to fibronectin surfaces for 45 min. qPCR was carried out as explained in 
section 2.6. The activation of the Notch pathway was investigated by analysing 
the expression of JAG1, DLL4, HES1 and HEY1 in cells that have been cultured 
in 2% O2 or 20% O2. On the other hand, the effect of cell preconditioning in low 
oxygen compared to the untreated cells was assessed by analysis of HIF1 and 
HIF3. It is notable that in some experiments HIF3 (Figure 5-4 and Figure 5-5) and 
DLL4 (Figure 5-4 and Figure 5-5) were not measured. The single experiment for 
the individual donor hBM-MSCs showed that the expression of HIF1, JAG1, 
HES1 and HEY1 was consistently higher in cells preconditioned with sJag1 (see 
grey and black bars, Figure 5-4 A, B, C, and D). This was more evident for the 
expression of HES1 in sJag1 samples pre-treated in hypoxia (Figure 5-4 C). In 
fact, the results showed that HES1 expression for the hypoxic-hBM-MSCS pre-
treated with sJag1 was almost double than the one observed for the control 
groups (Figure 5-4 C). On the other hand, the expression of HIF1, JAG1, HES1 
and HEY1 for the hMSCs pre-treated with sDll4 cultured in 20% O2 was 
consistently lower than that of the control groups (Figure 5-4 A, B, C, and D). The 
data also suggested that all of the samples pre-treated with sDll4 appeared to 
show higher values of the JAG1, HES1 and HEY1 genes when using the hypoxic 
hMSCs compared to the cells treated in ambient oxygen conditions (Figure 5-4 A, 
B, C, and D). This result indicated that low oxygen may be beneficial for the 
expression of genes involved in Notch through sDll4 pre-treatment. 
The SD error bars indicated that there was very little variation between the 
technical replicates hence confirming low pipetting errors and validating the 
methods’ measurements. However, in order to get more accurate results there is 
the need to repeat the experiment at least twice more.  
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Overall these preliminary results indicated that for the P5 hBM-MSCs the 
untreated cells performed similarly at either 20% O2 or 2% O2 (Figure 5-4 A, B, C, 
and D). On the other hand, low oxygen conditions appeared to increase the 
expression of HIF1, JAG1, HES1 and HEY1 in the sDll4-treated cells in 
comparison to those expanded in ambient oxygen conditions (see sDll4 grey bars 
versus black bars, Figure 5-4 A, B, C, and D). Next, the cells pre-treated with 
sJag1 showed consistently higher expression of HIF1, JAG, HES1 and HEY1 
compared to the control groups; in particular for the HES1 gene in Figure 5-4 C. 
These trends suggested that the expression of HES1 may be up-regulated by 
sJag1 priming (at 20% O2 and 2% O2) and down-regulated by sDll4 priming (only 
at 20% O2). In addition, the data also showed that culturing sDll4-treated cells in 
hypoxia could upregulate the expression of Notch ligand genes. 
Figure 5-4: The normalised relative expression of HIF1, JAG1, HES1 and HEY1, was 
analysed for normoxic or hypoxic individual donor P5 (PDL 7) hBM-MSCs after they were 
preconditioned with either sJag1 or sDll4 or left untreated and seeded on FN-coated wells for 
45 min. Data for A, B, C and D are shown as one independent experiment with duplicate 
observations for each sample (UT, sJag1, and sDll4) as mean ± SD.  
 
qPCR was also carried on commercial PDL 14 hBM-MSCs for the expression of 
HIF1, HIF3, JAG1, HES1, and HEY1. The data showed that treating the cells in 
hypoxia did not activate the HIF1 gene, this was observed in both experiment 1 
and experiment 2 (Figure 5-5 A). On the other hand, even though there was 
variation between the two experiments, looking at HIF3 expression, the trend was 
that HIF3 was overexpressed in the cells conditioned to low oxygen (see grey 
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bars for UT, sJag1 and sDll4 Figure 5-5 B) in comparison to the control groups 
(see black bar UT, Figure 5-5 B). The expression of HIF3 in sDll4 and sJag1 
samples was at least 5-fold higher than that of the control groups (Figure 5-5 B). 
However, the big variations between the two experimental repeats for HIF3 
suggested that experiments need to be carried out at least two more times to see 
whether this trend is maintained or not.  
 
Following this, the study investigated whether low oxygen had an effect on the 
expression of Notch target genes or not. The data indicated that preconditioning 
the cells with sJag1 had no effect on JAG1 expression (Figure 5-5 C). On the 
other hand, the Notch target gene HES1 was almost two-fold higher for the sDll4 
and sJag1-treated cells at 20% O2 in comparison to the control groups (see black 
bars 20% O2; Figure 5-5 D). In addition, the HES1 gene appeared to be 
expressed at least five-folds more at low oxygen (see grey bars 2% O2; Figure 
5-5 C). In particular, the hBM-MSCs treated with sDll4 and low oxygen exhibited a 
15 fold expression of HES1 in comparison to the UT groups (Figure 5-5 C).  
 
Next, the results showed that in experiment 1 (Figure 5-5 E), HEY1 was 
upregulated in cells expanded at ambient oxygen conditions and exposed to 
either sJag1 or sDll4. However, in the second experiment, it appeared that Notch 
priming had no effect on HEY1 expression. For this reason, it was not possible to 
make any conclusion from this data (Figure 5-4 E). Overall these results should 
be treated carefully and they could be used to support other observations but on 
their own, they cannot be used to draw any conclusion as more repeats will need 
to be carried out.  
157 
 
 
Figure 5-5: The normalised relative expression of (A) HIF1 (B) HIF3, (C) JAG1, (D) HES1 and 
(E) HEY1 was analysed for normoxic or hypoxic commercial PDL 14 hBM-MSCs after they 
were preconditioned with either sJag1 or sDll4 or left untreated and seeded on FN-coated 
wells for 45 min. Gene expression was normalised to 18S and control group. Data are shown 
for single representative experiments carried out with separately prepared cell suspensions on 
2 different days with duplicate observations for each bar as mean ± SD. 
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The qPCR data for the P11 hUC-MSCs showed that there was approximately a 
two-fold increase in HIF1 expression in comparison to the control groups for the 
normoxic cells exposed to either sDll4 or sJag1 (see black bars; Figure 5-6 A). 
Next, it was not possible to make a conclusion regarding the effect of HIF1 
expression for the hypoxic cells exposed to sJag1 (see grey bars for sJag1; 
Figure 5-6 A). In fact, experiment 1 showed that sJag1 priming had no effect on 
HIF1 expression, whilst experiment 2 showed that sJag1 priming downregulated 
HIF1 expression. On the other hand, the data for the hypoxic sDll4-treated cells 
showed that there was an increase in HIF1 expression in comparison to the UT 
groups. However, in experiment 2, the sDll4 cells exhibited strong upregulation 
(see grey bars for sDll4; Figure 5-6 A) and in experiment 1 there was only a 
modest increase in comparison to the UT groups. Therefore, more experiments 
will need to be carried out to perform statistical analysis and obtain conclusive 
answers. 
 
Following this, exposing the hypoxic hMSCs to sJag1 appeared to downregulate 
JAG1 activation (Figure 5-6 B). On the other hand, when either normoxic or 
hypoxic hMSCs were exposed to sDll4 there was no effect on JAG1 activation 
(see grey and black bars; Figure 5-6 B).  
 
Next, when the hypoxic hMSCs were primed with sJag1 there was a 
downregulation of HES1 expression (see grey bars for sJag1 in experiment 1 and 
2; Figure 5-6 D). On the other hand, the normoxic sJag1-treated cells showed an 
increase in HES1 expression. However, this was more evident in experiment 1 
with a 3 fold increase in expression over the UT cells. Next, the sDll4-treated 
normoxic and hypoxic cells only showed a modest increase in HES1 expression 
(Figure 5-6 D). Following this, the sDll4-treated hypoxic hMSCs only showed a 
modest increase in HEY1 expression. As only an n = 1 was carried out for the 
hypoxic hMSCs with 2 measurements, it was not possible to make any conclusion 
for the 2% O2 sDll4-treated cells (HES1 and HEY1, Figure 5-6 D and E).  
 
The results also showed that the expression of the HEY1 gene in sJag1-treated 
hypoxic cells was low in comparison to the UT cells, this was observed in both 
experiment 1 and 2 (Figure 5-6 E). On the other hand, there was at least a three-
fold increase in expression of HEY1 in the sJag1-treated normoxic cells (see 
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black bars 20% O2, Figure 5-6 E). Similarly, HEY1 also appeared to be 
overexpressed in sDll4-treated normoxic cells but the variation between the two 
experiments was not enough to say whether these differences were significant or 
not (see black bars for sDll4 20%, Figure 5-6 E). 
Figure 5-6: The normalised relative expression of (A) HIF1 (B) JAG1, (C) DLL4, (D) HES1 and 
(D) HEY1 was analysed for normoxic or hypoxic P11 hUC-MSCs after they were 
preconditioned with either sJag1 or sDll4 or left untreated and seeded on FN-coated wells for 
45 min. Data are shown for single representative experiments carried out with separately 
prepared cell suspensions on 2 different days with duplicate observations for each bar as 
mean ± SD. 
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5.3.3: Co-culture assays  
5.3.3.1: Staining of cell monolayer with viable cell fluorescent 
dyes 
hMSCs (see phase contrast; Figure 5-7) and HUVECs (see phase contrast; 
Figure 5-7) were visualised under an inverted light microscope to confirm that 
they were still actively proliferating and to estimate if they reached 80-90% 
confluency by ensuring that most of the area in the flask was covered. hMSCs 
and HUVECs were stained separately (see red and green staining; Figure 5-7) 
and successful staining was observed by the red fluorescence of the hBM-MSCs 
and the green fluorescence of the HUVECs which would allow for the cells to be 
distinguished in the in vitro co-culture assays (Figure 5-7).  
 
 
Figure 5-7: Representative phase contrast and staining images of P5 (PDL 7) gx11 hBM-
MSCs and P10 HUVECs with viable fluorescent cell dyes for in vitro vascular assays. 
Successful staining was confirmed by observing the uptake of the dye using a fluorescence 
microscope where hMSCs were stained in red and HUVECs were stained in green. Scale 
bars = 400 µm. 
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5.3.3.2: Interaction of hMSCs with HUVECs in co-culture 
assays 
Following successful staining cells were diluted at 0.67 x 105 cells/ml in complete 
EGM-2 medium, mixed at a 1:1 ratio and seeded on either Matrigel-coated or 
Geltrex-coated wells. HUVECs cultured separately on top of the gel-coated wells 
were used as positive controls. The phase contrast images for the control groups 
indicated the formation of well-connected vascular networks on Matrigel and 
Geltrex respectively at both 20% O2 and 2% O2 (Figure 5-8 A). Furthermore, no 
apparent differences in network formation were observed for the different 
conditions (Figure 5-8 A). Following this, the fluorescence images data (Figure 
5-8 B) confirmed that all of the HUVECs stained with the green fluorescent dye 
and that the stain did not fade off after 18 hours of incubation. 
 
 
Figure 5-8: Representative staining images of P10 HUVECs (control groups) in (A) phase 
contrast and (B) stained with CellTracker Green CMFDA using Matrigel and Geltrex. 
Experiments were carried out at 20% O2 and 2% O2. Scale bars = 400 µm. 
 
Co-culture assays were carried out to assess the interactions between HUVECs 
and individual donor hBM-MSCs on the gel-coated wells. The staining images 
showed that the normoxic and hypoxic hBM-MSCs exerted a pericyte-like 
behaviour by aligning at the periphery of the tubules or bridging between them, 
this was observed for both Matrigel and Geltrex (see UT, sJag1, sDll4 at 20% O2 
or 2% O2; Figure 5-9 1-6 and Figure 5-10 7-12).  
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Figure 5-9: Co-culture vessel formation after 18 hours of P5 (PDL 7) gx11 hBM-MSCs (in red) 
and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments were carried out on GFR 
Matrigel. Images were visualised using a fluorescence microscope. Yellow arrows represent 
the hBM-MSCs bridging between HUVECs. White arrows represent the hBM-MSCs 
surrounding the network structures. Scale bars = 400 µm. 
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Figure 5-10: Co-culture vessel formation after 18 hours of P5 (PDL 7) gx11 hBM-MSCs (in 
red) and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments were carried out on GFR 
Geltrex. Images were visualised using a fluorescence microscope. Yellow arrows represent 
the hBM-MSCs bridging between HUVECs. White arrows represent the hBM-MSCs 
surrounding the network structures. Scale bars = 400 µm. 
 
Next, it was observed that the PDL 14 commercial hBM-MSCs co-localised with 
the HUVEC structures. This behaviour suggested that the hMSCs (in red) were 
exerting a pericyte-like behaviour by and aligning around the endothelial cells (in 
green, Figure 5-11, 13-18; Figure 5-12, 19-24).  
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Figure 5-11: Co-culture vessel formation after 18 hours of commercial PDL14 hBM-MSCs (in 
red) and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments were carried out on GFR 
Matrigel. Images were visualised using a fluorescence microscope. Yellow arrows represent 
the hBM-MSCs bridging between HUVECs. White arrows represent the hBM-MSCs 
surrounding the network structures. Scale bars = 400 µm. 
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Figure 5-12: Co-culture vessel formation after 18 hours of commercial PDL14 hBM-MSCs (in 
red) and P10 HUVECs (in green) seeded at a 1:1 ratio. Experiments were carried out on GFR 
Geltrex. Images were visualised using a fluorescence microscope. Yellow arrows represent 
the hBM-MSCs bridging between HUVECs. White arrows represent the hBM-MSCs 
surrounding the network structures. Scale bars = 400 µm. 
 
The fluorescence images of the P11 hUC-MSCs seeded with P10 HUVECs at a 
1:1 ratio (Figure 5-13) indicated no formation of vessel structures. However, the 
images suggested the hUC-MSCs were still co-localizing with the HUVECs in the 
clump structures (Figure 5-13 25-30). These images also suggested that hMSCs 
may have a modulatory role in the formation of vessel-like structures by HUVECs 
as when the hUC-MSCs were co-cultured with the HUVECs there was no tubule 
formation, whilst the endothelial cells alone were able to form vessel-like 
structures (Figure 5-8). As shown in Figure 5-13, the hUC-MSCs appeared to 
engulf around the HUVECs which might have hindered the ECs from migrating 
and forming networks. On the other hand, when hBM-MSCs were co-cultured on 
the same day and with the same HUVECs used for the hUC-MSCs they also co-
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localised with the HUVECs but cells were able to form vessel-like structures 
(Figure 5-9 and Figure 5-10). This observation further suggests that hMSCs may 
modulate network formation and that differently-sourced hMSCs may behave 
differently.  
 
Figure 5-13: Co-culture vessel formation after 18 hours of P11 hUC-MSCs (in red; hUC-MSCs 
were previously cultured in either 20% O2 or 2% O2) and P10 HUVECs (in green; previously 
cultured in ambient oxygen conditions). Experiments were carried out using either GFR 
Matrigel or GFR Geltrex. Images were visualised using a fluorescence microscope. White 
arrows represent the hUC-MSCs surrounding the HUVEC structures. Scale bars = 400 µm. 
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5.3.3.3: Branch point quantification of co-culture assays using 
P10 HUVECs and individual donor P5 (PDL 7) hBM-
MSCs 
Co-culture assays were performed using P10 HUVECs and P5 (PDL 7) individual 
donor hBM-MSCs to assess differences in tubule network morphology and 
efficiency. The phase contrast images showed that the formation of tubule-like 
structures was different in HUVECs-only and co-culture assays. In fact, the 
tubules formed in the co-culture assays (see UT, sJag1, and sDll4; Figure 5-14 B 
and C) appeared to be more heterogeneous than the control groups (Figure 5-14 
A) consisting of more elongated interconnecting tubules that more closely 
resembled capillaries in vivo than the HUVECs-only assays. Vascular networks 
formed in the co-cultures (Figure 5-14 B and C) also demonstrated a diminished 
ability to form endothelial networks on gel-coated wells (Figure 5-14 A).  
 
Figure 5-14: (A) Positive controls were run for the co-culture assays by seeding P10 HUVECs 
on either GFR Matrigel or GFR Geltrex. Co-cultures were carried by seeding P10 HUVECs 
with either (B) normoxic P5 (PDL 7) gx11 hBM-MSCs or (C) hypoxic P5 (PDL 7) gx11 hBM-
MSCs mixed at a ratio of 1:1 and seeded on either 35 µl of GFR Matrigel or 35 µl of GFR 
Geltrex. Experiments were carried out at 2% O2. Scale bars = 1000 µm. 
 
 
The branch point quantification data indicated 2-3 folds increase in the number of 
branch points formed using the HUVECs-only positive control groups (coated on 
either GFR Matrigel or GFR Geltrex) in comparison to the co-cultures (see 
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normoxic hBM-MSCs and hypoxic hBM-MSCs, Figure 5-15 A and B). This might 
be due to the fact that the co-cultures only had half the number of vascular 
endothelial cells in the system which was going to in itself reduce the number of 
branch points. Next, the normoxic hBM-MSCs and the hypoxic hBM-MSCs 
seemed to work similarly on both Matrigel and Geltrex coated wells, this was 
observed for both individual experiments (Figure 5-15 A and B).  
 
Following this, the data for the gx11 hBM-MSCs showed that Matrigel performed 
better than Geltrex in forming branch networks in co-culture (Figure 5-15 A). 
However, since only one experiment was performed using this donor it was not 
possible to establish whether these differences were significant or not, hence 
these findings were deemed to be inconclusive. Both Matrigel and Geltrex are 
derived from mouse sarcoma explaining why they might have worked similarly 
well. Furthermore, the results for the gx10 hBM-MSCs indicated that Matrigel and 
Geltrex worked similarly well in co-culture assays (see experiment 2, Figure 5-15 
B). The values of Matrigel in both experiments were similar whilst the values of 
Geltrex were higher in experiment 2 (Figure 5-15 B) with the number of branch 
points using the normoxic hMSCs being almost double in experiment 2 compared 
to experiment 1 (Figure 5-15 A and B). The overall conclusion from this data is 
that when HUVECs alone are seeded on either Matrigel or Geltrex, they form a 
higher number of branch points compared to co-cultures. Moreover, priming the 
hBM-MSCs with Notch ligands did not seem to impact on the tubule formation 
efficiency.  
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Figure 5-15: Branch point quantification of P10 HUVECs seeded with either (A) gx11 P5 (PDL 
7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs previously cultured under normoxic (20% 
O2) and hypoxic (2% O2) conditions respectively for 5 days. Error bars represent observations 
of three technical replicates for each biological repeat as mean ± SD. Experiments were 
carried out twice using hMSC batches isolated and expanded from two different donors; A 
(gx11) and B (gx10). 
 
5.3.3.4: Average tubule length quantification of co-culture 
assays using P10 HUVECs and individual donor P5 
(PDL 7) hBM-MSCs 
The average tubule length of the co-culture assays in both the GFR Matrigel and 
GFR Geltrex assays was at least double that of the HUVECs-only control groups 
(see HUVECs against UT, sJag1, and sDll4; Figure 5-16 A and B). The results 
showed that the pre-stimulation of the hMSCs by Notch ligands did not impact on 
the length of the vessels. However, it is notable that for the gx11 hBM-MSCs the 
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normoxic sJag1-treated cells seeded on Geltrex appeared to be longer than those 
formed in the UT and the sDll4 groups (Figure 5-16 A). Overall Matrigel and 
Geltrex worked similarly well at all of the conditions. 
 
Figure 5-16: Average tubule length quantification of P10 HUVECs seeded with either (A) gx11 
P5 (PDL 7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs previously expanded in normoxic 
(20% O2) or hypoxic (2% O2) conditions. Error bars represent observations of three technical 
replicates for each biological repeat as mean ± SD. Experiments were carried out twice using 
hBM-MSC batches isolated and expanded from two individual donors; A (gx11) and B (gx10). 
 
5.3.3.5: Cumulative tubule length quantification of co-culture 
assays using P10 HUVECs and individual donor P5 
(PDL 7) hBM-MSCs 
The HUVECs-only control groups showed higher cumulative tubule length values 
than the co-cultures (see HUVECs against UT, sJag1, and sDll4; Figure 5-17 A 
and B). In particular, on Geltrex the normoxic sJag1-treated and UT gx11 hBM-
MSCs showed almost 2 fold decrease in cumulative tubule length values in 
comparison to the HUVECs-only groups (Figure 5-17 A). Next, the data for 
experiment 1 showed that the sDll4-treated normoxic hMSC groups seeded on 
Geltrex, appeared to show higher cumulative length values than the UT and the 
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sJag1 groups, but this was trend was not observed in experiment 2 and that could 
be related to using a different MSC donor (see experiment 1; Figure 5-17 A). On 
the other hand, for the hypoxic hBM-MSCs, there was a trend where the sJag1 
groups appeared to show higher values than the UT and the sDll4-treated cells 
and this was observed using both Matrigel and Geltrex (see hypoxic hMSCs; 
Figure 5-17 A and B). This observation indicated that preconditioning hMSCs in 
low oxygen may enhance the effects of sJag1 in co-culture assays. Following this, 
there was no obvious trend for the normoxic gx11 hMSCs seeded on Matrigel and 
the normoxic gx10 hMSCs seeded on either Matrigel or Geltrex (see UT against 
sJag1 and sDll4; Figure 5-17 A and B). More experiments will need to be 
performed to confirm whether these differences are significant or not. It is notable 
that the HUVECs-only groups had double the number of endothelial cells than the 
co-cultures where the other half was replaced by hBM-MSCs. This might have 
contributed to the higher cumulative tubule length values observed for the 
HUVEC-only groups.  
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Figure 5-17: Cumulative tubule length quantification of P10 HUVECs seeded with either (A) 
gx11 P5 (PDL 7) hBM-MSCs or (B) gx10 P5 (PDL 7) hBM-MSCs previously cultured under 
normoxic (20% O2) or hypoxic (2% O2) conditions. Error bars represent observations of three 
technical replicates for each biological repeat as mean ± SD. Experiments were carried out 
twice using hBM-MSC batches isolated and expanded from two individual donors; A (gx11) 
and B (gx10). 
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5.3.3.6: Quantification of vessel-like networks in the presence 
of commercial hBM-MSC/HUVEC co-cultures  
The phase contrast images showed that the HUVECs that were co-cultured with 
the MSCs demonstrated a diminished ability to form vascular-like networks 
(Figure 5-18 B and C). On the other hand, when HUVECs were seeded 
separately on either Matrigel or Geltrex, they acquired an increased ability to form 
vascular tubules (Figure 5-18 A). This indicated that the physical interaction of the 
hBM-MSCs with the HUVECs was inhibitory to the angiogenic potential of 
endothelial cells to form networks. In addition, branches formed in the co-culture 
assays looked more elongated (Figure 5-18 B and C) than those observed for the 
control groups (Figure 5-18 A). Next, it was observed that when the ECs were 
seeded with the hypoxic hBM-MSCs (Figure 5-18 C), more vascular networks 
were formed than when using the normoxic hBM-MSCs (Figure 5-18 B). Vascular 
efficiency was measured by manually counting the number of branch points 
formed (Figure 5-19). 
 
Figure 5-18: (A) Positive controls were run for the co-culture assays by seeding P10 HUVECs 
on either GFR Matrigel or GFR Geltrex. Co-culture assays were carried out by seeding P10 
HUVECs with either (B) normoxic commercial PDL14 hBM-MSCs or (C) hypoxic commercial 
PDL14 hBM-MSCs mixed at a ratio of 1:1 and seeded on either 35 µl of GFR Matrigel or 35 µl 
of GFR Geltrex. Experiments were carried out at 2% O2. Scale bars = 1000 µm. 
 
The cumulative quantification data for the PDL14 commercial hBM-MSCs showed 
that the positive controls (with endothelial cells alone) formed a significantly 
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higher number of branch points than the co-cultures (see HUVECs, Figure 5-19 
E). The very low number of branch points for the co-culture assays suggested 
that the presence of hMSCs might have been inhibitory to efficient network 
formation. In fact, the physical interaction between hMSCs and HUVECs might 
have also changed the release of a soluble factor(s) that affects the angiogenic 
capacity of endothelial cells (Menge et al., 2012). In addition, the ratio chosen for 
the hMSCs and HUVECs might not have been optimal for network formation. 
Each experimental repeat indicated large error bars between technical replicates 
(Figure 5-19 A-C). Sources of variability might have been associated with the 
methodology of the assays (e.g. extensive serial dilutions of samples to obtain 
wanted concentrations), mixing of the samples or decrease in cell viability during 
the experiments, suggesting the need for assay optimization. Next, the trend 
between the first two experiments was similar and the number of networks formed 
when using the untreated hypoxic hMSCs seeded on Geltrex was at least 10 folds 
higher than when the normoxic hBM-MSCs were used (see UT, Figure 5-19 A 
and B). Similarly, when the hypoxic sJag1-treated hBM-MSCs were used, the 
number of branch points formed was at least 4 times higher than that obtained 
when using the sJag1-treated normoxic hBM-MSC groups, this trend was 
maintained in both experiment 1 and experiment 2 (see sJag1; Figure 5-19 A and 
B). Next, experiment 3 showed that the number of branch points formed when 
using the hypoxic hBM-MSCs was considerably higher in comparison to the 
normoxic hBM-MSCs, and this trend was observed for each UT, sJag1 and sDll4 
groups. In particular, the networks formed on Geltrex using the hypoxic hBM-
MSCs were at least 60 folds higher than those formed using the normoxic hBM-
MSCs (see UT, sJag1, and sDll4 groups; Figure 5-19 C). 
 
The variability dependent on the different batches of hMSCs was shown in the 
cumulative data (Figure 5-19 D). However, there was a trend where the number 
of branch points formed using the hypoxic hMSCs was higher than those 
observed in the normoxic hMSC group. In particular, this trend was more evident 
on Geltrex, with at least double the number of branch points formed in the 
normoxic UT and sJag1 groups in comparison to those obtained when the cells 
were seeded on Matrigel (Figure 5-19 D). These results suggest that hypoxic 
preconditioning may have a positive effect on the angiogenic abilities of MSCs. 
Furthermore, differences between UT and sJag1 were more apparent in the 
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Matrigel groups, especially using the hypoxic hMSCs where the number of branch 
points formed using the sjag1-primed hMSCs was almost two-fold higher than 
that of the UT group (see black bars, UT 2% against sJag1 2%, Figure 5-19 C).  
 
Based on the mean data (Figure 5-19 A, B and C), experiment 3 (Figure 5-19 C) 
might have been considered as an outlier as shown in the raw data in Figure 5-18 
E as there was less variance between the other two experiments (Figure 5-19 C). 
However, as it performed best especially at low oxygen and considering that there 
was a high degree of variability within the experiments themselves, it was not 
possible to draw any clear conclusion from this study. 
 
 
Figure 5-19: Branch point quantification for P10 HUVECs seeded at a 1:1 ratio with 
commercial PDL14 hBM-MSCs expanded in normoxic (20% O2) and hypoxic (2% O2) 
conditions. The results in (A), (B) and (C) are shown as three independent experimental 
repeats using different hMSC batches derived from the same donor. Error bars represent 
observations of three technical replicates for each experimental repeat as mean ± SD. 
Cumulative data is shown in (D) and error bars represent the mean ± SEM of the three 
independent experimental repeats. Raw data of the three repeated experiments are shown in 
(E).  
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5.3.3.7: Average tubule length quantification of co-culture 
assays using P10 HUVECs and commercial low serum 
hBM-MSCs 
The average tubule length quantification data for the commercial PDL 14 hBM-
MSCs indicated that when hBM-MSCs were present, there was at least a two-fold 
increase in branch length compared to the HUVECs-only groups (Figure 5-20). 
Therefore, the vascular networks observed in the co-culture assays were more 
representative of the capillaries in vivo than those formed when endothelial cells 
alone were present. Also, no obvious differences were observed in relation to 
oxygen environment or type of matrix (Figure 5-20). However, in the hypoxic 
hMSCs group there was a modest trend where cells primed with sJag1 showed 
higher average tubule length in both the Matrigel and Geltrex groups. Overall 
networks formed using HUVECs alone showed lower average length values than 
that observed for the co-cultures.   
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Figure 5-20: Average tubule length quantification for P10 HUVECs seeded with commercial 
PDL 14 hBM-MSCs which were previously cultured under normoxic (20% O2) and hypoxic 
(2% O2) conditions respectively. Error bars represent the mean ± SEM of three independent 
experimental repeats carried out using different hMSC batches derived from the same donor. 
Refer to text for a detailed description of results. 
 
5.3.3.8: Cumulative tubule length quantification of co-culture 
assays using P10 HUVECs and commercial low serum 
hBM-MSCs 
The results showed that the cumulative tubule length values for the normoxic and 
hypoxic co-cultures on either Matrigel or Geltrex were at least two-fold lower than 
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those of the HUVECs-only groups, except for the hypoxic UT and the sJag1 
groups which showed similar values to the assays performed using only 
endothelial cells (Figure 5-21). Next, for the assays performed on Matrigel and 
using the hypoxic hMSCs, it was evident that sJag1 priming appeared to have a 
positive effect on cumulative tubule length with almost a two-fold increase in 
comparison to the UT samples.  
 
 
Figure 5-21: Cumulative tubule length quantification for P10 HUVECs seeded with commercial 
PDL 14 hBM-MSCs which were previously cultured under normoxic (20% O2) and hypoxic 
(2% O2) conditions respectively. Error bars represent the mean ± SEM of three independent 
experimental repeats carried out using different hMSC batches derived from the same donor. 
Refer to text for a detailed description of results. 
 
5.3.3.9: Quantification of P11 hUC-MSCs/HUVECs vascular 
structures  
The phase contrast images showed that when the P11 hUC-MSCs were co-
cultured with the HUVECs, the experiments failed as there was no formation of 
vessel structures (Figure 5-22 B and C). This observation was further confirmed 
by the HUVECs-only positive controls which were able to successfully form 
vessel-like structures in all of the 8 independently carried out experiments (Figure 
5-22 B and C). One reason explaining these results could be that the seeding 
ratio of hMSCs to HUVECs was not optimal for vascular network formation. Also, 
it was previously demonstrated in Chapter 3 that P11 hUC-MSCs had enhanced 
adhesion capabilities especially when the cells were primed with sJag1. 
Furthermore, their strong adhesion might have been another factor in reducing 
their spreading and hindering the formation of vessel-like networks. 
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Figure 5-22: (A) Positive controls were run for the co-culture assays by seeding P10 HUVECs 
on either GFR Matrigel or GFR Geltrex. Co-cultures were carried out with either (B) normoxic 
P11 hUC-MSCs or (C) hypoxic P11 hUC-MSCs mixed at a ratio of 1:1 with P10 HUVECs 
using either 35 µl of GFR Matrigel or 35 µl of GFR Geltrex. Experiments were carried out at 
2% O2. No tubule formation was observed after 18 hours incubation. n = 8 independent 
experimental repeats were carried out using different hMSC batches derived from the same 
donor. Scale bars = 1000 µm. 
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5.3.4: Testing the functionality of commercial hBM-MSCs in 
support assays  
Studies were carried out to investigate the supportive role of hBM-MSCs primed 
with Notch ligands when these were seeded below the HUVECs (Figure 5-23). 
The fluorescence images indicated that there the hMSCs formed a supportive 
layer beneath the HUVECs. However, no physical interaction was observed 
between the two cell types. Next, the fluorescence images showed that there 
were fewer MSCs for sJag1 and sDll4 whilst it appeared that there was a strong 
labelling for UT hBM-MSCs. 
 
Figure 5-23: Vessel formation in support assays after 18 hours of seeding P10 HUVECs 
(green cells) on top of the commercial PDL14 hBM-MSCs (red cells) stacked with either 
Matrigel or Geltrex and previously left untreated or primed with either sJag1 or sDll4. 
HUVECs-only positive controls were run in parallel. Scale bars = 400 µm. 
 
The phase contrast images in Figure 5-24 showed that network formation and 
vessel length in the support assays (see UT, sJag1, and sDll4; Figure 5-24 B and 
C) was similar to that of the control groups (see HUVECs; Figure 5-24 A). 
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Branches appeared to be more robust when using the normoxic hBM-MSCs 
(Figure 5-24 B) 
 
Figure 5-24: Phase contrast representative images of (A) HUVECs-only control groups (B) 
support assays using normoxic hBM-MSCs and (C) support assays using hypoxic hBM-
MSCs. Scale bars = 1000 µm. 
 
One aim of the support assays was to assess if priming the hBM-MSCs with 
sJag1 or sDll4 was going to enhance the secretion of paracrine factors that could 
further promote enhanced angiogenesis in the overlying endothelial cells. Another 
aim of this work was to compare the performance of Geltrex over Matrigel to 
promote efficient tubule formation which was quantified in terms of the number of 
branch points. The study also compared the effect of expanding hBM-MSCs in 
low oxygen (2% O2) on their ability to support angiogenesis. The results indicated 
that there appeared to be no obvious differences between the experiments that 
were carried out using either normoxic hMSCs or hypoxic hMSCs (see black bars 
versus white bars, Figure 5-25). Furthermore, the differences between the 
normoxic and the hypoxic hBM-MSCs might have been decreased by running the 
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support assays at 2% O2 for 18 hours hence by this point the normoxic hBM-
MSCs could have been affected by the low oxygen conditions. However, there 
was a trend where more branch points formed on Geltrex over Matrigel when 
using hypoxic hBM-MSCs (see black bars versus white bars, Figure 5-25). GFR 
Geltrex comes at a consistent protein concentration of 15 mg/ml (Life 
Technologies, Paisley UK) whilst the protein concentration for GFR Matrigel 
ranges from 8-12 mg/ml (BD Biosciences, Maryland USA) and it is batch specific. 
For this reason, the slightly lower concentration of Matrigel could have led to 
differences between the two matrices.  
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Figure 5-25: Branch point quantification of vascular support by commercial PDL14 hBM-MSCs 
previously cultured under hypoxic (2% O2) or normoxic (20% O2) conditions followed by 
priming with either sJag1, sDll4 or left untreated (UT). Error bars represent the mean ± SEM 
of n = 3 independent experimental repeats carried out using different hBM-MSC batches 
derived from the same donor.   
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5.4: Discussion 
In the current work, qPCR was carried to compare differences in expression of 
Notch ligand genes between hypoxic and normoxic hMSCs (Figure 5-4, Figure 
5-5 and Figure 5-6). The findings from this study showed an increase in the level 
of Notch signalling and its downstream gene HES1 by hypoxia, in individual 
donor hBM-MSCs primed with either sDll4 or sJag1 (Figure 5-4 C and D). This 
was in line with previous work which showed that culturing MSCs in low oxygen 
was linked with an increase in the expression of its downstream gene HES1 
(Moriyama et al., 2014) or its ligands which included JAG1 and DLL4 (Gonzalez-
King et al., 2017). These findings were also in line with previous work on hBM-
MSCs (Detela, 2014) which indicated that the soluble forms of Dll4 and Jag1 
stimulate Notch signalling better at 2% O2 than at 20% O2. The upregulation of 
HES1 was also evident in hypoxic commercial hBM-MSCs (Figure 5-5 C). 
However, this trend was not observed for the hUC-MSCs where low oxygen 
appeared to have no effect or downregulate the expression of JAG1, DLL4, 
HES1 and HEY1 (Figure 5-6 B-E). More experiments will need to be carried out 
to make strong conclusions on the upregulation of Notch signalling by hypoxia.  
 
Several studies looked into the effect of hypoxia on hBM-MSCs however, not as 
much work has been carried out on hUC-MSCs (Lavrentieva et al., 2010; Griffon 
et al., 2016). The current work indicated that the effect of hypoxia and priming 
with Notch ligands on hMSCs may be source-specific. In support of this finding, 
some studies showed that umbilical cord hMSCs displayed metabolic 
differences in response to hypoxia when compared to hBM-MSCs. For example, 
even though hUC-MSCs were previously shown to increase metabolism and 
hence lactate production from glucose in response to hypoxia, these were 
reported to be significantly lower than those observed in hBM-MSCs and 
adipose-derived MSCs (Lavrentieva et al., 2010). Although it may be true that 
the effect of hypoxia on MSCs may be source-specific, previous studies 
reported an increase in mRNA expression levels of HIF1 in hUC-MSCs which is 
known to regulate the expression of the Notch signalling pathway (Lavrentieva 
et al., 2010; Ejtehadifar et al., 2015). However, this trend was not observed in 
this study and no clear trend was observed for the effect of hypoxia on HIF1 
expression (Figure 5-6 A). Furthermore, in terms of process optimization, cells 
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could be expanded in low oxygen for more than two passages since the effects 
of hypoxia on hMSCs have been shown to be also time-dependent (Bain et al., 
2014; Ding et al., 2014). 
 
The variability in the qPCR experiments made it difficult to make clear 
conclusions. Variability in the experiments may be linked to variations in the 
master mix preparation and differences in the volume of cDNA added as 
volumes in PCR are small. For this reason, future work could include more 
qPCR experiments to confirm the qPCR results. In addition, other methods such 
as western blot could be investigated to make a comparative analysis.  
 
Previous studies have reported that hMSCs may have a pericyte-like role 
(Crisan et al., 2008). For example, in one study pericytes were recovered from 
different organs such as the placenta or adipose tissue and they were shown to 
exhibit osteogenic, chondrogenic and adipogenic potential, they expressed MSC 
markers and they were myogenic in culture (Crisan et al., 2008). These findings 
indicated that pericytes might be giving origin to MSCs or that MSCs may in fact 
be pericytes (Crisan et al., 2008).  
 
The current work was in line with the findings of Crisan et al., 2008 as hMSCs 
appeared to co-localize with the endothelial cells at the periphery of the vessels, 
bridging between and around the capillary-like structures (Figure 5-10-Figure 
5-13). Moreover, this study suggested that similarly to pericytes, hMSCs might 
have a role in modulating vascular network formation through direct physical 
contact and paracrine signalling. hMSCs are known to release several growth 
factors including platelet-derived growth factor (PDGF), transforming growth 
factor (TGF-β) and vascular endothelial growth factor (VEGF) which are known 
to promote angiogenesis (Shi et al., 2012; Tao et al., 2016). 
 
Both individual donor and commercial hBM-MSCs appeared to have a role in 
modulating vessel formation in the co-culture assays (fluorescence staining 
images Figure 5-9, Figure 5-10, Figure 5-11 and Figure 5-12; phase contrast 
images Figure 5-14 and Figure 5-18). The results for the hBM-MSCs were in line 
with previous work which showed that when HUVECs were co-cultured with the 
hBM-MSCs there was still the formation of vascular networks (Menge et al., 
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2012). The data in Figure 5-15 and Figure 5-19 showed that the number of 
vessels formed in the co-culture assays was 2-3 fold lower than those formed in 
the HUVEC-only groups. Some studies hypothesized that the reduction in 
branch point formation in MSC:EC co-cultures may be due to the MSCs 
inhibiting endothelial cell proliferation and angiogenesis via physical contact 
(Menge et al., 2012). However, the significant reduction in branch points in the 
co-cultures can be attributed to the presence of only half of the HUVECs in the 
co-cultures with the other half being replaced by hMSCs. Previous gene 
expression studies indicated that MSCs cultured in direct contact with HUVECs 
differentiated towards a pericyte-like phenotype in vitro with the upregulation of 
the pericytes markers CD146, NG2, and αSMA (Loibl et al., 2014) therefore 
branch point quantification is not the only metric of vascular efficiency (Donovan 
et al., 2001).  
 
Even though there were significantly fewer branch networks formed in co-culture 
assays compared to the HUVECs-only groups, the phase contrast images in 
Figure 5-14 and Figure 5-18 and the quantification data of average length for the 
individual donor hBM-MSCs (Figure 5-16), showed that the branches formed in 
the co-culture assays were more elongated than those formed when ECs alone 
were seeded on the gel-coated wells. This indicated that the branches formed in 
the co-culture assays more closely mimicked the capillaries in the in vivo 
environment. Next, the cumulative tubule length values in the co-culture assays 
for the individual donor hBM-MSCs (Figure 5-17 A and B) were similar to those 
of the HUVECs. This may be associated with the fact that the co-culture groups 
included only half of the HUVECs and the other half was the hBM-MSCs, hence 
the HUVECs-only groups were expected to form more branches than that of the 
co-cultures and this will have increased the values for the cumulative length.  
 
The higher values of cumulative tubule length due to the addition of only half of 
the HUVECs in the co-cultures was more evident when using the commercial 
hBM-MSCs (Figure 5-21), this may be because they formed fewer branches 
than the individual donor hBM-MSCs.  
 
The addition of hMSCs can be seen as one more factor to make the process of 
tubule formation in vitro more complex and closer to what it would be expected 
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in a physiological environment (Donovan et al., 2001). In terms of bioprocessing 
and optimized quality control testing, using co-culture in vitro tests as surrogate 
potency tests or in pre-clinical studies would be more beneficial because it 
would allow the screening of the molecules in an environment that more closely 
reflects the complexity of the in vivo milieu.  
 
Next, both phase contrast and staining results for the P11 hUC-MSCs co-culture 
assays (Figure 5-13 and Figure 5-22) indicated that the stem cells appeared to 
hinder vessel formation rather than promoting the ECs to form vessel structures. 
The lack of vessel formation was observed in 8 experiments using two different 
hUC-MSC donors. This result was not expected as recent work showed that UC-
MSCs have higher angiogenic abilities than hBM-MSCs (Shen et al., 2015). In 
addition, it has been shown that UC-MSC conditioned medium increases the 
lengths of the tubes formed in UC-MSC and HUVEC angiogenesis assays in 
comparison to BM-MSCs (Shen et al., 2015). Therefore, the lack of tubule 
formation in the UC-MSC co-cultures may be related to the ratio of MSC:HUVEC 
used in this study. More experiments will need to be carried out on a bigger 
number of donors, as outcomes in branching may be different between different 
populations of MSCs derived from the same source.  
 
Next, commercial and individual donor hBM-MSCs displayed similar 
functionalities in co-culture assays. However, as only one or two donors were 
used in these experiments, there is also a need to test more donors to confirm 
these results. 
 
In vitro co-culture and support assays include a lot variability because of the use 
of biological materials such as the media used, the cells and the matrices. For 
this reason, it was decided to test Geltrex and Matrigel side to side and see 
whether the former could also be used to replace Matrigel. The main 
components of Matrigel and Geltrex are laminin and collagen IV which are 
known to promote endothelial cell proliferation and differentiation (Stamati et al., 
2014). However, Matrigel needs to be bought in bulk when carrying out 
experiments because there is a great deal of batch to batch variability and the 
relative concentration of different components can vary considerably, whilst 
Geltrex has been put on the market as an alternative due to more consistent 
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protein concentration lot-to-lot, which would reduce assay variability (Life 
Technologies, Paisley UK).  
 
The current work showed that Geltrex worked as well as Matrigel for the co-
culture assays (Figure 5-15, Figure 5-16, Figure 5-19 and Figure 5-20), whilst 
for the support assays there was a consistent trend of Geltrex forming more 
networks than Matrigel especially using the hypoxic hBM-MSCs, with the branch 
point values of Geltrex being almost two-fold higher than that of Matrigel. 
Furthermore, this study confirmed that Geltrex could be used in co-culture and 
vascular support assays as an alternative to Matrigel as part of assay 
optimization. In addition, Geltrex can be used at a 1 in100 dilution (Life 
Technologies, Paisley UK; Ulrich and Negraes, 2016), whereas Matrigel is 
typically used at a 1 in 30 dilution (BD Biosciences, Maryland USA; Gage et al., 
2013). For this reason, more comparative support assays could be carried out to 
investigate the use of diluted GFR Matrigel and GFR Geltrex to reduce the 
interphase between the MSCs and the endothelial cells giving further insights 
into the vasculogenic potential of the stem cells and also to make the assays 
cheaper for future cell-therapy routine screening.  
 
Capillaries in vivo are reported to consist of a single layer of ECs with 
occasional pericytes present in the basement membrane (Truskey, 2010). For 
this reason, reducing the interphase between MSCs and ECs could give more 
insights into the pericyte-like behaviour of hMSCs. In addition, the effect of the 
MSCs in the co-culture and the support assays could be further investigated by 
checking vessel-forming efficiency after 24 hours, one week and three weeks. In 
this way, it would be easier to see whether the presence of MSCs in the 
vascular assays has a beneficial effect in supporting angiogenesis. In the 
current work, hMSCs were expanded in 20% O2 and 2% O2 and the assays 
were performed in hypoxic conditions. The data for the individual-donor hBM-
MSCs (Figure 5-15) is not in agreement with previous results which showed that 
hypoxia drives angiogenesis and the formation of capillary-like structures in 
MSCs (Annabi et al., 2003). The lack of differences between hypoxic and 
normoxic hMSCs might indicate that the cells previously cultured in ambient 
oxygen might have adapted to hypoxia during the 18 hours of incubation in the 
assays. In fact, based on previous studies from which this work was pursued, it 
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was observed that low oxygen may increase the vascular efficiency of 
MSC:HUVEC networks after 18 hours of incubation (Detela, 2014; Bain, 2014). 
On the other hand, the hypoxic preconditioning of commercial hBM-MSCs 
appeared to show positive outcomes especially on Geltrex (Figure 5-19 A, B, C 
and D). However, the large error bars in the results, suggest that more 
experiments will need to be performed to validate the results. In addition, as only 
one or two donors were used in these experiments, future work will need to 
include the use of a bigger number of hBM-MSC donors. 
 
Future work could also look into culturing the hMSCs in a continuous normoxic 
or hypoxic environment to detect any differences. However, as part of assay 
development it would be beneficial to expand the hMSCs in a hypoxic 
environment to better mimic the physiological environment in which MSCs 
naturally reside in.  
 
Following this, the current work also showed that Notch ligand pre-stimulation 
did not/modestly impacted on vascular efficiency compared to the untreated 
cells, even at low oxygen (Figure 5-15, Figure 5-16, Figure 5-19, Figure 5-20 
and Figure 5-25). These results are contradictory to previous work, which 
indicated that when sJag1-treated individual donor hBM-MSCs were used in co-
culture, these formed significantly higher branch networks than the untreated 
cells especially in hypoxia (Detela, 2014). The different trends observed 
between this study and previous studies (Detela, 2014), indicate that these 
assays may not be robust and that there is a need to further optimize them to 
obtain similar results between different users, as well as including SOPs that are 
more detailed where possible and introduce automation to avoid errors related 
to the user. As part of assay development, vascular assays could be performed 
in microfluidic devices that would enable 3D angiogenesis models and more 
accurately mimic the physiological environment. For example, by subjecting 
cells to shear stresses similar to those found in vivo (Zhang and Austin, 2012; 
Reichen et al., 2013) and this would significantly reduce the number of reagents 
used in the assays. 
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Chapter 6: Discussion and future work 
6.1: Key findings, process development and limitations 
The driving force behind developing in vitro potency assays that could closely 
reflect the physiologic environment was the current limitation associated with 
release assays such as ELISA and gene expression microarrays. In fact, such 
tests may not be able to address the complexity of the cell therapy product, they 
are time-consuming and they include a lot of variability due to the very low 
volumes, the dilutions involved and the long steps involved in obtaining the data 
(Leng et al., 2008). This work focused on the validation and optimization of in vitro 
tests that could give an indication of functional characteristics of hMSCs and 
endothelial tubule formation that may be useful in the clinical setting.  
 
Comparative studies were carried out between MSCs derived from the bone 
marrow and the umbilical cord, as well as commercial hBM-MSCs cultured in their 
own High Performance Medium (<5% serum). Initially, the differently-sourced 
MSCs were characterized according to the ISCT guidelines which revealed that 
they were all able to undergo trilineage differentiation and that they expressed the 
positive MSC surface markers (>95%) and lacked the negative markers (<2%).  
 
Next, in vitro static (adhesion assays) were carried out on fibronectin-coated 
surfaces in low/hypoxic (2% O2) and ambient/normoxic (20% O2) oxygen 
conditions. Due to limitations in the stocks of individual donor hBM-MSCs and 
hUC-MSCs, it was decided to carry out the dynamic (migration assays) only using 
the commercial hBM-MSCs. Comparative studies were carried out with 
commercial low serum hBM-MSCs expanded under hypoxic and normoxic 
conditions. Similarly to previous in vitro work that used individual donor hBM-
MSCs (Detela, 2014) there was a trend where the cells primed with sJag1 
showed higher adhesion than the UT and the sDll4 groups but differences were 
modest. These results unveil a major issue in assay development where the 
outcomes from different research groups can be majorly attributed to the different 
users performing the experiments. Therefore, there is a need for more detailed 
SOPs and automated methods that can standardize and make the processes 
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more robust by excluding user error. In addition, different results could also be 
attributed to inter-donor variability issues between BM-MSCs.  
 
Contrarily to the initial hypothesis that changing the source of MSCs was not 
going to impact on cell adhesion, the results from chapter 3 showed that Jag-1 
priming considerably enhanced the adhesion capabilities of the slightly-younger 
hUC-MSCs. In addition, the umbilical cord MSCs showed higher adhesion than 
those derived from an adult source. The higher engraftment capabilities of hUC-
MSCs over bone marrow-derived MSCs were previously reported by other 
research groups (Acosta et al., 2013; Broxmeyer et al., 2003). However, since the 
adhesion assays for the differently-sourced MSCs were performed at different 
times this in itself might have contributed to different outcomes. In addition, one of 
the limitations of this study was that the umbilical cord MSC stocks arrived at 
higher passages than the hBM-MSCs, which meant that the outcomes from the 
experiments might have also resulted from different cell age. It is notable that the 
characterization studies reported no differences between the differently-sourced 
MSCs at the different passages, and therefore it may be beneficial to perform the 
experiments again in parallel using cells of similar age. Also, since only one or 
two donors were used, there is a need to perform further experiments using a 
bigger number of donors to confirm the results from these studies and to establish 
whether differences in adhesion and angiogenesis are attributed to inter-donor 
variability between MSC populations or the use of different cell source.  
 
Next, a higher degree of variability was observed in the adhesion assays 
performed with the P6 individual donor hBM-MSCs compared to the slightly-
younger cells. Moreover, from a manufacturing and process development 
perspective, the increase in cell heterogeneity observed in the older cells might 
have affected the consistency of the experimental data. Whilst, for the hUC-MSCs 
the slightly-older cells displayed less adherence to fibronectin when compared to 
the younger UC-MSCs. In support to the theory that sJag1 priming may be 
beneficial to MSC adhesion, the β-integrin staining experiments performed on 
commercial hBM-MSCs showed that the integrin β-1 / total integrin β-1 mean 
intensity was higher in sJag1 treated cells over the control groups.  
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Chapter 4 focused on using a methodological approach to identify key functions 
of endothelial tubule formation that could be used as the basis of the co-culture 
assays. The first aim was to test a series of variables that could impact on the 
abilities of endothelial cells to form tubules to then make the assays more cost-
effective. The second aim was to find the best way to measure successful 
vascular formation and assess the effectiveness of automated counting 
techniques over manual measurements. The first aim was achieved by using 
Geltrex, a similar matrix to Matrigel that has the advantage of less variation lot-to-
lot. In addition, lower matrix volumes were investigated to see whether they could 
induce efficient tubule formation or not and also reduce costs associated with 
performing the assays. The second aim was achieved by looking at different 
magnifications for branch counting. For example, the x2 magnification was able to 
show the whole well however, it was more difficult quantify the vessels and 
therefore it involved more inaccuracies especially for automated counting. For this 
reason, it was decided to take x4 magnification images instead and put them 
together through Panorama Pro. In order to avoid quantification issues due to the 
meniscus, the edges of the wells were excluded and a large area of the well was 
selected for quantification, this also made it easier to carry out the automated 
batch measurements.  
 
The manual and automated comparative studies showed that although the latter 
would always give the same output and it followed the same trend as the manual 
counts, it was not efficient in separating debris from vessels and this might have 
accounted for a less consistent analysis. Ultimately, the automated counting 
method is advantageous for quantification as it is less time-consuming and there 
is no variation between repeated counts on the same image. However, there is a 
need to refine the system for it to recognize debris from tubules.  
 
Next, the in vitro studies in chapter 5 demonstrated that the individual donor and 
commercial BM-MSCs displayed a pericyte-like behaviour in co-cultures, whilst 
this was not observed when using hUC-MSCs. It is possible that the functional 
differences observed between the hBM-MSCs and hUC-MSCs may be attributed 
to different populations of MSCs as only two donors were used for each or to the 
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different tissues of origin and cell age. In fact, the age of the hUC-MSCs (P11) 
may have contributed to a decrease in their angiogenic potential. It is notable, that 
the MSC/HUVEC ratio may not have been optimal for the umbilical cord MSCs. 
For example, the data in Appendix C showed that although the commercial hBM-
MSCs formed branches at the MSC:HUVEC 1:1 ratio, increasing the ratio of the 
HUVECs to 1:4 showed a significant increase in networks. Similarly, the hUC-
MSCs might have shown network formation by increasing the ratio of HUVECs in 
the co-cultures. One of the limitations in co-culture assays was the cell 
manipulation involved in achieving specific concentrations and the inherent 
biological variability of the reagents used such as Matrigel. This was particularly 
observed in the co-culture assays when using the commercial hBM-MSCs (Figure 
5-18). In fact, these assays showed high variability between both technical and 
biological repeats even though the cells were derived from the same donor.  
 
Since both umbilical cord and bone marrow-derived MSCs are found in low 
oxygen concentrations in vivo, it was decided to carry out comparative studies 
assessing differences in angiogenic potential between cells expanded in hypoxia 
and normoxia. The results in chapter 5, showed that hypoxic individual donor 
hBM-MSCs performed similarly to those expanded in normoxia. On the other 
hand, the co-culture and support assays for the commercial hBM-MSCs showed 
that cells expanded in low oxygen were generally performing better than those 
expanded under normoxic conditions. This suggests that hypoxia/HIF signalling 
pathway may be a key therapeutic target for vascular diseases. This data 
confirms that in vitro potency assays can give better insights into the mechanism 
of action of cell products. Overall, the findings from this study are fundamental 
bioprocess development data in the cell therapy industry and for the use of MSCs 
in clinics. 
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6.2: Future work 
 Construct metabolic gene knockout mutants involving the deletion of one 
or more genes to assess the importance of signalling pathways. This work 
could also investigate the impact of different orders of gene deletion on the 
proliferation of MSCs and their angiogenesis, adhesion and migration 
abilities. Therefore, future work may involve constructing MSC strains with 
industrial relevance. 
 This study showed that the expansion of MSCs in low oxygen after one 
passage did not have significant effects on the efficiency of the co-cultures 
and support assays. Further work could be carried out to assess the effect 
of long-term cell culture in low oxygen on the angiogenesis, migration, 
proliferation and surface marker expression of MSCs, since the effects of 
hypoxia on mesenchymal cells have been shown to be time dependent 
(Bain et al., 2014; Ding et al., 2014). Future work could also look into 
assessing the effect of a range of low oxygen conditions (e.g. 1% O2, 2% 
O2, 5% O2, and 20% O2) on the functional abilities of MSCs. In fact, 
different research groups have shown contrasting results due to 
differences in oxygen tension ranging from 0.1 to 5%, and different culture 
times ranging from a few minutes to 2 months (Bain et al., 2014; Basciano 
et al., 2011). In addition, the effect of hypoxia may also be source-specific 
(Lavrentieva et al., 2010). Therefore, comparative studies could be carried 
out to assess the effect of various oxygen conditions on the functionalities 
and characteristics of differently-sourced MSCs. A DOE approach could 
be used to investigate the interaction between key input variables and 
minimise the number of reagents used.  
 The experiments performed in this study involved the use of hMSCs from 
one or two donors. Furthermore, future studies need to be performed on a 
bigger number of donors to confirm the differences observed in this study. 
 The lack of tubule formation in the hUC-MSC:HUVEC co-cultures (chapter 
5) suggests that although umbilical cord MSCs are very similar to those 
obtained from the bone marrow (Dalous et al., 2012) they may have 
different functional characteristics (Lavrentieva et al., 2010). For this 
reason, it is necessary to carry out further optimization work such as 
testing different MSC:HUVEC ratios for the differently-sourced MSCs. In 
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this way it would be possible to gain further understanding on the effect of 
MSCs cultured in direct contact with endothelial cells, the functional 
differences between MSCs from various sources and the optimal 
MSC:HUVEC ratio for tubule formation.  
 More titration experiments will need to be performed to identify the 
optimum concentration range of sJag1 and sDll4 respectively for 
differently-sourced MSCs. hMSCs could also be pre-stimulated with sJag1 
and sDll4 at the same time to see whether the combination of the two will 
affect the functional properties of these cells. 
 Carry out comparative chemotaxis studies between differently-sourced 
MSCs and also assess the effect of other substrates other than fibronectin 
on cell migration.  
 Investigate the impact of cryopreservation, cell age (much older and much 
younger MSCs) and seeding density on the functionality of differently-
sourced MSCs.  
 Carry out comparative studies between different users who will follow the 
same SOP to assess the impact of user error on the experiments and to 
identify the effect of biological reagents on the consistency of the results. 
 Perform further optimization work using DOE by investigating lower matrix 
volumes to reduce assay costs or by diluting the matrices further. In 
addition, there is a need to optimize cell-seeding density in the co-culture 
assays to make sure that there are enough cells to contribute to adequate 
vessel formation at lower ratios.  
 The tubule formation assays were performed using HUVECs with n = 3 
donors. Future work could investigate a bigger number of donors and also 
test the functional differences between differently-sourced HUVECs. 
 The studies performed with the commercial low serum hBM-MSCs have 
raised questions about the effectiveness of serum free media for cell 
expansion, migration and angiogenesis potential. In addition, one bottle of 
High Performance Medium costs £1379 with a shipping charge of £400 
compared to DMEM medium, which costs £8 per bottle. Therefore, even 
though it is fundamental to reduce or eliminate serum for the reasons 
highlighted in section 1.4.2.1 the costs for the low serum RoosterBio Inc 
High Performance Medium need to be reduced, especially since the use of 
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medium for large scale applications may be high. Although the low serum 
medium has <5% FBS it is still boosted with various growth factors which 
can mask the effects of priming by candidate molecules. Chemically 
defined media can be used as a replacement to animal-derived media thus 
enabling for the complete removal of serum from small and large-scale 
processes (A. K.-L. Chen et al., 2013; Tekkatte et al., 2011). The 
components in serum-free media are usually basal media (e.g. DMEM) 
onto which is added albumin, transferrin, growth factors, attachment and 
spreading factors, hormones, lipoproteins and trace elements. Other 
alternatives to serum and serum-free media include human platelet lysate 
(hPL), autologous or allogeneic human blood-derived materials and 
umbilical cord blood serum (UCB). Human sourced media supplements 
seem to be viable alternatives to serum. However, they also present 
drawbacks for the successful expansion and therapeutic use of hMSCs. 
For example, the issues relating to batch-to-batch variation due to the 
inherent variability that is associated with using biological materials and 
the risk of contamination linked to the presence of human pathogenic 
agents in blood-derived alternatives. Future work could look into 
comparing the effects of different types of media.  
 The automated method is more robust than the manual counting technique 
however, further work is required to refine it. For example, develop 
automated counting methods that can recognise cells from debris.  
 Current in vitro migration and vascular assays do not precisely reflect the 
local environment in vivo. Moreover, they are not easy to control and they 
are time-consuming in terms of data analysis. Microfluidics may represent 
a more robust system to mimic the in vivo environment for example, by 
investigating the effect of static/flow conditions in MSC:HUVEC co-cultures 
in the microfluidic channels or by monitoring cell migration (Tanimura et 
al., 2013). Microfluidic platforms would enable the high throughput 
screening of several variables.  
 In vivo and ex vivo procedures such as Langendorff could be used to 
assess the reliability of the in vitro assays and to assess the percentage of 
primed MSCs that have engrafted on the heart of murine or rats that have 
undergone a coronary ligation occlusion. 
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Chapter 8: Appendices 
8.1: Appendix A Analysis of the effect of passage number, 
type of matrix and matrix volume on number of branch 
points 
Comparative studies were carried out between HUVECs at passage 7, passage 
10, passage 13 and passage 15 to study the effect of cell age on branch network 
formation. HUVECs were cultured for 3 to 4 days, trypsinized and seeded on GFR 
Geltrex and GFR Matrigel respectively at two different volumes, 55 µl and 35 µl 
for each substrate. A screening model was then designed using the Design 
Expert software to identify the key parameters involved in branch network 
formation. The interaction plot in Figure 8-1 indicated an increase in vascular 
efficiency up to passage 13 with the peak decreasing at passage 15.  
 
 
Figure 8-1: Interaction plot comparing the effect of passage number for GFR Matrigel and 
GFR Geltrex at higher (55 µl) and lower (35 µl) volumes. 
 
A 3-D plot was then generated to better visualize the interactions between the 
different input variables in the model (Figure 8-1 and Figure 8 2). The 3-D plot 
indicated that GFR Geltrex was more efficient than GFR Matrigel in forming 
branch networks. Firstly the plane for GFR Matrigel was lower than the plane for 
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the GFR Geltrex and secondly, the z plane of the graphs showed that GFR 
Geltrex was able to form more branch points. In addition, the flat planes observed 
in both the GFR Matrigel and GFR Geltrex 3-D plots confirmed that using the 
lower substrate volumes and higher passage numbers did not impact on branch 
efficiency hence suggesting that lower substrate volumes and higher passage 
numbers could be used to obtain more cost-effective high throughput assays. 
 
 
 
Figure 8-2: Interaction plot comparing the effect of passage number for (A) GFR Matrigel and 
(B) GFR Geltrex at higher (55 µl) and lower (35 µl) volumes. 
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8.2: Appendix B Effect of matrix volume and type of 
matrix on vascular network formation in co-cultures 
The gx11 individual donor hBM-MSCs were stained with Vybrant DiI Cell-
Labelling Solution (in red) whilst the HUVECs were stained with Green Cell 
Tracker (in green). The wells were imaged after 18 hours. As shown in the 
results, the hBM-MSCs co-localized with and bridged between the HUVECs 
(Figure 8-3). 
 
 
Figure 8-3: Co-culture vessel formation after 18 hours of individual donor gx11 P5 (PDL 7) 
hBM-MSCs (in red) and P10 HUVECs (in green; previously cultured in ambient oxygen 
conditions) seeded at a 1:1 ratio. Experiments were carried out on GFR Matrigel (M) and GFR 
Geltrex (G) at 35 µl and 55 µl respectively. Images were visualised using a fluorescence 
microscope. Yellow arrows represent the hBM-MSCs bridging between HUVECs. White 
arrows represent the hBM-MSCs co-localizing with the HUVECs. Scale bars = 1000 µm. 
 
As part of the current optimization studies, different variables were assessed to 
obtain the best condition for tubule formation, and one of them was matrix volume. 
This was done to understand if reducing matrix volume would still allow for 
efficient network formation and could therefore be used to decrease costs 
associated with performing the assays. Next, different seeding densities of 1:1 
hBM-MSCs:HUVECs were tested to see if fewer cells could be used to achieve 
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similar performance to the higher seeding densities. The phase contrast images 
(Figure 8-4) showed that more networks formed at 0.5 x 105 cells/ml and 0.67 x 
105 cells/ml than at 0.3 x 105 cells/ml. The images also showed that tubule 
formation on Geltrex was less efficient than that observed for Matrigel, and this 
was more evident  when using the lower seeding densities of 0.3 x 105 cells/ml 
and 0.5 x 105 cells/ml (see J, K, N, O; Figure 8-4).  
 
 
Figure 8-4: Representative phase contrast images of gx11 P5 (PDL 7) hBM-MSCs: P10 
HUVECs co-cultures seeded at a 1:1 ratio for a total cell concentration of either 0.3 x 105 
cell/ml, 0.5 x 105 cell/ml or 0.67 x 105 cell/ml respectively using either 35 µl or 55 µl of GFR 
Matrigel and GFR Geltrex respectively. Scale bars = 2000 µm. 
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As shown in Figure 8-5, the values for Geltrex at either 55 µl or 35 µl appeared to 
be lower than those observed in Matrigel especially at the higher cell 
concentrations where the values of Matrigel were almost two-fold higher than 
those of Geltrex (see M 55 µl and M 35 µl versus G 55 µl and G 35 µl; Figure 8-5). 
In addition, the differences in branch point efficiency between the higher and the 
lower cell concentrations were more evident in the Matrigel groups. In particular, 
when using M 55 µl there was a concentration-dependent trend where the branch 
point values obtained using 0.67 x105 cells/ml were at least two-fold higher than 
those obtained using 0.3 x105 cells/ml (Figure 8-5). 
 
 
Figure 8-5: Branch point quantification of gx11 P5 (PDL 7) hBM-MSCs: P10 HUVECs co-
cultures seeded at a 1:1 ratio for a total cell concentration of either 0.3 x 105 cell/ml, 0.5 x 105 
cell/ml or 0.67 x 105 cell/ml respectively. Experiments were carried out at 2% O2. The data 
indicated the mean ± SEM of triplicate samples from 3 independent experiments using 
different hBM-MSC batches derived from the same donor (gx11 donor).  
 
8.3: Appendix C Co-culture optimization study  
Co-culture assays were carried out after the hMSCs reached 80-90% confluency. 
Three different MSC:HUVEC ratios were investigated 1:1 ratio, 1:4 ratio and 4:1 
ratio using either GFR Geltrex (G) or GFR Matrigel (M). In order to investigate the 
effect of priming hMSCs with Notch ligands, 0.67 x 105 cells/well was seeded on 
the substrates. In order to count the number of branch points, wells were imaged 
using an inverted light microscope at X4 magnification. An example of triplicate 
wells of co-cultures seeded on Geltrex using normoxic hBM-MSCs is shown in 
Figure 8-6. As shown in Figure 8-6, the number of networks formed using the 1:4 
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ratio appears to be superior to the 1:1 and 4:1 ratio. This observation was 
confirmed in the quantification data in Figure 8-7. 
 
 
Figure 8-6: Sample phase contrast representative images of tubule networks formed in 
commercial PDL 14 hBM-MSCs:P10 HUVECs co-cultures seeded at 1:1, 1:4 and 4:1 ratios on 
35 µl Gelltrex. Experiments were carried out at 2% O2. Scale bars = 1000 µm 
 
8.3.1: Effect of commercial low-serum hMSCs:HUVECs ratio and 
type of matrix on vascular efficiency  
The results showed that the number of branch points formed on Geltrex at the 1:4 
ratio using the sJag1-treated hBM-MSCs was higher than that of the UT and the 
sDll4-treated groups (see G 1:4; Figure 8-7). However, more experiments will 
need to be performed to confirm whether these differences are statistically 
significant or not. Next, the data for Geltrex showed that higher branch point 
numbers (at least four-fold increase) were observed for the UT, sJag1 and sDll4 
groups at the 1:4 ratio in comparison to the branch point values obtained at the 
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1:1 and 4:1 ratios.(Figure 8-7). These results could be associated with the higher 
number of HUVECs in the 1:4 ratio.  
 
Next for sJag1, the M 1:4 group showed at least a five-fold decrease in vascular 
efficiency in comparison to the G 1:4 group. A similar trend was also observed for 
the UT (~2-fold increase for G 1:4 vs M 1:4) and the sDll4 groups (~4-fold 
increase for G 1:4 vs M 1:4). Overall, the 1:4 ratio led to the formation of evidently 
higher number of branch points compared to the 1:1 ratio and the 4:1 ratio which 
worked similarly. The data also suggested that sJag1 priming enhances 
angiogenesis when using Geltrex at the higher HUVEC ratio of 1:4. Furthermore, 
the trend for all of the experiments performed on Geltrex was that the groups with 
sJag1-treated hBM-MSCs showed higher adhesion than the UT groups even 
though the results for the G 1:1 and G 4:1 were modest (see G 1:1, G 1:4 and G 
4:1; Figure 8-7).  
 
 
Figure 8-7: Branch point quantification of normoxic commercial PDL 14 hBM-MSCs:P10 
HUVECs co-cultures seeded at 1:1, 1:4 and 4:1 ratios. Experiments were carried out at 2% 
O2. The data indicated the mean ± SEM of triplicate samples from 3 independent experiments 
using different hBM-MSC batches derived from the same donor. Refer to text for a detailed 
description of the results. 
 
Next comparative studies were carried out between MSC:HUVEC 1:1 ratio and 
4:1 ratio by using hBM-MSCs previously expanded in hypoxic conditions at 2% 
O2. The data indicated that for M 1:1 the sJag1 group showed at least a three-fold 
increase in branch points in comparison to the UT group (M 1:1, UT versus 
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sJag1; Figure 8-8). On the other hand for G 1:1 the UT group demonstrated at 
least a two-fold increase in branch points in comparisons to the sJag1 group and 
at least a three-fold increase in branch points in comparison to the sDll4 group 
(Figure 8-8). Next, Geltrex showed at least a three-fold increase in branch points 
in comparison to Matrigel for the UT 1:1 groups (see M1:1 versus G 1:1, UT; 
Figure 8-8). On the other hand, Matrigel showed at least a two-fold increase in 
branch points in comparison to Geltrex for the sJag1 1:1 groups (see M 1:1 
versus G 1:1, sJag1; Figure 8-8). However, there were no evident differences in 
vascular efficiency between the M 4:1 group and the G 4:1 groups. The very low 
values of branch points for the 4:1 groups in comparison to the 1:1 groups, 
indicated inefficient branch formation. Furthermore, the results suggested that 
seeding the co-cultures at a 1:1 ratio promotes a higher number of branch points 
than using the 4:1 ratio. This result was expected as the 4:1 ratio involves using a 
higher number of hBM-MSCs than HUVECs. Also, there was a trend where the 
sDll4 groups showed a lower number of branch points in comparison to the UT 
and the sJag1 groups and this trend was maintained for all of the conditions (see 
M 1:1, M 4:1, G 1:1 and G 4:1; Figure 8-8). Therefore, sDll4 priming of hBM-
MSCs appeared to hinder angiogenesis.  
 
Figure 8-8: Branch point quantification for hypoxic commercial PDL 14 hBM-MSCs:P10 
HUVECs co-cultures seeded at 1:1, 1:4 and 4:1 ratios. Experiments were carried out at 2% 
O2. The data indicated the mean ± SEM of triplicate samples from 3 independent experiments 
using different hBM-MSC batches derived from the same donor. Refer to text for a detailed 
description of the results. 
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8.3.2: Effect of low oxygen and type of matrix on vascular 
efficiency  
The data showed that there were mostly no evident differences in branch points 
between the co-cultures that were performed using the normoxic and the hypoxic 
hBM-MSCs. However, the M 1:1 sJag1 group showed at least a three-fold 
increase in branch points when using the hypoxic hBM-MSCs compared to the 
experiments performed using the normoxic hBM-MSCs (see M 1:1 normoxic 
versus M 1:1 hypoxic; Figure 8-9). Similarly, the G 1:1 UT condition showed at 
least a four-fold increase in branch points using the hypoxic hBM-MSCs in 
comparison to the normoxic group (see G 1:1 normoxic versus G 1:1 hypoxic; 
Figure 8-9).  
 
Figure 8-9: Comparative study between co-cultures carried out using normoxic (20% O2) and 
hypoxic (2% O2) commercial PDL 14 hBM-MSCs at 1:1 and 4:1 MSC:HUVEC ratios using 
either GFR Matrigel (M) or Geltrex (G). Experiments were performed under 2% O2. The data 
indicated the mean ± SEM of triplicate samples from 3 independent experiments using 
different hBM-MSC batches derived from the same donor. Refer to text for a detailed 
description of the results. 
 
 
